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Reduced Disease-free Survival Associated With Anaplastic
Lymphoma Kinase Translocation (ALK) in Lung Adenocar-
cinoma Patients With No Cigarette Smoking History
P. Yang1, A. Oliveira1, J. Wampfler1, J. Boland1, S. Stoddard1, M. Erickson-
Johnson1, H. Tang1, K. Kulig2, E. S. Yi1, 1Mayo Clinic, Rochester, MN,
2Pfizer Oncology, New York, NY
Purpose/Objective(s): The natural history of ALK and NSCLC clinical
outcome needs to be defined. We designed a nested case-control study using
the ongoing Mayo Clinic Lung Cancer Cohort to evaluate clinical outcomes
of never-smoking lung adenocarcinoma patients with respect to ALK trans-
location status and report preliminary results.
Materials/Methods: We employed IHC (Dako clone ALK1 with AD-
VANCE detection chemistry, Carpinteria, CA) and FISH with dual color
break-apart probe (Vysis, Des Plaines, IL) on formalin-fixed paraffin-em-
bedded tissue to test for ALK. In this study, we have analyzed disease-free
survival (DFS), which was defined as free of progression and/or recurrence
and was systematically assessed in the Mayo Lung Cancer Cohort study
through medical record abstraction, supplemented with direct outreach to
patients or family members and by requesting necessary records from
external health care providers. We considered ALK if FISH or IHC
scored 23, ALK- if FISH- or IHC scored 0. To control for known
prognostic indicators of lung cancer survival, matching criteria were used to
create comparable sets of ALK vs ALK- cases. Matching variables were
age, sex, and stage. Set 1 includes 10 FISH and 10 FISH- cases with age
10 years and 2 stages (III, IIIIV); Set 2 includes 7 FISH and 7 FISH-
with age 5 years and 3 stages (III, III, IV). A multivariable Cox
proportional hazard model was also applied to all ALK vs ALK- cases
adjusting for age, sex, and stage, by FISH and IHC separately.
Results: To date, a total of 159 cases were tested by IHC, of which, 100 were
confirmed by FISH, 10 ALK and 90 ALK-. IHC scored 0, 1, 2, and 3,
respectively for 95, 46, 7, and 11 cases. We found a complete concordance
between FISH- and IHC-0 cases, and 10 of 11 (91%) IHC-2 and IHC-3 were
FISH. For Set 1, median DFS is 30.3 months for ALK vs. 57.4 months
for ALK- cases (p  0.195). For Set 2, median DFS is 26.5 months for
ALK vs. 63.4 months for ALK- cases (p  0.193). The multivariable Cox
model revealed a hazard ratio of 1.93 (p0.09) for DFS for ALK vs ALK-
cases by FISH test, and a hazard ratio of 1.87 p0.06) by IHC test.
Conclusion: Our preliminary analysis of 159 never-smoking adenocarci-
noma cases suggests a trend of worse outcome, as measured by DFS, in
patients with ALK tumors. Our continued screening for ALK status in this
cohort will allow more robust analyses, including evaluation of treatment-
specific outcomes in matched ALK vs. ALK- patients.
Author Disclosure Block: P. Yang, None; A. Oliveira, None; J. Wamp-
fler, None; J. Boland, None; S. Stoddard, None; M. Erickson-Johnson,
None; H. Tang, None; K. Kulig, None; E.S. Yi, None.
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FEV1 as Prognostic Marker in Stage III Non-small Cell Lung
Cancer (NSCLC) Patients Treated With Chemoradiation:
Pooled Analysis of Two Multicenter Phase II Trials
P. R. Germonpre1,2, A. Janssens1,2, V. Nowe´1,2, C. De Pooter2,3, C. Goor1,4,
1Antwerp University Hospital, Edegem, Belgium, 2Thoracic Oncology Group
Antwerp - University of Antwerp, Antwerp, Belgium, 3St. Augustinus, Wilrijk,
Belgium, 4ZNA Middelheim, Antwerp, Belgium
Purpose/Objective(s): Lung cancer mortality has been shown to be signif-
icantly associated, both in smokers and non-smokers, with emphysema and
chronic bronchitis. An exploratory analysis of the HOG 01-24 trial suggests
that FEV1 (forced expiratory volume in 1 sec) 2L was associated with
improved OS in stage III NSCLC patients (pts) treated with chemoradiation.
In this analysis we evaluated the prognostic value of FEV1 (expressed as %
of predicted value).
Materials/Methods: We used individual data from 71 pts enrolled in two
multicenter phase II trials to perform a univariate analysis of prognostic
factors using the log-rank test. Pts with unresectable stage III NSCLC and
performance status (PS) 0-2, weight loss 10%, FEV1 1.2L or 45%,
diffusion capacity (DLCO) 50% and adequate organ function were en-
rolled in the Cher@Nos (from 02/2003 to 11/2005) and the Paccora trials
(from 01/2006 to 12/2008). Treatment consisted of 3 cycles of carboplatin 
gemcitabine followed by thoracic radiotherapy with concurrent weekly
low-dose cisplatin in the Cher@Nos trial, and of 3 cycles of cisplatin 
pemetrexed (either as induction or consolidation) and thoracic radiotherapy
with concurrent 3-weekly pemetrexed in the Paccora trial. In both trials the
radiotherapy was administered as 2 Gy/fraction, 5 fractions/week for a total
dose of 60 Gy.
Results: Pts with an FEV1 70% predicted had a significantly better
progression-free survival (PFS) and overall survival (OS) compared to pts
with an FEV1 70% predicted: HR 0.289 (0.132-0.633; Chi
2 P .002) for
PFS and HR 0.319 (0.161 - 0.635; P .002) for OS. Gender, PS, stage (IIIA
vs. IIIB), histology (squamous vs. non-squamous) and trial (Paccora vs.
Cher@Nos) were not associated with a significant difference in PFS or OS.
Conclusion: Our data confirm the prognostic value of FEV1 (70% vs.
70% predicted) in pts with unresectable stage III NSCLC treated with
chemoradiation. Furthermore these results indicate that FEV1 is a potentially
important but often ignored confounder when interpreting results from
different chemoradiotherapy trials or when designing new trials comparing
different chemoradiotherapy regimens.
Author Disclosure Block: P.R. Germonpre: None. A. Janssens: None.
V. Nowe´: None. C. De Pooter: None. C. Goor: None.
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Stereotactic Body Radiotherapy (SBRT) in Patients Aged 75 and
Older With Stage I Non-small Cell Lung Cancer (NSCLC):
Retrospective Results From a Multi-Center Consortium
M. A. Samuels1, S. Kandula2, J. A. Bogart3, J. Salama4, P. Aridgides3, A.
Gajra3, R. C. Lilenbaum1, 1Mount Sinai Community Clinical Oncology
Program, Miami Beach, FL, 2University of Miami School of Medicine,
Miami, FL, 3SUNY Upstate Medical University, Syracuse, NY, 4University of
Chicago School of Medicine, Chicago, IL
Purpose/Objective(s): Patients aged 75 and older comprise an increasing
proportion of patients with early lung cancer, and represent an even larger
proportion of patients unsuitable for definitive surgery due to medical
comorbidity or patient refusal. SBRT has recently become an accepted
treatment option for patients with contraindications to surgery. We report a
retrospective analysis of the clinical outcomes of a series of elderly patients
treated with SBRT in the setting of a multi-institutional clinical research
consortium.
Materials/Methods: Three institutions pooled retrospective data on all
patients aged 75 or over who received SBRT for stage I NSCLC. 47 patients
were available for analysis, with ages ranging from 75 to 92 years (median
81). Treatment was delivered during the 2007-2009 time period with a
median follow-up of 8.1 months. All patients had staging with PET-CT. 87%
of patients had biopsy-proven disease. 55% had poor pulmonary function,
19% had other medical comorbidities, 21% refused surgery and for 5% the
reason was unknown. 51% had T1a tumors, 32% had T1b and 17% had T2a
tumors. Total doses were 35-60 Gy in 3-9 fractions. All patients were treated
using a linear accelerator, with 96% receiving 3D conformal RT and 4%
undergoing IMRT. Patients were followed for toxicity and tumor control.
Results: At the time of analysis, the local failure rate was 2% (1/47). The
regional failure rate was 9% (4/47). The distant failure rate was 6% (3/47).
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The combined failure rate was 15% (7/47) due to one patient experiencing
both regional and distant failure. There were no grade 3 or greater toxicities.
Pneumonitis grades 1 and 2 were seen in 11% and 13% of patients,
respectively. Fatigue was seen in 15% and chest wall pain in 11%. Risk
factors for complications included female sex (41% total complications vs.
20% for males), larger tumor size (mean tumor volume with complications
was 14.7 cm3 vs. 4.8 cm3 without) and prior lung resection (44% with vs.
26% without).
Conclusion: SBRT in stage I NSCLC patients aged 75 or older proved
tolerable, with toxicity rates comparable to series treating younger patients.
Excellent rates of local, regional and distant control were achieved at a
median follow-up of 8.1 months. Patients 75 and older represent a rapidly-
growing segment of the early lung cancer population and SBRT appears to
be a safe and effective treatment option for patients who either refuse or are
not optimal candidates for surgery.
Author Disclosure Block: M.A. Samuels: None. S. Kandula: None. J.A.
Bogart: None. J. Salama: None. P. Aridgides: None. A. Gajra: None.
R.C. Lilenbaum: None.
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Substantial Incidental Mediastinal and Hilar Irraditiation is
Delivered during Definitive Stereotactic Body Radiation Ther-
apy for Peripheral Non-small Cell Lung Cancer
K. L. Martin, J. Gomez, D. P. Nazereth, G. W. Warren, A. K. Singh, Roswell
Park Cancer Institute, Buffalo, NY
Purpose/Objective(s): To determine the amount of incidental radiation dose
received by the mediastinal and hilar nodes for patients with non-small cell
lung cancer (NSCLC) treated with stereotactic body radiation therapy
(SBRT).
Materials/Methods: Fifty consecutive patients with NSCLC, treated using
an SBRT technique, were identified. Of these patients, 38 had a prescription
dose of 60 Gy in 20 Gy fractions and were eligible for analysis. For each
patient, ipsilateral upper (level 2) and lower (level 4) paratracheal, and hilar
(level 10) nodal regions were contoured on the planning CT images. Using
the clinical treatment plan, dose and volume calculations were performed
retrospectively for each nodal region.
Results: SBRT to upper lobe tumors resulted in an average total ipsilateral
mean dose of between 5.2 and 7.8 Gy for the paratracheal nodal stations (2R
and 4R for RUL lesions, 2L and 4L for LUL lesions). SBRT to lower lobe
tumors resulted in an average total ipsilateral mean dose of between 15.6–
21.5 Gy for the hilar nodal stations (10R for RLL lesions, 10L for LLL
lesions).
Conclusions: Considerable incidental dose to mediastinal and hilar lymph
nodes is delivered during SBRT. This incidental dose to the lymph nodes
likely is considerable enough to have therapeutic effect on subclinical
disease.
Author Disclosure Block: K.L. Martin: None. J. Gomez: None. D.P.
Nazereth: None. G.W. Warren: None. A.K. Singh: None.
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Is Stereotactic Body Radiotherapy Warranted in Medically
Operable Stage I NSCLC? A Markov Model Based Decision
Analysis
A. V. Louie1,2, G. Rodrigues1,2, M. Hannouf1, D. A. Palma1,2, J. Q. Cao1,2,
B. P. Yaremko1,2, R. Malthaner1,2, J. D. Mocanu1, G. S. Zaric1, 1University
of Western Ontario, London, ON, Canada, 2London Regional Cancer Pro-
gram, London, ON, Canada
Purpose/Objective(s): A growing body of evidence suggests that stereotac-
tic body radiation therapy (SBRT) should be considered the standard of care
option for medically inoperable stage I non-small cell lung cancer (NSCLC)
patients. Two randomized control trials are ongoing to determine the role of
SBRT in medically operable patients. The purpose of this study is to compare
the quality-adjusted life expectancy and overall survival in patients with
stage I NSCLC treated with either SBRT or surgery.
Materials/Methods: We constructed a Markov model to simulate the clin-
ical history of medically operable patients with stage I NSCLC that undergo
either SBRT or lobectomy for a 5-year timeframe. Rates of recurrence and
Markov state utilities, consistent with the four stages of the AJCC staging
system, were extracted and adapted to monthly time intervals from the
literature. Age- and sex-specific rates of death from all other causes were
extracted from standard life tables from the Centre for Disease Control and
Prevention (CDC) and were varied according to smoking habit. Surgical
outcomes from the model were compared to an external outcome prediction
tool commonly used by clinicians: Adjuvant! Online. We report various
treatment strategy overall and quality adjusted survival outcomes stratified
by age, sex, and pack-year history of smoking. Sensitivity analyses on the
quality of life of SBRT, treatment related death, and proportion of patients
with recurrent disease receiving radical treatments were performed to deter-
mine thresholds for treatment modality preference.
Results: Overall survival, cancer specific survival, and other causes of death
as predicted by our model correlated closely with those predicted by
Adjuvant! Online ranging from 0.0% to 3.8%, 0.1% to 1.0%, and 0.1% to
3.5% respectively. Mean quality-adjusted life expectancy ranged from 3.28
to 3.78 quality adjusted life years (QALYS) after surgery and 3.35 to 3.87
QALYS for SBRT. Differences in overall survival between the two modal-
ities ranged from 2.2% to 3.0% and 0.07 to 0.09 QALYs for all patient
cohorts. The utility threshold for preferring SBRT over surgery was 0.90.
Outcomes were sensitive to quality of life, the proportion of local and
regional recurrences treated with radical versus palliative treatments, and the
surgical and SBRT treatment related mortalities.
Conclusions: The role of SBRT in the medically operable patient is yet to be
defined. Our model indicates that SBRT may offer comparable overall
survival and quality adjusted life expectancy as compared to surgical resec-
tion. Well powered prospective studies comparing surgery versus SBRT in
early lung cancer are warranted to further investigate the relative survival,
quality of life and cost characteristics of both treatment paradigms.
Author Disclosure Block: A.V. Louie: None. G. Rodrigues: None. M.
Hannouf: None. D.A. Palma: None. J.Q. Cao: None. B.P. Yaremko:
None. R. Malthaner: None. J.D. Mocanu: None. G.S. Zaric: None.
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Modeling Risk of Lung Secondary Malignancy in patients
Treated with Breast Radiation Therapy
J. Ng, I. Shuryak, Y. Xu, R. Burri, Columbia University Presbyterian
Medical Center, New York, NY
Purpose/Objective(s): Conventional supine treatment of patients with breast
radiation therapy results in significant doses of radiation to the lungs. The
purpose of this study was to estimate the absolute and relative risks of
developing secondary lung malignancies in patients treated with standard
whole breast fractionated radiotherapy and to compare these risks using both
prone and supine irradiation techniques.
Materials/Methods: Twelve post-lumpectomy, early-stage breast cancer
patients underwent CT simulation and treatment planning in both the prone
and the supine positions. The simulations were used to generate standard
fractionated whole breast radiation treatment plans. Dose-volume histograms
of the ipsilateral breast and the ipsilateral and contralateral lungs were
calculated. The dose-volume data were imported into a secondary malig-
nancy modeling program, and the predicted absolute and relative risks of
secondary lung malignancies were computed via the Shuryak-Brenner
model. The risks of secondary lung malignancies associated with breast
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irradiation in the prone and supine positions at different patient ages were
compared.
Results: The predicted excess relative risk for secondary lung malignancies
for patients treated in the supine position was higher than the risk for patients
treated in the prone position. The predicted lifetime absolute risk of a
secondary lung malignancy in the setting of standard supine breast irradiation
was higher than the predicted lifetime risk of lung cancer for the general
population. By comparison, the predicted lifetime absolute risk of a second-
ary lung malignancy from standard prone breast irradiation was about the
same as the background risk of lung cancer for the general population. The
magnitude of the excess absolute risk was greater in the supine versus the
prone position for each patient and increased with younger patient age.
Conclusions: Treatment with breast irradiation in the supine position ap-
pears to increase the risk of developing secondary lung malignancies, a risk
which increases with younger patient age. The excess relative risk of
secondary lung malignancies in this predictive analysis is consistent with
previously published large retrospective series of women treated using
supine breast irradiation techniques. Prone breast irradiation may reduce the
incidence of secondary lung malignancies in this patient population.
Author Disclosure Block: J. Ng: None. I. Shuryak: None. Y. Xu: None.
R. Burri: None.
129
Defining Imaging Changes After SBRT for NSCLC
B. J. Greenfield1, C. Vargas2, C. Shang2, 1University of Miami Miller School
of Medicine, Miami, FL, 2Lynn Cancer Institute of Boca Raton Hospital,
Boca Raton, FL
Purpose/Objective(s): CT-PET findings after stereotactic body radiation
therapy (SBRT) for non-small cell lung carcinomas (NSCLC) have different
appearances and progression timelines compared to conventional radiation
therapy. In this study the extent and timing of these imaging changes were
assessed.
Materials/Methods: Analysis of 44 consecutive patients with NSCLC
staged T1-T2a ( 5cm) treated with SBRT. ITV was 90% of total measured
movement with daily respiratory gating 90% of average position. PTV based
on 3mm axial and 5mm superior/inferior expansions. Patients treated with
IMRT employing 8-phase 4D CT. PTV dose was 50Gy (BED100Gy
/10) in 5 consecutive fractions to 95% of PTV and a minimum dose
47.5Gy to 0.5%. Dose constraints: lung V15 of 15%, mean lung dose
4.5Gy, and rib dose was 50Gy0.5cc and optimized for rib cage exposure
80% of prescribed dose. Follow-up alternating CT and PET-CT at 3 month
intervals. Post radiation changes (PRC) and tumor response determined by
PET-CT review. PRC defined by consolidation/scarring changes categorized
by: no change, minimum (confined to GTV), intermediate (outside GTV),
and large (more than twice the GTV within segment treated). Tumor
response evaluated by RECIST criteria.
Results: Median age was 82-years (63-92) with histology of 70% adenocar-
cinoma, 15% squamous cell carcinoma, and 15% non classifiable based on
fine-needle aspiration. Laterality was 60% left lung and 40% right lung.
Median pack-years were 50 (0-150). Median size was 22mm (9-39) with
median GTV of 7.1cc (1.0-45.1) and median PTV of 25.2cc (5.7-97.0).
Median last follow-up was 165 days (34-377). Median tumor response was
30% reduction in diameter. CR seen in 27.3% (12/44) at median of 174 days
(62-226); of these, 33.3% (4/12) were first observed 100 days follow-up
and 66.7% (8/12) 100 days. Intermediate or large post radiation changes
observed in 16.3% (7/43) 100 days follow-up and 65.4% (17/26) 100
days. PTV size as prognostic factor: CR seen in 45.5% (5/11) of 1st PTV
quartile (median 11.6cc, 17) in comparison to 21.2% (7/33) of 2nd-4th
quartiles combined (median 33.1cc, 17.0-97.0) (p0.1); also, large post
radiation changes seen in 72.7% (8/11) of 4th PTV quartile (median 57.9cc,
40) in comparison to 39.4% (13/33) of 1st-3rdquartiles combined (median
20.1cc, 5.7-39.1) (p0.06). Significant SUV mean percent change seen at
180 days (mean 64.8%, SV 16.2%) follow-up in comparison to 180
days (mean 6%, SV 54.1%) (p 0.01). One failure (2.3%) observed after
175 days follow-up.
Conclusions: Relative low dose SBRT is associated with good response
rates. PTV size was correlated with complete tumor response and inversely
with post radiation changes. Follow-up longer than 6 months may be
necessary to define SBRT affect on response rates, post radiation changes,
and PET SUV values.
Author Disclosure Block: B.J. Greenfield: None. C. Vargas: None. C.
Shang: None.
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The Accuracy of Orthogonal KV Matching to Bony Anatomy
for Patient Positioning in Patients Receiving Stereotactic Body
Radiation Therapy for Early-Stage Non-small Cell Lung Cancer
M. N. Corradetti, K. Teo, N. Anderson, C. Barlow, R. R. Rengan, University
of Pennsylvania, Philadelphia, PA
Purpose/Objective(s): Stereotactic Body Radiation Therapy (SBRT) is a
promising treatment for patients with early-stage non-small cell lung cancer
(NSCLC). Due to the large fractional doses and small treatment margins
employed with SBRT, precise patient positioning is critical in order to
deliver adequate dose to the tumor and to reliably spare nearby organs at risk.
The aim of this study was to determine the accuracy of orthogonal kilovolt-
age (KV) image-matching to bony anatomy for tumor positioning in SBRT.
Materials/Methods: Eight patients with early stage NSCLC receiving SBRT
were enrolled on an IRB-approved prospective image guided radiotherapy
protocol. All patients underwent 4D-CT simulation with acquisition of 8
images from various phases of the respiratory cycle. A gross target volume
(GTV) was contoured on the free breathing CT, and an IGTV that encom-
passed the motion envelope of the GTV was generated from the 4D-CT data
set. Patients on treatment underwent initial positioning with orthogonal
KV-matching to bony anatomy followed by conebeam CT (CBCT) acquisi-
tion with matching of the CBCT-visualized tumor to the internal gross target
volume (IGTV). A total of 96 consecutive shift events were analyzed with
vertical, longitudinal, and lateral shifts recorded.
Results: Matching of the CBCT-visualized tumor to the contoured IGTV
after initial orthogonal KV matching to bony anatomy was performed by the
attending physician (RR) prior to delivery of treatment. The average CBCT-
based shifts after initial patient positioning using orthogonal KV matching to
bony anatomy were as follows: the vertical shift was 3.8 mm (n 32;  
5.4); the longitudinal shift was 1.8 mm (n32;  2.2); and the lateral shift
was 1.4 mm (n32;  2.0). The mean total shift vector for all CBCT shifts
was 5.4 mm (n96;  5.5). There were a total of 26/96 CBCT-based shifts
which were greater than 3 mm (12 in the vertical axis, 8 in the longitudinal
axis, and 6 in the lateral axis).
Conclusions: We reasoned that if orthogonal KV matching to bony anatomy
resulted in accurate tumor positioning, no additional shifts should be required
to match the tumor as visualized on the CBCT to the contoured IGTV.
However, the current study shows that matching of the tumor to the IGTV
required average shifts up to nearly 4 mm, and CBCT-based shifts were
required approximately 27% of the time. Of note, the routine IGTV-PTV
expansion employed in RTOG protocols is 3 mm. Taken together, these data
suggest that orthogonal KV matching to bony anatomy may be inadequate
for accurate tumor positioning for SBRT. Caution should therefore be
employed when relying on KV imaging alone for patient positioning for
SBRT, and CBCT-based positioning with tumor matching should be utilized
when available.
Author Disclosure Block: M.N. Corradetti: None. K. Teo: None. N.
Anderson: None. C. Barlow: None. R.R. Rengan: None.
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Preliminary Results in the Treatment of Recurrent Non-small
Cell Lung Cancer (NSCLC) With Stereotactic Body Radiation
Therapy (SBRT): Does Total Dose and Tumor Volume Impact
Local Control?
J. E. Costello1,2, E. P. Finnerty2, R. L. Deming1, D. K. Strom2, K. J.
Bernstein1, N. J. Bellville1, C. M. Burgin1, R. P. Jacobsen1, D. R. Puri1,
1Mercy Medical Center, Department of Radiation Oncology, Des Moines, IA,
2Des Moines University, College of Osteopathic Medicine, Des Moines, IA
Purpose/Objective(s): Recently published results of RTOG 0236 highlight
outstanding local control (LC) rates when SBRT is used for inoperable
early-stage NSCLC. However, data concerning efficacy and safety of SBRT
for recurrent NSCLC remains limited. The main purpose of this retrospective
study was to identify treatment and tumor characteristics that might predict
for better LC when SBRT is employed for solitary pulmonary recurrences.
We also report on short- and intermediate-term toxicities in this cohort of
patients, many of whom received prior thoracic radiotherapy (TRT).
Materials/Methods: From 4/05-7/09, 28 patients with recurrent NSCLC
were treated with SBRT using a robotic system (CyberKnife, Accuray,
Sunnyvale, CA) with fiducial-based respiratory tracking. All recurrences
were biopsy-proven and/or PET-avid (SUV4.5) solitary lesions. Median
SBRT dose was 48Gy (range:24-60Gy in 3-5 fractions), with treatment
margins (GTV-to-PTV) of 0-5 mm. Median GTV was 21cc (range:2-83cc).
75% of patients received prior TRT for their primary NSCLC. Median time
between TRT and SBRT was 29 months (range:7-113 months). Toxicities
were scored by the RTOG criteria.
Results: With a median follow-up of 12.6 months (range:4-34 months), 1-
and 2-year actuarial LC was 66% and 44%, respectively. Overall survival
was 56% at 1 year and 40% at 2 years. Both total dose and GTV were found
to be predictive of LC. Nine local failures occurred at a dose of 0.009). An
inverse correlation (p  0.018) was found between GTV and LC, as 80% of
local failures occurred with a GTV of 25cc. Grade 2 pulmonary fibrosis
and cough were the two most common adverse effects, occurring in 57% and
35% of patients, respectively. Grade 2 pneumonitis occurred in 28% of
patients, with no statistically significant relationship between incidence of
pneumonitis and prior TRT (p  0.33). One Grade 3 (fibrosis) and no Grade
4 toxicities were reported. Pneumothorax occurred in 25% of patients who
underwent fiducial placement.
Conclusion: SBRT appears to be a reasonable and well-tolerated approach
in the local management of recurrent NSCLC, especially when higher total
doses are used. Our current practice is to deliver 60Gy in 3 fractions to
low-volume thoracic recurrences whenever possible. Recurrent lesions
25cc may benefit from higher total doses or a non-SBRT treatment
approach. Our preliminary results will need to be validated by prospective
studies of SBRT in the recurrent setting so that more concrete practice
guidelines can be established for the stereotactic treatment of recurrent
NSCLC. Longer follow-up is required to determine the full extent of late
effects in this mostly previously irradiated cohort.
Author Disclosure Block: J.E. Costello: None. E.P. Finnerty: None. R.L.
Deming: None. D.K. Strom: None. K.J. Bernstein: None. N.J. Bellville:
None. C.M. Burgin: None. R.P. Jacobsen: None. D.R. Puri: None.
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Morbidity Analysis of Medically Inoperable Patients Treated
with Lung Stereotactic Body Radiotherapy (SBRT)
K. Kotinsley, F. Alite, O. Gayou, D. S. Parda, A. Kirichenko, A. Colonias,
Allegheny General Hospital, Pittsburgh, PA
Purpose/Objective(s): To report the morbidity of patients with medically
inoperable stage I lung cancer or lung metastasis treated with stereotactic
body radiotherapy (SBRT).
Materials/Methods: Patients with either medically inoperable stage I lung
cancer or oligometastatic disease to the lung who completed SBRT at
Allegheny General Hospital (AGH) were eligible. All patients underwent
4-D CT simulation followed by daily multi-field 3-D conformal or intensity
modulated irradiation using conebeam CT for image-guidance. The elec-
tronic medical records of these patients were retrospectively reviewed.
Prospectively acquired morbidity data (including rib fracture incidence and
CTCAE v3.0 morbidity grading for pneumonitis, cough, fatigue, hemoptysis,
dysphagia, and skin reaction) was obtained for analysis. Multivariate analysis
was performed using logistic regression analysis.
Results: A total of 65 patients underwent SBRT at AGH between April 2007
to January 2010. Staging was as follows: 50.7% (33/65) patients had
T1N0M0; 13.8% (9/65) had T2N0M0; 16.9% (11/65) had metastatic disease,
and 9.2% (6/65) had recurrences (after resection or conventional radiation).
The remaining six patients had lung cancer staged as Stage IIA to IIIA.
Dosing was as follows: 27 patients received 48 Gy in 4 fractions, 15 received
50 Gy in 5 fractions, 3 received 45 Gy in 5 fractions, 11 received 40 Gy in
5 fractions, 1 received 42 Gy in 7 fractions with the remaining 8 patients
receiving 30-36 Gy in 4-5 fractions. At a median follow-up of 5 months
(range 1-22 months), the incidence of rib/compression fracture was 6% (4/65
patients). The incidence of CTCAE grade 2 or greater toxicity was as
follows: 3.1% (2/65) for pneumonitis; 10.8% (7/65) for cough; 30.8%
(20/65) for fatigue; 1.5% (1/65) for dysphagia; and 4.6% (3/65) for skin
reaction. No patient developed hemoptysis. There were no grade 4-5 toxic-
ities with 5 patients (7.7%) experiencing grade 3 toxicity (4 with grade 3
fatigue and 1 with grade 3 cough). Multivariate analysis revealed no factors
(including total dose, dose/fraction, tumor size, tumor volume, pretreatment
FEV1, V20 and mean lung dose) as predictors for toxicity.
Conclusions: Lung SBRT is a well tolerated treatment with acceptable
morbidity in this frail patient population.
Author Disclosure Block: K. Kotinsley: None. F. Alite: None. O. Gayou:
None. D.S. Parda: None. A. Kirichenko: None. A. Colonias: None.
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Early Results With Rapid Arc Radiosurgery for Inoperable
Non-small Cell Lung Cancer
C. Biggs1,2, C. Mican2, D. Reed1, T. T. K. Lee1, F. Rafie1, K. Rogers1,
1Arizona Center for Cancer Care, Peoria, AZ, 2Northwest Cardiovascular &
Thoracic Surgeons, Glendale, AZ
Purpose/Objective(s): Recent publication of results from RTOG 0236 has
established radiosurgery for early stage lung cancer as a standard of care for
treatment. Here we describe our experience using RapidArc radiosurgery.
RapidArc is a continuous dynamic IMRT system with cone beam CT
localization, and few results have been described with the use of this system
for radiosurgery. Here we show that SBRT to lung in the community setting
can achieve the same results as this prospective trial.
Materials/Methods: From Jan. 2009 to July 2010, 87 tumor sites in 76
patients were definitively treated with RapidArc radiosurgery at our outpa-
tient radiation facility. Average age was 75yo (54-91). All patients were
deemed to be medically inoperable. The majority were evaluated by a board
certified thoracic surgeon prior to treatment. T1 or T2 N0, M0, NSC lung
cancers were treated with RapidArc intensity modulated radiosurgery con-
sisting mostly of 5 fractions (95%) of 10 Gy per fraction (95%) to a total dose
of 50Gy to the tumor periphery, with margin defined by gated CT. Inspira-
tion, expiration, and normal breathing CT were used to delineate a “gated”
volume of treatment showing tumor motion. The entire area of motion was
treated as tumor volume. Delivery of RapidArc was not, however, gated.
Central lesions, including juxtaposition to the trachea, mainstem bronchus,
and esophagus were allowed, (unlike RTOG 0236, which excluded central
lesions).
Results: With an average follow up of 8 months, PET/CT shows local
control of 97%, with one local recurrence (3%) at 9 months. Overall survival
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is 85% with 11 deaths, 4 of which are from metastatic disease. Grade I or II
dyspnea at 3 months is reported in 9.8% of patients, with no grade III-V
toxicity. 2 cases of chest wall pain are reported, with 3 cases of transient
grade I esophagitis. Patients with central lesions did not show any difference
in toxicity or local control.
Conclusions: RapidArc based radiosurgery is effective and safe at our
current follow up period. A dose of 50Gy in five fractions is tolerated well,
and is safe in the treatment of central lesions. Gated volume delineation also
appears to be safe and effective. These results match closely those of RTOG
0236 in a community setting.
Author Disclosure Block: C. Biggs: None. C. Mican: None. D. Reed:
None. T.T.K. Lee: None. F. Rafie: D. Speaker’s Bureau/Honoraria; Varian
systems. K. Rogers: None.
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Comparison of 30 Day Mortality of Right Lobectomy Versus
Right Pneumonectomy for Curative Resection of Non-small Cell
Lung Cancer
S. P. Thomas1, D. Mueller2, R. Anderson3, H. Wang4, S. Foiles5, 1Illinois
CancerCare, Peoria, IL, 2Heart Care Midwest, Peoria, IL, 3Peoria Surgical
Group, Peoria, IL, 4UICOMP, Dept of Medicine, Peoria, IL, 5OSF St
Francis Medical Center, Peoria, IL
Purpose/Objective(s): NSCLC is potentially curable with surgical resection.
Common surgical procedures include Lobectomy and less frequently Pneu-
monectomy. A right pneumonectomy is thought to result in increased
mortality and morbidity. INT-0160 demonstrated increased mortality in
patients who underwent right sided pneumonectomy following Neo-Adju-
vant Chemotherapy with Radiation.
Materials/Methods: OSF St Francis Medical Center in Peoria, IL is a large
volume Thoracic surgery center of excellence that participates in the STS
database. We analyzed the 30 day mortality between right sided Lobectomy Vs
a right pnemonectomy, for patients undergoing curative up front resection for
NSCLC.
Results: Between 1/1/06 and 7/8/10, 141 patients underwent a Right Lobec-
tomy, 1 underwent a Sleeve Lobectomy, 13, had a Bi-Lobectomy performed
and 9 patients underwent a Right sided Pneumonectomy. All patients had
appropriate pre-operative evolution and were deemed to be candidates for
surgery. Data was collected via a query submitted to the STS database. The
30 day mortality was 2.1% (N3) for the Right sided lobectomy group and
11.1% (N1) in the Pneumonectomy group. Fishers test was used to
calculate the 30 day mortality difference between patients who had a Right
sided Lobectomy versus a Right Pneunonectomy. P value was 0.221. Con-
clusion: There is no statistical difference in 30 day mortality between right
sided lobectomy and right pneumonectomy at this center.
Author Disclosure Block: S.P. Thomas: None. D. Mueller: None. R.
Anderson: None. H. Wang: None. S. Foiles: None.
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Stereotactic Body Radiotherapy (SBRT) for Unbiopsied Medi-
cally Inoperable Primary or Recurrent Lung Tumors
M. M. Harkenrider, A. B. Freeman, R. R. Johnson, S. Y. Woo, A. E. Dragun,
University of Louisville, Louisville, KY
Purpose/Objective(s): To report on the outcomes of treating medically
inoperable patients with unbiopsied primary or recurrent carcinoma of the
lung with stereotactic body radiotherapy (SBRT).
Materials/Methods: Since 2008 sixteen patients with non-pathologically di-
agnosed carcinoma of the lung were treated with SBRT. Patients had docu-
mented CT and PET imaging that was clinically consistent with lung malig-
nancy. All patients were medically inoperable with lesions that were not
pathologically confirmed with biopsy or bronchial washings. Fourteen patients
had either primary or recurrent tumors without biopsy whereas 2 patients had 2
synchronous primary lesions with biopsy confirmation of only 1 tumor. The 2
unbiopsied tumors are included in this study. Nine patients had primary lung
tumors and 7 patients had recurrent tumors. Patients in the study were treated
with SBRT to a median dose of 50 Gy (range 40–55 Gy) in a median of 5
fractions (range 4–10 fractions) with either static field or arc-based IMRT with
a median BED of 100 (range 72–115.5). Local control classifications are
concordant with the RTOG definitions.
Results: Median follow up for the study is 4.5 months (range 1–16.5 months).
The median age of patients in this report is 74 years (range 53–84 years). The
median Karnofsky performance status is 80% (range 40–100%). Three patients
had attempted invasive diagnostic procedures, and thirteen patients had none.
The mean tumor size on initial CT was 1.4 cm (range 0.5–3.3 cm) for all nine
primary tumors. Six patients with primary tumors had documented tumor
dimensions on multiple CT scans and a mean greatest dimension increase from
1.1 cm (range 0.5–2.0 cm) to 1.5 cm (range 1.0–2.5 cm). Mean SUV on PET
imaging prior to treatment was 8.0 (range 2.6–12.0) for all patients. Local
control was achieved in all 16 patients. One patient had a complete response, 3
patients had a partial response, and 13 patients had stable disease. There were no
regional nodal failures, and two patients had distant failures. There were no acute
or chronic treatment-related toxicities reported. Overall survival was 87.5%.
Conclusion: In medically inoperable patients, a diagnosis of carcinoma of the
lung can be provisionally made by imaging without pathologic confirmation.
Local control can be achieved with minimal toxicity with the use of SBRT.
Author Disclosure Block: M.M. Harkenrider: None. A.B. Freeman:
None. R.R. Johnson: None. S.Y. Woo: None. A.E. Dragun: None.
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The Art of Managing Lung Cancer in Never Smokers: A Case
Report of a 56 Year Old Pastel Artist
S. R. Schuster, H. R. Paripati, H. J. Ross, Mayo Clinic Arizona, Scottsdale,
AZ
While the strong association between tobacco exposure and lung cancer is
well known, 10-20% of patients with non-small cell lung cancer are never
smokers. We present a case of a 56 year old female pastel artist, never-
smoker, who presented with three weeks of cough and hemoptysis. Chest
x-ray revealed a 4.5cm thick-walled cavitary lesion in the left lower lobe
with left hilar adenopathy. Surprisingly, final pathology revealed poorly
differentiated squamous cell carcinoma measuring 4.2cm in greatest dimen-
sion with no lymph node involvement (T2aN0M0, Stage IB). She completed
four cycles of post-operative adjuvant chemotherapy with cisplatin and
gemcitabine and remains free of recurrence 18 months after treatment. We
offer a review of the distinctions between lung cancer in never smokers
(LCINS) compared to patients with a history of tobacco smoking as well as
a focus on recent advances in targeted therapies. We also discuss occupa-
tional exposures in lung cancer, such as Cadmium in pastel dusts. A better
understanding of these differences will contribute to improved individualized
treatment plans in lung cancer.
Author Disclosure Block: S.R. Schuster: None. H.R. Paripati: None. H.J.
Ross: None.
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Standardized Uptake Values on [18f]Fluorodeoxyglucose
Positron Emission Tomography (FDG-PET) After Intensity
Modulated Radiation Therapy for Non-small Cell Lung Cancer
Are Associated With Locoregional Control, Disease-Free Sur-
vival and Distant Metastasis-Free Survival
J. L. Lopez Guerra1,2, G. W. Gladish1, R. Komaki1, D. Gomez1, P. Qing-
song1,3, Y. Zhuang1, X. Wei1, M. S. O’Reilly1, J. D. Cox1, Z. Liao1, 1The
University of Texas M.D. Anderson Cancer Center, Houston, TX, 2Virgen del
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Rocı´o University Hospital, Seville, Spain, 3Tianjin Medical University Can-
cer Hospital, Tianjin, China
Purpose/Objective(s): To evaluate the association between standardized
uptake values (SUVs) on [18F]fluorodeoxyglucose positron emission tomog-
raphy (FDG-PET) after intensity modulated radiation therapy (IMRT) in
primary tumor (PT) and lymph nodes (LNs) and survival outcomes for
patients with non-small cell lung cancer (NSCLC).
Materials/Methods: We reviewed 60 patients with newly diagnosed
NSCLC who had FDG-PET after IMRT. None of them had prior other
cancer. The stage distribution according to the American Joint Committee on
Cancer 2002 staging system was as follows: 2 stage IA, 3 stage IB, 26 stage
IIIA and 29 stage IIIB. Fifty-five (91.6%) of the 60 patients received
concurrent chemoradiation. We correlated survival outcomes with the SUVs
of the PT, LNs (the highest maximal SUV of all LNs and the sum of all PET
positive LNs), the sum of maximal SUV of both PT and LNs and the highest
maximal SUV of all target lesions after IMRT. One experienced radiologist
reviewed all FDG-PET images and provided the maximal SUVs on all
patients. The prognostic significance was assessed by Cox’s proportional
hazards regression analysis.
Results: Median follow-up was 20 (range, 4-52) months. Median radiation
dose was 66 (range, 60-73.85) Gy at 1.8-2.12 Gy per day. Median lag time
between the end of the IMRT and the time of best response by FDG-PET
evaluation was 138 days (25th-75th percentile range, 82-213 days). There
were statistically significant associations between the SUVs of the PT, the
sum of all PET positive LNs and the highest maximal SUV of all target
lesions after IMRT and the risk of locoregional recurrence (LRR) both inside
and outside the radiation field (P  0.001, P  0.011 and P  0.0001,
respectively), disease-free survival (DFS) (P  0.003, P  0.039 and P 
0.001, respectively) and distant metastasis-free survival (DMFS) (P 0.049,
P  0.006 and P  0.017, respectively). We also found statistically
significant associations between the highest maximal SUV of all PET
positive LNs and the sum of the maximal SUVs of the PT and the LNs after
IMRT and the risk of LRR both inside and outside the radiation field and
DFS (P  0.0001 in all of them).
Conclusion: SUVs of the PT, the sum of the LNs and the highest maximum
of all the target lesions after IMRT are statistically significant prognostic
factors for LRR, DFS and DMFS in NSCLC. The highest maximal SUV of
all the LNs and the sum of the SUVs of the PT and the LNs after IMRT are
also statistically significant prognostic factors for LRR and DFS.
Author Disclosure Block: J.L. Lopez Guerra: None. G.W. Gladish:
None. R. Komaki: None. D. Gomez: None. P. Qingsong: None. Y.
Zhuang: None. X. Wei: None. M.S. O’Reilly: None. J.D. Cox: None. Z.
Liao: None.
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Overexpression of p16(CDKN2A) Protein: Relationship With
RB loss and Human Papillomavirus in Non-small Cell Lung
Cancer
N. Yanagawa, A. Wang, D. Kohler, G. da Cunha Santos, M. Tsao, University
Health Network, Princess Margaret Hospital/Ontario Cancer Institute site,
and University of Toronto, TORONTO, ON, Canada
Purpose/Objective(s): The CDNK2A tumor suppressor gene encodes the
p16(INK4A) protein which regulates G1/S cell cycle checkpoint by inhibit-
ing the binding of cyclin dependent kinase 4 (Cdk4) with Cyclin D1. Loss of
p16 tumor suppressor can be achieved through mutation, deletion and/or
hypermethylation of CDKN2A gene. Nevertheless, some cancer types such
as HPV positive cervical and head and neck squamous cell carcinomas show
overexpression of the p16 protein. This p16 overexpression has been asso-
ciated with the negative feedback mechanisms resulting from HPV E7 RB
inactivation. In this study, we assessed the expression of p16 protein and
correlated its expression level with both RB protein expression and HPV
status in a large cohort of surgically resected primary non-small cell lung
cancer (NSCLC) patients.
Materials/Methods: Tissue microarrays (TMAs) were constructed from archi-
val paraffin blocks of 425 NSCLC that included 254 adenocarcinomas (ADC)
and 171 squamous cell carcinomas (SCC). DNA was isolated from tumor cores
of the same blocks. TMA sections were stained immunohistochemically for p16
(clone E6H4) and RB (clone 1F8) using the Ventana’s BenchmarkXT (Tucson,
AZ). The p16 was scored as overexpressed (positive/) when any tumor cells
showed staining regardless of number or intensity. The RB was scored as
negative when 10% or less of tumor cells was stained. Presence of HPV
sequences was assessed by in situ hybridization (ISH) using the INFORM®HPV
III Family 16 Probe (Ventana Medical Systems).
Results: Normal lung shows negative p16 staining in all cell types. Over-
expression of p16 was found in 123/254 (48%) of ADC and 42/171(25%) of
SCC. Lack of RB expression (RB-) was found in 116 (94%) of p16 ADC
and in 31 (74%) of p16 SCC. RB- was also found in 98/131 (75%) p16
negative (-) ADC and 60/129 (46%) p16- SCC. There was significant inverse
correlation between the expression of p16 and RB in both ADC and SCC
(P0.0002 and P0.002, respectively). HPV ISH was positive in 5 of 171
(2.9%) of SCC, but in 0 of 254 ADC. All HPV cases showed strong p16
staining and negative RB staining. Double negative (RB-/p16-) tumors were
noted in 98 (39%) and 60 (35%) of ADC and SCC, respectively. Only 7 (3%)
and 11 (6%) of ADC and SCC were RB/p16, which may represents the
only tumors that had preserved G1/S checkpoint.
Conclusion: In this cohort of North American patients, p16 protein over-
expression is mainly associated with RB protein loss and is uncommonly
associated with presence of HPV genome. Inactivation of P16/RB pathway
occurs in a majority of NSCLC.
Author Disclosure Block: N. Yanagawa: None. A. Wang: None. D.
Kohler: None. G. da Cunha Santos: None. M. Tsao: None.
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Proton Beam Versus IMRT for Post-Operative Radiotherapy in
Completely Resected IIIA Non-small Cell Lung Cancer
A. T. Berman, K. Teo, K. Shahnazi, R. Rengan, Hospital of the University of
Pennsylvania, Philadelphia, PA
Purpose/Objective(s): Post-operative radiotherapy (PORT) for stage IIIa
completely resected non-small cell lung cancer has been previously shown to
improve local control; however, it is unclear that this improvement translates
into a survival benefit. One potential explanation is that the detrimental effect
of post-operative radiotherapy on critical organs at risk (OARs) negates any
potential improvement in outcome. The aim of this study is to perform a
comparative analysis of proton beam PORT with intensity modulated photon
beam radiotherapy (IMRT) based PORT to determine whether PB-PORT
could provide dosimetric sparing of the critical OARs.
Materials/Methods: The computed tomography treatment planning scans of
four patients with completely-resected IIIA NSCLC treated at our institution
with IMRT-PORT were used for this study. The IMRT and double-scatter
proton beam plans were generated using the Eclipse treatment planning system
(Varian) and were analyzed for dosimetric endpoints. The four proton plans were
constructed with two or three beams. Three of the original IMRT plans were
optimized to deliver 50.4 Gy and one to deliver 54 Gy, all in 1.8 Gy fractions.
The proton plans were optimized to deliver the same biologically equivalent
dose as was originally delivered in the IMRT plans. DVHs were analyzed for all
OARs.
Results: The average mean lung dose (MLD) for PB-PORT was 8.7 Gy (RBE)
and 12.8 Gy with IMRT-PORT for a relative reduction of 32.3%. The average
lung volumes treated to 5, 10, and 20 Gy (V5, V10, V20) were 30, 26, and 18%
for PB-PORT versus 54, 40, and 25.1% for IMRT-PORT. The lung V5 had a
relative reduction of 43.8% (p0.009) with PB-PORT compared with PORT,
the V10 had a relative reduction of 35.9% (p0.006), and the V20 had a relative
reduction of 28.6% (p0.046). All cord doses were below 50 Gy and the
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average cord maximum dose was 28.6 Gy (RBE) with PB-PORT versus 46.3 Gy
with IMRT-PORT (p0.13). The average esophageal volume treated to 55 Gy
(V55) for IMRT-PORT was 10% versus 0.2 % for PB-PORT (NS). The average
heart volume treated to 40 Gy (V40) for IMRT-PORT was 13% versus 16.2%
PB-PORT (NS). Both plans achieved adequate coverage of the PTV with the
average volume treated to 95% of the prescribed dose (V95) for PORT at 98.0%
and PB-PORT 98.7% (NS).
Conclusions: PB-PORT appears to reduce dose to most critical OARS when
compared with IMRT-PORT. Additionally, in this study, PB-PORT signif-
icantly reduced dose to normal lung for dosimetric parameters that have been
predictive of radiation pneumonitis. This reduction may correlate with a
decrease in the incidence of this dose limiting toxicity and thus improve the
therapeutic ratio.
Author Disclosure Block: A.T. Berman: None. K. Teo: None. K. Shah-
nazi: None. R. Rengan: None.
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Enhanced Local Control and Survival With Concurrent Che-
moradiation Using Accelerated Hypofractionated Radiotherapy
J. Maguire1,2, V. Kelly1, M. Ledson1, M. Walshaw1, 1Liverpool Heart and
Chest Hospital, Liverpool, United Kingdom, 2Clatterbridge Oncology Cen-
tre, Bebington, United Kingdom
Purpose/Objective(s): Concurrent chemoradiation is the most effective
form of treatment for inoperable stage 3 NSCLC, with a survival advantage
of between 6 13% compared to sequential treatment. This advantage is
believed to be due to improved local tumor control, although reported local
control rates are generally less than 40%. Local control might be improved
by radiotherapy dose escalation and the addition of cetuximab, which are
being investigated in RTOG 0617. An alternative approach is to deliver
radical radiotherapy concurrent with chemotherapy within a four week
period - the objective being to minimize the effects of accelerated repopu-
lation and thus enhance local control and survival.
Materials/Methods: In a ten year period, we have treated 104 patients with
confirmed NSCLC with chemoradiation using cisplatinum (30 patients) or
cisplatinum and vinorelbine (74 patients) concurrently with radical hypo-
fractionated radiotherapy using 50 - 55Gy in 20 fractions over 26 days. Two
thirds of the patients were male, one third female. The median age was 64
years (range 36 - 80). 90 patients had stage 3 NSCLC (83 stage 3B, 7 stage
3A), 12 had bulky inoperable stage 2 disease, and 2 patients had stage 4
disease. 84 patients were PS 0-1, 18 PS 2 and 2 PS 3 at presentation. 64
patients received between two and four cycles of chemotherapy starting
between four and eight weeks after completion of concurrent treatment.
Results: Median survival for the whole group was 23 months. Survival rates
at three, five and ten years (all causes mortality) were 41.7%, 30.1% and
16.2% respectively. For stage 3 patients, the addition of two to four cycles of
chemotherapy after concurrent treatment increased median survival (26.6
versus 14.6 months) and survival at two years (53.1% versus 40%) but made
no difference to survival rates at three and five years, which were 42% and
33% respectively. In a non-randomized comparison, there was an advantage
for patients who received 55Gy compared to those who received 50 - 52.5Gy,
with median survival of 37.9 months versus 20.6 months, two year survival
64.2% versus 40%, three year survival 56.2% versus 34.2% and five year
survival 36% versus 28.5%. The local tumor control rate was 76% for
patients receiving 55Gy and 68.6% for patients receiving 50 - 52.5 Gy. There
were no treatment related deaths. The commonest early side effect was CTC
grade 2 oesophagitis, which was observed in 86 patients. 9 patients suffered
CTC grade 3 oesophagitis and eight required dilation of oesophageal stricture
between eight weeks and three years after treatment.
Conclusion: Chemoradiation using accelerated hypofractionated radiotherapy
concurrent with cisplatinum and vinorelbine enhances local control and survival
for patients with locally advanced NSCLC and good performance status.
Author Disclosure Block: J. Maguire: D. Speaker’s Bureau/Honoraria;
Pierre Fabre Ltd. F. Consulting/Advisory Board; Eli Lilly. V. Kelly: None.
M. Ledson: None. M. Walshaw: None.
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Delineation of Gross Tumor Volumes in Maximum Intensity
Projection Images for Four Dimensional Computed Tomogra-
phy Based Radiotherapy in Lung Cancer - Are We Looking
Through The Right Window?
M. Sujith Kumar, M. A. Laviraj, P. Subhas, M. Renu, S. Mazumder, P. K.
Julka, B. K. Mohanti, G. K. Rath, All India Institute of Medical Sciences,
Delhi 110029, India
Purpose/Objective(s): To determine the optimum CT window-level thresh-
olds for gross tumor volume delineation in Maximum Intensity Projection
images(MIP) for four-dimensional (4-D) computed tomography (CT)based
radiotherapy planning in Non Small Cell Lung Cancer.
Materials/Methods: The 4D-CT image datasets of 5 patients of locally
advanced NSCLC who underwent 4DCT based radiotherapy treatment plan-
ning in our institution was analyzed for this study. The primary gross tumor
volume (GTV) in each data set was delineated by combining the GTV
contours from ten respiratory phases(GTVALL PHASES) at standard CT win-
dow level of 1,600 and 300 Hounsfield units (HU) . Also, contouring of
GTV on corresponding MIP images was done for different CT window-level
thresholds at 1600 and 300HU(GTVMIP1);1,600 and 400HU(GTVMIP2);
1,600 and 450HU(GTVMIP3); 1,600 and 600HU(GTVMIP4) and 1,200
and 700HU(GTVMIP5).Nodal GTVs were not included in this study.The
total volumes and maximum diameter (MD) of each image based GTV in
three dimensional orientation was determined and compared with GTVALL
PHASESwhich was taken as the optimum GTV. Underestimation and overes-
timation of total volume also was measured.Statistical analysis was done.
Results: The median volume of GTVMIPchanged from 113(GTVMIP1) to
147(GTVMIP5) and the median MD changed from 7.5(GTVMIP1) to
9.3(GTVMIP5) as CT thresholds were varied. The correlation coefficient of
the GTVMIP volume compared with the GTVALL PHASES ranged from 0.73 to
0.90.The correlation coefficient of GTVMIP3was best(r0.90) followed by
GTVMIP4(r0.89) .The correlation coefficient of the GTVMIP MD compared
with the GTVALL PHASESranged from 0.82 to 0.99.The correlation coefficient
of GTVMIP4was best(r0.988) followed by GTVMIP3(r0.98).The total
volumes of GTVMIPwere not statistically significant from GTVALL PHAS-
ES.Overestimation of total volumes was seen consistently in GTVMIP5when
compared to GTVALL PHASES.
Conclusions: With advent of 4DCT, tracking the respiratory motion of
tumors in NSCLC has been addressed but the accurate delineation of GTV
in MIP images is absolutely necessary for accurate treatment.MIP images
differs qualitatively from other CT images. With limitations of small dataset,
our study indicates that CT window thresholds of 1600 and 450HU; and
1600 and 600HU may be better than standard CT window-level thresholds
for GTV delineation in MIP images. Further studies are indicated.
Author Disclosure Block: M. Sujith Kumar: None. M.A. Laviraj: None.
P. Subhas: None.M. Renu: None. S. Mazumder: None. P.K. Julka: None.
B.K. Mohanti: None. G.K. Rath: None.
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Increasing 18F-fluorodeoxyglucose (FDG) Uptake in Non-small
Cell Lung Cancer is Associated With Higher Clinical Stage but
has a Non-linear Relationship With Survival
M. P. MacManus, M. Lin, G. Wu, D. L. Ball, R. Fisher, S. Brennan, M.
Campeau, D. Binns, B. Solomon, R. Hicks, Peter MacCallum Cancer
Centre, East Melbourne 3002, Australia
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Purpose/Objective(s): It has been reported that higher levels of glucose
metabolism, as indicated by higher standardized uptake vales (SUV), are
associated with a worse prognosis in non-small cell lung cancer NSCLC.
However, the nature of the relationship is not well characterized and it is
premature to assume that it holds true for all levels of SUV. In this
retrospective study we analyzed the prognostic significance of maximum
SUV (SUVmax), as a continuous variable in patients with treated with
radical radiation therapy (RT)/ChemoRT.
Materials/Methods: Eligible patients had pathologically confirmed NSCLC,
were treated with radical RT or chemoRT as their primary treatment and had
pre-treatment staging PET-CT scans. The maximum SUV (SUVmax) was
defined as the maximum pixel SUV value retrieved from the primary tumor.
SUV max was analyzed as both a dichotomous and a continuous variable for
risk of death.
Results: There were 88 eligible patients. Stage groupings were; stage I
n19, stage II n10 and stage III n 59. Median SUVmax was 15.0 (range
2.5-56.1). Higher stage was associated with higher values of SUVmax
(P0.048). In univariate analysis, using the median cutpoint of SUVmax 
15.0, the hazard ratio (HR) for risk of death (high:low) was 0.71 (95% CI
0.44 to 1.15; P0.18). When viewed as a continuous variable there was an
observed trend in the relationship between SUVmax and risk of death
towards improved survival with increasing SUVmax. However this trend was
not statistically significant (HR of SUVmax on risk of death (per doubling)
0.83, 95% CI 0.62–1.11, P0.22).
Conclusions: In patients treated with RT for NSCLC, increasing SUVmax
was associated with increasing TNM stage but there was no evidence for an
association with a higher risk of death in patients with higher levels of
SUVmax.
Author Disclosure Block: M.P. MacManus: None. M. Lin: None. G. Wu:
None. D.L. Ball: None. R. Fisher: None. S. Brennan: None.M. Campeau:
None. D. Binns: None. B. Solomon: None. R. Hicks: None.
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The EphB4 Receptor Tyrosine Kinase is Aberrantly Expressed
in Lung Cancer
B. D. Ferguson1, M. Tretiakova1, P. S. Gill2, R. Salgia1, 1University of
Chicago, Chicago, IL, 2University of Southern California, Los Angeles, CA
Purpose/Objective(s): Lung cancer represents roughly 15% of annual can-
cer incidence in the United States across both sexes, yet it is responsible for
nearly 30% of total cancer deaths. Importantly, little progress has been made
over the past three decades in its treatment success, a fact that highlights the
continued need for additional therapeutic targets. Receptor tyrosine kinases
are frequently implicated in the progression of these cancers, and some
tyrosine kinase inhibitors are effective clinically. However, these inhibitors
are frequently met with drug resistance and subsequent relapse, suggesting
the importance of investigations into these mechanisms and alternative
targets. The Eph RTK family has recently emerged as important players in
cancer biology, especially in the lung. Our overall objective was to determine
whether EphB4 could be an important target in lung cancer therapeutic
strategies.
Materials/Methods: We investigated the possible role of EphB4 in lung
cancer pathobiology by examining its protein expression in tumor microar-
rays using an Automated Cellular Imaging System (ACIS) and/or manual
IHC scoring and in cell lines via immunoblotting and assessed correlation
with patient characteristics.
Results: EphB4 expression was demonstrated in all subtypes of lung cancer
analyzed and was overexpressed more than threefold compared to matched
normal tissues in a pairwise analysis (p0.0001) with the strongest expres-
sion in adenocarcinoma and small cell carcinoma, followed by large cell
carcinoma, squamous cell carcinoma, and non-small cell carcinoma-not
otherwise specified (p0.0078). Centers versus edges of tumors did not
demonstrate differential expression (p0.9512), nor did primary tumors
versus lymph node metastases (p0.5181), suggesting that expression is
maintained throughout disease progression. Interestingly, EphB4 expression
was positively correlated with survival in a Kaplan-Meier analysis, suggest-
ing that EphB4 may be a positive prognostic indicator in lung cancer.
Conclusions: Taken together, these data indicate that EphB4 may play an
important role in lung cancer and that further characterization and investi-
gation into its cellular role is warranted.
Author Disclosure Block: B.D. Ferguson, None; M. Tretiakova, None;
P.S. Gill, Co-founder and Director, VasGene Therapeutics, E. Ownership
Interest; R. Salgia, None.
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Survival Benefit of Surgery for Single Station N2 NSCLC: Is
Surgery Still Indicated or Not?
T. Hishida, J. Yoshida, M. Nishimura, Y. Ohe, K. Nagai, National Cancer
Center Hospital East, Chiba, Japan
Purpose/Objective(s): Clinical N2 (stage IIIA) NSCLC are generally tar-
geted for chemoradiotherapy but not for initial resection, even if the tumor is
resectable. However, single station pathologic N2 (pN2) disease has been
reported to have favorable prognosis after surgical resection followed by
adjuvant chemotherapy. Therefore, single station clinical N2 (scN2) NSCLC
patients might be borderline candidates for initial surgical resection, and
have been mainly treated by initial surgery in the clinical practice of our
institution. We investigated survival outcome after initial surgery for scN2
patients.
Materials/Methods: We retrospectively reviewed of a total of 103 consec-
utive scN2 patients between 1992 and 2006. The definition of scN2 was
single N2 node measuring 1-2cm (non-bulky size) by contrast-enhanced CT
in one lymph node station. During the study period, adjuvant chemotherapy
after resection was not standard of care.
Results: Eighteen-two patients (79%) were treated by initial surgery and 21
patients underwent other modalities because of pN2 confirmation by preop-
erative or intraoperative lymph node biopsy. Eighteen patients underwent
chemoradiotherapy (CRT), a standard of care for unresectable N2 disease,
and the remaining 3 underwent induction chemotherapy followed by surgery.
Among 82 scN2 patients who underwent initial surgery, only 39 (48%)
revealed pN2 in resected specimen and 43 (52%) were pathologically N0-1
(pN0; n  31, pN1; n  12). In CRT group, 15 (83%) received cisplatin and
vinorelbine with a total of 60 Gy irradiation. Radiation therapy was admin-
istered concurrently in 11 (61%) patients. The 5-year overall survival (OS) of
scN2/pN2 patients was significantly worse than that of scN2/pN0-1 patients
(22.4% versus 73.8%, p0.01), however, it was not statistically different
from that of scN2/pN2 patients who underwent chemoradiotherapy (31.7%,
p  0.253).
Conclusions: On the CT-based criteria, about a half of scN2 disease was
pathologically N0-1 with favorable prognosis, and even scN2/pN2 patients
showed non-inferior survival relative to that after chemoradiotherapy. De-
tailed biological analyses of resected specimen might be helpful to determine
optimal adjuvant therapeutic regimen. NSCLC with scN2 might be still
candidates for initial surgical resection.
Author Disclosure Block: T. Hishida: None. J. Yoshida: None. M.
Nishimura: None. Y. Ohe: None. K. Nagai: None.
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Paraneoplastic Cutaneous Leukocytoclastic Vasculitis and Iron
Deficiency Anemia in Squamous Cell Lung Carcinoma
M. P. Anstadt1, D. E. Thomas2, S. K. Kathula3, 1Miamii Valley Heart &
Lung Surgeons, LLC, Dayton, OH, 2Wright State University Boonshoft
School of Medicine, Dayton, OH, 3Wright State University, Dayton, OH
A 64-year-old white male presented with microcytic anemia which was
discovered by routine laboratory work, as well as a non-pruritic rash of one
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month duration. The patient had previously seen a dermatologist for the rash
and it was thought to be possibly either vasculitic in nature or medication-
related based on appearance. The rash did not respond to the discontinuation
of possible causative medications. Physical exam revealed a macular rash
involving the patient’s entire body, more pronounced on his extremities, as
the only abnormal finding. The patient had previously smoked two to three
packs of cigarettes per day for 25 years and quit more than 20 years ago.
Review of systems was negative.The patient had a hemoglobin of 10.9
gm/dL, MCV of 84 fl, serum iron of 22 g/dL, saturation of 9%, TIBC of
251 g/dL and a ferritin of 161 ng/mL. WBC and platelet counts were within
normal limits. A biopsy of the rash showed findings characteristic of
lukocytoclastic vasculitis. The ESR was 50mm/hr, CRP of 1.7mg/dL, and
anti-nuclear antibodies c-ANCA, p-ANCA and cryoglobulins negative. A CT
scan of the chest showed a non-calcified, lobulated mass in the left lung apex
abutting the chest wall with anterior mediastinal adenopathy. A CT guided
biopsy revealed invasive moderate to poorly differentiated squamous cell
carcinoma. A PET scan showed a7 cm focus of increased uptake in the left
upper lobe of the lung with no evidence of distant metastases. CT scan
demonstrated anterior mediastinal adenopathy (1.5cm lymph nodes). Cer-
vical mediastinoscopy was negative, (clinical stage either IIb/IIIa). The
patient received neoadjuvant chemotherapy and radiation as a result of tumor
location and size. Following the initiation of chemotherapy and radiation the
patient’s rash completely resolved. Repeat CT scan showed a decrease in size
of the tumor to approximately 4cm. The patient underwent lobectomy. Final
path revealed a tumor 2cm with all lymph nodes were negative for
malignancy, (Stage Ia). The patient has since recovered uneventfully and has
had no recurrence of his presenting rash. This patient’s presentation with
cutaneous leukocytoclastic vasculitis (CLV) and iron deficiency anemia
appears to be the only signs of his underlying malignancy. Review of the
literature identified only two case reports of patients with squamous cell lung
carcinoma and paraneoplastic CLV. CLV represents a cutaneous paraneo-
plastic manifestation of lung cancer. Treatment for paraneoplastic CLV can
be directed either against the vasculits or the underlying malignancy. In this
case the paraneeolastic response to neoadjuvant therapy was associated with
a reduction in the tumor size and down staging of the clinical stage (IIb or
IIIa) to a more favorable pathologic stage (Ia).
Author Disclosure Block: M.P. Anstadt: None. D.E. Thomas: None. S.K.
Kathula: None.
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Extrapleural Pneumonectomy for Lung Cancer; Cause of
Death1⁄4 H1N1 Influenza
I. Carranza-Martı´nez, L. A. Martin-del-Campo, P. Santillan-Doherty, J. C.
Jacinto-Tinajero, L. M. Argote-Greene, Instituto Nacional de Ciencias Medi-
cas y Nutricio´n “Salvador Zubiran”, Mexico, Mexico
Purpose/Objective(s): To discuss the evidence and potential benefits of
Extrapleural pneumonectomy (EPP) in advanced stage lung cancer and
AH1N1 vaccination in this group of patients.
Materials/Methods: We present a case with advanced NSCLC due to
malignant pleural effusion treated initially with chemotherapy with good
response. An EPP was performed. He had abdominal recurrence from
celomic dissemination. He received treatment with Tarceva with excellent
response.He died 15 months after diagnosis and 7 months after surgical
treatment. His cause of death was respiratory failure secondary to A H1N1
influenza.
Results: Extrapleural pneumonectomy is a controversial treatment for ad-
vanced stage lung cancer. Patients with unilateral malignant pleural effusion
due to lung cancer have been rarely considered for surgical treatment. EPP
has shown to have a survival advantage in carefully selected patients with
celomic dissemination of disease, when N2 nodes are negative for metastasis.
The Influenza A H1N1 virus was classified in April 2009 as a public health
event of international concern by the World Health Organization, and by
August 2009 de CDC	s Advisory Committee on Immunization Practices
(ACIP) issued recommendations regarding the use of vaccine against infec-
tion with novel influenza A (H1N1) virus. These publications recommended
vaccinating five target groups. First, persons aged 25-64 years who have
medical conditions that put them at higher risk for influenza-related compli-
cations. The medical conditions that confer a higher risk for influenza-related
complications include chronic pulmonary (including asthmas), cardiovascu-
lar (except hypertensio´n), renal, hepatic, cognitive, neurologic/neuromuscu-
lar, hematologic or metabolic (including diabetes mellitus) and immunosu-
pression (including immunosuppresion caused by medications of by human
immunodeficiency virus).
Conclusions: Vaccination against AH1N1 influenza has major impact if it is
used like preventive strategy. Its greater utility is the protection focused in
groups of higher risk. Due to the special conditions presented in post-EPP
patients, they could be included in one of this target groups.
Author Disclosure Block: I. Carranza-Martı´nez: None. L.A. Martin-del-
Campo: None. P. Santillan-Doherty: None. J.C. Jacinto-Tinajero: None.
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Immunohistochemical Detection of Ercc1 and Class III -tubu-
lin in 54 Malignant Pleural Mesotheliomas Treated With Cis-
platin and Vinorelbine: Association With Treatment Response
and Survival.
Z. G. Zimling, C. Bech, J. B. Sørensen, E. Santoni-Rugiu, Univeristy hospital
of Copenhagen, Copenhagen, Denmark
Purpose/Objective(s): DNA repair mechanisms are involved in the resis-
tance to platinum-based chemotherapy by removing platinum-induced cross-
links in the DNA strands. Excision repair cross-complementation group 1
enzyme (ERCC1) plays a rate-limiting step in this process. Several studies
have linked ERCC1 expression to cisplatin resistance in different cancers.
Overexpression of class III -tubulin, which is insensitive to the suppression
of microtubule dynamics induced by tubulin-binding agents, apparently leads
to a resistant phenotype, as it has been proposed for some of the major
cancers. Few data exist, though, regarding the baseline expression of these
biomarkers in MPM and their association with outcome. We correlated
ERCC1 and class III -tubulin expression with clinical outcome in malignant
pleural mesotheliomas (MPMs) treated with cisplatin and vinorelbine.
Materials/Methods: Fifty-four consecutive patients were enrolled between
February 2003 and September 2006 into a phase II trial with cisplatin and
vinorelbine. Formalin-fixed paraffin-embedded bioptic tumor specimens
from these patients were retrospectively evaluated for ERCC1 and class III
-tubulin expression by immunohistochemistry (IHC) using an H-score
(staining intensity multiplied by a proportion score based on the percentage
of positive tumor cells). The cut-off point was a priori chosen as the median
value of the H-scores to separate positive (H-score  median) from negative
(H-score  median) tumors.
Results: Fifty patients had enough tumor tissue for IHC. For ERCC1 the
median H-score was 2, yielding 20 positive and 30 negative tumors. For class
III -tubulin the median H-score was 2, resulting in 10 positive and 40
negative tumors. There was no significant difference in overall survival (OS)
between positive and negative tumors for either marker. Median time to
progression (TTP) in the ERCC1-positive and -negative population was 28
and 47 weeks respectively (p0.053). No difference in TTP was seen
between class III -tubulin-positive and -negative tumors. A multivariate
analysis of TTP using Cox proportional hazard model yielded ERCC1 as the
only significant variable in a model containing age, stage, histology and sex
(p0,003). There was a significant interaction between male sex and ERCC1
status. The hazard ratio for progression for an ERCC1-positive male was 2.8
(95% CI: 1.4 - 5.7).
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Conclusion: Immunohistochemical determination of ERCC1 status pre-
dicted the response to cisplatin-based chemotherapy among males with MPM
in this phase II trial.
Author Disclosure Block: Z.G. Zimling: None. C. Bech: None. J.B.
Sørensen: None. E. Santoni-Rugiu: None.
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In Vitro Efficacy of Bcl-2/bcl-xl Family Inhibitor Abt-737 and
Docetaxel in a Bcl-xl-expressing Human Malignant Pleural Me-
sothelioma Cell
X. Liu, W. Qi, D. Mahadavan, L. L. Garland, Arizona Cancer Center,
Tucson, AZ
Purpose/Objective(s): Bcl-XL, a member of the Bcl family of pro-apoptotic
proteins, is highly expressed in malignant pleural mesothelioma (MPM); this
expression is thought to contribute to the chemotherapy-resistant nature of
MPM. ABT-737 (Abbott Laboratories, Abbott Park, IL) is a BH3 mimetic
which antagonizes Bcl-2/Bcl-xl. We hypothesized that there would be a
favorable interaction between ABT-737  docetaxel (DOC), a chemother-
apeutic agent with apoptosis-inducing properties, in a Bcl-XL-expressing
MPM cell line.
Materials/Methods: The cytotoxic effect of ABT-737 alone and in combi-
nation with DOC was evaluated in vitro in the human REN MPM cell line
(gifted by Joseph Testa) using the MTS assay. We used flow cytometry to
measure % apoptosis by Annexin V and Western blotting to measure
expression of Bcl-XL and Mcl-1 protein (associated with resistance to
ABT-737) with ABT-737, DOC or combinations.
Results: The IC50 for single agent ABT-737 was 36 M and the IC50 for
single agent DOC was 0.01 M. With the addition of ABT-737 to fixed dose
DOC 0.005 M, the ABT-737 IC50 was reduced to 0.8 M. Consistent with
these data, increasing doses of ABT-737 (0.5-10 M) with DOC 0.005 M
increased the apoptotic fraction 2-3 fold over single agent ABT-737 or DOC
alone. Increasing concentrations of ABT-737 from 2-10 M with fixed dose
DOC 0.005 M resulted in a decrease in Bcl-XL expression in a dose-
dependent manner but there was no significant decrease in Mcl-1 expression
over DOC alone.
Conclusion: Low dose DOC enhanced the antitumor activity of ABT-737 in
the REN human MPM cell line. The antitumor activity of the ABT-737 
DOC induced apoptosis to a greater degree than either single agent, and the
reduction of Bcl-XL expression by ABT-737  DOC suggests a mechanism
by which the combination induces apoptosis. These data provide a rationale
for further preclinical study of ABT-737  DOC as a novel therapy for
Bcl-XL-expressing MPM.
Author Disclosure Block: X. Liu, None; W. Qi, None; D. Mahadavan,
None; L.L. Garland, None.
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Esophageal Cancer Secular Trends in U.S., 1975-2006
M. TenNapel, University of Iowa Hospitals and Clinics, Iowa City, IA
Purpose/Objective(s): Esophageal cancer is an aggressive disease with
dismal outcome. Over the past 30 years there has been a dramatic shift in the
histological and racial trends of esophageal cancer. Identification of these
trends through descriptive epidemiology can aid in hypothesis generation to
discover the reasons for the shift.
Materials/Methods: SEER*Stat 6.6.2 was accessed to identify trends in
esophageal cancer from 1975-2006. For incidence and mortality statistics the
following 9 SEER registries were used: San Francisco-Oakland, Connecticut,
Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah and Atlanta. Chi-square
tests were performed on rate ratios for 10 year increments to determine
statistically significant increases or decreases in incidence.
Results: Comparing incremental ten-year periods 1985-94 to 1975-84 and
1995-2004 there was significant increase in the incidence of esophageal
adenocarcinoma (EA) in white males and females (p0.01 for all). Incidence
in black males did not see a significant increase from 1975-84 to 1985-94
(p0.06) but did see a significant increase from 1985-94 to 1995-04
(p0.02). Incidence in black females did not see any significant increase
(p0.11 and p0.12 respectfully). Using the same comparison time incre-
ments for esophageal squamous cell carcinoma (ESCC) there was a decrease
in incidence in white males (p0.01 for both increments), as well as black
males (p0.01 for both increments). No decrease in white or black women
was seen from 1975-84 to 85-94 (p0.21and p.69 respectfully) but there
was decrease from 1985-94 to 95-04 (p0.01 for both). In the late 70’s
squamous cell carcinoma in black males comprised a majority of the
esophageal cancer cases. Over time adenocarcinoma of the distal esophagus
in white males has risen exponentially. Overall, this study shows that the
incidence of EA has surpassed the rate of ESCC since 1997 and the gap is
continuing to increase. The most dramatic increase in location of EA for
white males and females was seen in the lower esophagus (all p0.01 for
both sex and time increments). The rise of lower EA within the white
population corresponds to the increase in ambulatory care visits and hospital
discharge rates for gastrointestinal esophageal reflux disease (GERD).
Conclusion: Trends in histology, race and location for esophageal cancer
have changed dramatically over the past 30 years. This study shows the
alarming increase of adenocarcinoma mainly in white males. Rate of squa-
mous cell cancer is decreasing with the most dramatic change in black males.
Rates of GERD are similar between white males and black males; however
rates of Barrett’s esophagus and EA are markedly different. Further inves-
tigation and clinical studies of these differences will help to better understand
esophageal cancer, identify its risk factors, and decrease mortality.
Author Disclosure Block: M. TenNapel: None.
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Optimizing Locoregional Control in Unresected Pleural Me-
sothelioma and Avoiding Major Toxicity with High Dose
Hemithoracic Intensity-Modulated Radiotherapy
M. Feigen, C. Lawford, M. Lawlor, K. Churcher, M. Wada, D. Lim Joon,
C. Hamilton, Austin Health, Heidelberg W 3081, Australia
Purpose/Objective(s): Management guidelines for patients with pleural
mesothelioma recommend trimodality therapy comprising surgical resection,
chemotherapy and postoperative radiotherapy for better outcomes. Ex-
trapleural pneumonectomy produces the most complete cytoreduction but
has a high risk of significant morbidity and requires hemithoracic radiother-
apy to minimize locoregional recurrence. However, this operation has fallen
out of favor and most patients undergo less radical procedures such as
pleurectomy/decortication (P/D) or pleurodesis. These patients are rarely
offered radiotherapy and almost all will suffer severe symptoms from
recurrences within the affected hemithorax.
Materials/Methods: We attempted to develop a technique based on ad-
vances in radiotherapy technologies to safely irradiate incompletely-resected
patients whose mesothelioma was confined to one hemithorax. Patients were
planned to undergo 3D-conformal radiotherapy by co-registration of 18F-
FDG PET scans with CT scans at simulation, to define the target volume and
boost selected regions of gross disease while respecting normal tissue
tolerances. Follow-up PET scans were analyzed to assess patterns of failure
and residual total glycolytic volumes.
Results: Between 2003 and 2010, thirty five patients with incompletely-
resected mesotheliomas were treated with radiation doses up to 60 Gy using
progressively more advanced technologies. No significant toxicities were
encountered as we increased the planning treatment volumes from 3000 to
9500 ccs, introducing intensity-modulated radiotherapy (IMRT) in 2006.
There are now nineteen patients who have received IMRT, in 16 cases to the
entire hemithorax. All had residual disease, six after P/D and eight after
pleurodesis alone. Two had only biopsies. Sixteen had progressed following
chemotherapy and three had no prior chemotherapy. Of the thirteen followed
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for over 4 months post-IMRT (median 7.8 months, range 4.7-35.6 months),
five have died from mesothelioma, one died of another malignancy and seven
remain alive, three of whom are disease-free. Based on follow-up PET/CT
scan analysis, only two patients have relapsed within the volume irradiated
above 40 Gy. There were no grade 4-5 radiation toxicities.
Conclusions: High dose IMRT using modern technologies can be safely
delivered to selected patients following suboptimal surgery and chemother-
apy. Toxicities are manageable and locoregional control is substantial.
Hemithoracic radiotherapy can be recommended for most mesothelioma
patients to achieve long term palliation and optimize locoregional control.
Author Disclosure Block: M. Feigen: None. C. Lawford: None. M.
Lawlor: None. K. Churcher: None. M. Wada: None. D. Lim Joon: None.
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Frameless 4DCT-Guided Stereotactic Body Radiotherapy With
Daily Image Guidance for Oligometastatic Pulmonary Disease:
Clinical Outcomes
D. Kim, S. K. Nath, A. P. Sandhu, A. Bharne, J. D. Lawson, M. Fuster, L.
Bazhenova, W. Read, W. Y. Song, A. J. Mundt, UCSD School of Medicine,
La Jolla, CA
Purpose/Objective(s): Oligometastatic lung cancer is potentially curable.
Stereotactic Body Radiotherapy (SBRT) has been shown to offer impressive
local control rates for metastatic pulmonary tumors. There are limited reports
using frameless systems and we report clinical outcomes utilizing such a
technique.
Materials/Methods: Twenty-one patients (pts) (33 lesions) with metastatic
pulmonary tumors (5 head and neck carcinoma, 5 colorectal, 4 sarcoma, 3
skin, 2 breast, 1 lung, 1 uterus) were treated between 2007 and 2009 with
SBRT without a body frame. Median patient age was 61 years (range,
42-79). Median lesion number was 2 (range 1-9, 4 patients with 4 lesions).
Average tumor size was 1.5 cm (range, 0.3-4.6 cm), and 73% of lesions were
located in the periphery according to the RTOG 0236 protocol definition.
Prescription doses ranged between 40-50 Gy in 3-5 biweekly fractions.
Patients were planned using a 4DCT acquisition protocol and daily image
guidance was performed using orthogonal kV-imaging (all pts) and cone-
beam computed tomography (CBCT) (17 pts). Follow-up occurred every 2-3
months and consisted of a clinical exam and imaging. Local control (LC),
progression-free survival (PFS), and overall survival (OS) were calculated
using the Kaplan-Meier method. Toxicity was graded by the Common
Toxicity Criteria version 3.0.
Results: At a median follow-up of 20.1 months (range 5.2-36.2 months), 14
pts were living. The 12 and 24 mo actuarial OS rates were 81% (95%
confidence interval [C.I.], 64-98%) and 59% (95% CI, 35-84%), respec-
tively. Of the 21 patients, 15 (76%) did not show evidence of local
progression. Actuarial 12 and 24 mo LC rates for patients were 80% (95%
CI, 62-98%) and 71% (95% CI, 43-100%), respectively. Actuarial 12 and 24
mo LC rates for tumors were 88% (95% CI, 77-99%) and 76% (95% CI,
59-92%), respectively. Actuarial progression-free survival at 12 and 24 mo
were 52% (95% CI, 31-74%) and 32% (95% CI, 9-55%), respectively. There
was a statistically significant correlation between longer OS and PFS of
greater than six months (Cox regression, p0.027). No statistically signifi-
cant correlations were found between OS or LC and history of chemother-
apy, size of tumor, number of tumors treated, or type of primary tumor.
Grade 3 or higher toxicity occurred in no pts.
Conclusions: Acceptable local control, overall survival, and toxicity rates
can be achieved in oligometastatic pulmonary disease using frameless
4DCT-guided SBRT with daily image-guidance. Toxicity rates were favor-
able compared to other reports. These data are comparable to traditional
SBRT techniques with body frames and support the continued role of this
modality for the management of oligometastatic pulmonary disease.
Author Disclosure Block: D. Kim: None. S.K. Nath: None. A.P. Sandhu:
None. A. Bharne: None. J.D. Lawson: None. M. Fuster: None. L. Bazhe-
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A Phase II Study Of Saracatinib (AZD0530), A Src Inhibitor,
Administered Orally Daily To Patients With Advanced Thymic
Malignancies
H. A. Wakelee1, M. A. Gubens1, M. Burns2, S. L. Barbeau1, S. Perkins2,
M. G. San Pedo-Salcedo1, P. J. Loehrer2, 1Stanford University, Stanford, CA,
2Indiana University, Indianapolis, IN
Purpose/Objective(s): Saracatinib (AZD0530) is an orally bioavailable
small molecule inhibitor of the Src family of tyrosine kinases. Src and its
ligands play a crucial role in thymocyte development and it was postulated
that Src pathway crosstalk with thymic stroma made Src a potential thera-
peutic target in thymic malignancies. The purpose of the study was to
determine the activity of saracatinib in patients with previously treated
advanced thymic malignancies.
Materials/Methods: This was a 2-institution phase II study with a primary
endpoint of overall response rate, with secondary endpoints of toxicity,
progression-free survival (PFS) and overall survival. Patients received sara-
catinib 175 mg orally daily on 28-day cycles until progression or intolerance.
Response was assessed by RECIST criteria every 2 cycles. An additional CT
scan was obtained after cycle 1 to evaluate for pulmonary toxicity. A Simon
2 stage design was used. 13 non-thymic carcinoma (TC) patients were to be
accrued in the first stage and if at least 1 response was seen, 26 more in the
second stage, with 4 responses suggestive of benefit at a power of 90%.
Results: 21 patients were enrolled at 2 institutions over 18 months (14
thymoma and 7 TC). 2 patients were not evaluable due to receiving less than
1 cycle. The age range of enrolled patients was 18-70 (11 males and 10
females). 16 patients were White, 3 were Asian, 1 was African American and
1 was unknown. 1 patient died within 30 days of last treatment due to PD.
1 patient was hospitalized due to pleural effusions that developed on therapy.
Though no pulmonary toxicity was identified on her 1 month CT, effusions
were visible on the 2 month CT and she was symptomatic. She was
discontinued from the trial due to PD and the pleural effusions responded to
local therapy. 1 patient had dyspnea while on therapy and was discontinued
for the SAE, with no evidence of effusion or interstitial infiltrates. There
were no other significant pulmonary toxicities. Grade 3 toxicities were
neutropenia (1), anemia (1) and hypophosphatemia (2). Other toxicities were
grade 1/2. After 13 evaluable thymoma patients were enrolled in the first
stage, no RECIST responses were observed, and so accrual to the study was
halted as pre-specified. 8 patients had stable disease beyond the first assess-
ment at 56 days (range 3-7 cycles, with 3 patients still on therapy). PFS was
3.4 months (95% CI 2.2-5.8) for thymoma patients and 1.4 months (0.8-3.6)
for TC patients. Median survival has not yet been attained with 15/21
patients still alive.
Conclusions: Though fairly well tolerated with no unexpected toxicities
observed, saracatinib does not appear to have efficacy as monotherapy in
advanced thymic malignancies. Updated survival and toxicity data will be
presented.
Author Disclosure Block: H.A. Wakelee: B. Research Grant; Astra Zeneca.
M.A. Gubens: None. M. Burns: None. S.L. Barbeau: None. S. Perkins:
None. M.G. San Pedo-Salcedo: None. P.J. Loehrer: Astra Zeneca.
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Interaction of Protein Kinase Cb and VEGF Receptor in Ma-
lignant Pleural Mesothelioma_Potential for Novel Therapeutic
Target
E. M. El-Hashani, R. Kanteti, M. Nickels, K. Vokes, W. Vigneswaran, H.
Kindler, R. Salgia, University of Chicago, Chicago, Il
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Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that is
largely unresponsive to conventional chemotherapy or radiotherapy and that
may have abnormalities in multiple signaling pathways. The PKC isoform
is a key componet in the vascular endothelial growth factor receptor (VEGF/
VEGFR) signaling cascade and is known to mediate cell proliferation,
differentiation, and apoptosis. Herein, we show that PKCI, PKCII and
VEGFR-2/KDR are overexpressed in 9 MPM cell lines (H2452, H2691,
H2461, H513, H2596, H2373, H28, MSTO, H2052) compared to normal
mesothelial cells (MeT-5A). We also observed similar dramatic increases in
tumor tissues (42 tumor samples of malignant pleural mesothelioma (MPM)
including 29 epithelioid (69%), 9 sarcomatoid (21%), 1 biphasic/mixed
(2.5%), 1 desmoplastic (2.5%), and 2 well differentiated papillary mesothe-
liomas (5%)) as compared to the surrounding normal tissues. A PKC
inhibitor, blocked angiogenesis and cell migration in H2461 cells. Alone or
in combination with KRN633 (a selective inhibitor of VEGFR-2 tyrosine
kinase) suppressed VEGF induced proliferation in 9 mesothelioma lines
including H2461 cells but not in H2373 and MeT-5A cells and the combi-
natorial effect of the two drugs was additive. This was characterized by
PKC-inhibition mediated reduction in VEGF induced tyrosine, serine and
threonine phosphorylation in H2461 epithelioid mesothelioma cells. Also,
phosphorylation of VEGR-2/KDR, p-PKCII and p-AKT (S473) was de-
creased. C. elegans, the common soil nematode expresses both PKC and
VEGFR orthologue KDR ubiquitously in the similar compartments. We have
shown that the phenotype of C. elegans is altered with asbestos fiber
exposure. As a proof of principle, we utilized transgenic C. elegans, express-
ing the wild type PKC fused with a GFP reporter gene, and showed that
treatment with PKC-inhibition resulted in significant inhibition of the ex-
pressed transgene demonstrating that C. elegans can be used as a valuable
multicellular model organism that is amenable to high throughput screening
of drugs that target VEGFR/ PKC and future drug discoveries.
Author Disclosure Block: E.M. El-hashani, None; R. Kanteti, None; M.
Nickels, None; K. Vokes, None; W. Vigneswaran, None; H. Kindler,
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Lung Volume Improvement for Malignant Pleural Mesotheli-
oma Patients Persists Months After Pleurectomy/Decortication
W. F. Sensakovic, S. G. Armato, A. Starkey, H. L. Kindler, W. T. Vigneswa-
ran, The University of Chicago, Chicago, IL
Purpose/Objective(s): Malignant pleural mesothelioma (MPM) is a neo-
plasm that presents in computed tomography (CT) scans as a rind of pleural
thickening growing about the lung parenchyma with or without concurrent
effusion. Mechanical restriction of the lung parenchyma by the tumor rind
and concurrent effusion (i.e., trapped lung) can reduce lung function. Pleu-
rectomy/decortication (P/D) is a surgical procedure that is employed to
debulk tumor, free the lung, and improve respiratory mechanics. This study
investigates whether the increased lung volume due to P/D persists after
surgery.
Materials/Methods: A database of 12 patients demonstrating unilateral
MPM was collected. A helical thoracic CT scan was acquired for each
patient before surgery (median 15 days) and after surgery at one month (n 
12, median 37 days) and four months (n  10; median 144 days) as part of
routine patient follow-up. A computerized segmentation algorithm was
applied to each CT scan to delineate the aerated lung parenchyma. An
observer then reviewed each three-dimensional delineation to ensure seg-
mentation accuracy. The lung volume in each scan was then automatically
calculated from the lung delineations. The ipsilateral lung volume was
normalized to the contralateral lung volume to mitigate measurement error
due to patient inspiration. A Wilcoxon signed-rank test (5% significance)
was applied to determine whether changes in normalized lung volume were
statistically significant between 1) pre-surgical and 1-month post-surgical
and 2) 1-month post-surgical and 4-month post-surgical scans.
Results: The median pre-surgical, normalized ipsilateral lung volume was
0.478. A statistically significant (p  0.027) median change in normalized
ipsilateral lung volume between the pre-surgical scan and 1 month post-
surgical scan of 0.212 (from 0.478 to 0.690) was observed. The median
change in normalized ipsilateral lung volume between the 1 month post-
surgical scan and the 4 month post-surgical scan was 0.044 (range: 0.338
0.189); however, this change was not statistically significant (p 0.322). An
increase in the normalized ipsilateral post-surgical lung volume was ob-
served for 10 of 12 patients (83%) one month after surgery and 8 of 10
patients (80%) four months after surgery. All patients demonstrating in-
creased lung volume one month after surgery continued to demonstrate
increased lung volume four months after surgery.
Conclusions: Debulking of MPM with P/D significantly increased the
ipsilateral lung volume. This improvement persisted months after surgery
indicating that neither surgical scarring nor progression of MPM negated the
beneficial effect of surgical intervention.
Author Disclosure Block: W.F. Sensakovic, None; S.G. Armato, None; A.
Starkey, None; H.L. Kindler, None; W.T. Vigneswaran, None.
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A Phase II Study of VEGF-AS Veglin With Pemetrexed and
Cisplatin, CAV Regimen, in the Treatment of Patients With
Malignant Mesothelioma
S. P. Chawla, C. B. Lazaro, A. Hendifar, R. R. Gupta, R. Rana, R. Nadadur,
P. R.G., V. S. Chua, Sarcoma Oncology Center, Santa Monica, CA
Purpose/Objective(s): Cisplatin(C) and Alimta(A) are the main chemother-
apy drugs for metastatic mesothelioma. An anti-angiogenesis drug, Veglin
(V), was recently developed which works to restrict the growth of tumors by
decreasing the Vascular Endothelial Growth Factor (VEGF) available for
stimulating angiogenesis. Veglin is an antisense oligonucleotide that binds
VEGF mRNA and quickens its degradation. Early trials with the drug have
shown encouraging results, however, effectiveness of combination chemo-
therapy with all three agents remains unknown. Objective: To be able to find
a beneficial therapy regimen for malignant mesothelioma that is, at the same
time, less toxic for the patient.
Materials/Methods: We treated 12 consecutive patients with malignant
pleural mesothelioma, and 2 patients with malignant mesothelioma of the
peritoneum, with Cisplatin, Alimta and Veglin (CAV) at a single center. The
CAV regimen consisted of Cisplatin 75 mg/m2, Pemetrexed 500mg/m2, and
Veglin 100 mg/m2 on day 1 and Veglin only on day 2-5, q 21 days. Efficacy
was assessed by RECIST 1.0 criteria.
Results: Patient characteristics: Male:Female 11:3; median age was 70 years
( range 44-82 years ). Diagnoses included Epithelioid type (4), Sarcomatoid
type (1), Biphasic type (5) with patients having predominantly sarcomatoid
(3) and epithelioid (2), and unclassified (3). Only one patient had prior chemo
with Cisplatinum and Alimta. He progressed with that. The CAV regimen
had a response rate of 64.3% (1 PR, 8 SD). Among these patients, 21.5%
was rendered no evidence of disease (3 CR surgically), and are still being
followed up for 14 months, 24 months and 27 months, respectively. Three
of the subjects were not evaluable. Progression free survival was 6.5
months (range 2-9 months). Over all toxicities were predominantly
nausea, vomiting and fatigue. Hematologic toxicities were tolerable
which included grade III neutropenia (1), grade III anemia (2), and grade
IV thrombocytopenia (1).
Conclusion: The CAV regimen shows potential activity in the patient
population. It is well tolerated by the patients, as well. This regimen merits
further evaluation as a promising therapy for malignant mesothelioma.
Author Disclosure Block: S.P. Chawla: None. C.B. Lazaro: None. A.
Hendifar: None. R.R. Gupta: None. R. Rana: None. R. Nadadur: None.
P. R.g.: None. V.S. Chua: None.
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Radiation Therapy in Thymic Tumors: An Institutional Expe-
rience
S. Mallick, N. Joshi, A. Gandhi, L. M.A., H. K.P., P. Julka, D. Sharma, G.
Rath, All India Institute of Medical Sciences, New Delhi, India
Purpose/Objective(s): Thymic tumors are a rare group of thoracic tumors.
We analyzed & audited our experience of radiation therapy practice in this
subset of thoracic tumors to obtain dose-volume parameters & outcome.
Materials/Methods: We performed a retrospective analysis of our database
from 1999 to 2009. The dose practice schedule, technique and dose-volume
parameters were recorded along with the demographic, surgical and his-
topathological data. Overall survival for the available patients was noted.
Results: 57 cases were analyzed. Age at presentation ranged from 18 to 64
years (median 40 years). The male: female ratio was 3.38. 48 patients
underwent a thymectomy, 1 case each underwent only a biopsy & debulking
surgery. 8 were unresectable. There were 54 cases of thymoma, 2 thymic
carcinoids & 1 atypical carcinoid. The WHO grade for thymomas was: AB-5,
B1-8, B2-14, B3-8, C-1 and not known for 18 cases. The Masaoka stage
distribution was: II-6, III-29, IV-19 and not known for 3 cases. 27 patients
had a paraneoplastic syndrome. Myasthenia gravis was the commonest (25
cases) with hypothyroidism and pure red blood cell aplasia in 1 case each. 50
cases were treated with radical intent & 7 with palliative intent. The dose for
radical therapy ranged from 12.6 to 61 Gy (median 55 Gy). Palliative
radiation was delivered as 20 Gy in 5 fractions. Technique used was 3DCRT
(3 field) in 42 cases and conventional AP-PA portals in 11 with radical intent.
The organ at risk dose-volumes were as follows: lung (V20: range 10.8 to
69.87%, median 31.60%), heart (V40: range 6.84 to 61.32%, median
20.66%), spinal cord (Maximum point dose: range 2.26 to 63.24 Gy, median
20.92 Gy), CTV90 (range 45.69 to 62.93 Gy, median 56.65 Gy) & PTV90
(range 38.59 to 59.71 Gy, median 54.49 Gy). 13 patients had chemotherapy
(adjuvant: 9, neo-adjuvant:3 & palliative:2). The overall survival data was
available for 21 patients (range: 3.2 months to 62.2 months, median: 13.25
months).
Conclusions: Modern radiation therapy practice with 3 dimensional confor-
mal radiation delivery achieves superior target volume coverage with ac-
ceptable organ at risk dose-volume parameters. Survival data analysis is
lacking owing to poor follow up.
Author Disclosure Block: S. Mallick: None. N. Joshi: None. A. Gandhi:
None. L. M.a.: None.H. K.p.: None. P. Julka: None. D. Sharma: None.G.
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Multidisciplinary Approach in Locally Advanced Malignant
Pleural Mesothelioma (mpm). A Ten Years Experience
R. Rollina1, P. Candido1, S. Della Torre1, P. Belloni1, F. Zannier1, D.
Toniolo1, B. Rho1, N. Bellaviti1, P. Aliprandi1, L. Cerizza2, 1G. Salvini
general Hospital, Rho, Italy, 2Varese General Hospital, Radiotherapy de-
partment, Varese, Italy
Purpose/Objective(s): MPM is an uncommon cancer often diagnosed by
recurrent pleural effusion. Aim of study was to prevent the recurrence of
malignant effusion by endopleural treatment in alternative to decortication;
to avoid cutaneous seeding using short-term radiotherapy; to determinate
safety, feasibility and efficacy of chemotherapy related to time to progression
(TTP) and survival time (ST).
Materials/Methods: From January 2000 to May2010 we observed 65
patients (pts) with locally advanced MPM; male/female: 46/19; median age:
70 years (41-88); 56 epithelial, 9 non-epithelial. Diagnosis was obtained by
pleural biopsy by video-assisted thoracoscopy (40), thoracic drainage (19),
fine needle aspiration (6). 45pts underwent pleurodesis by endocavitary
nebulisation of talcum powder, 7pts by pleuro-cath infusion of IL2. Short-
term irradiation on surgical trails was delivered in 47pts (21Gy: 7 Gy/day for
3 days). 26pts were treated with a platinum-based chemotherapy while 39pts
weren’t chemotreated (age75 and/or KPS2). After a local relapse, 18pts
went to a second line chemotherapy and 4pts received a third line chemo-
therapy.
Results: Pleural drainage followed by chemical or immunological pleu-
rodesis allowed an excellent control on recurrent malignant pleural
effusion, and after endocavitary treatment no early relapse ever occurred.
Precautional external short-term RT was always well tolerated without
major complications but a mild local erythema and no cutaneous recur-
rence was ever observed. Of 20/58 pts who performed a first-line
Platinum-based chemotherapy, 17 obtained an objective response
(9RP8SD85%) showing a mTTP of 9.7 mo (range 6-36), while 3 pts
died in early progression with a TTP of 2-4 mo and mST of 5 mo (range
3-6); 6/14 pts were treated with a second line therapy: 2RP and 4 SD
maintained the response rate with a mTTP of 4 mo (range 2-8) and 4 pts
were treated with further chemotherapy (2SD with a mTTP of 4 mo and
2PD). At February 2010, 53/58 pts died with a mST of 13.4 mo (range
5-33), while 2 pts “too early” are now performing the first-line chemo-
therapy (CDDPPEM) and one is ongoing the second line monochemot-
erapy (GEM) for abdominal relapse; 2 pts are alive with stable disease,
respectively at 44 and 52 mo.
Conclusions: chemo/immunopleurodesis is safe and local therapy obtaining
an effect comparable to decortications to ensure the control of symptoms.
Precautional irradiation improves pts’ quality of life and good local control
from cutaneous recurrence. Chemotherapy was feasible and well tolerated,
obtaining good RR (88.4%) although no strong impact on mTTP and mST.
Author Disclosure Block: R. Rollina: None. P. Candido: None. S. Della
Torre: None. P. Belloni: None. F. Zannier: None. D. Toniolo: None. B.
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Does Adding Cetuximab to Chemotherapy in Advanced Non-
small Cell Lung Cancer Improve Overall Survival? Combined
Analysis of Flex And Bms 099 Trials
I. Q. Ma, W. Gao, M. Berbaum, L. E. Feldman, University of Illinois at
Chicago, Chicago, IL
Purpose/Objective(s): There have been two large randomized phase III
studies (FLEX and BMS099) comparing cetuximab plus cytotoxic chemo-
therapy versus chemotherapy alone in advanced non-small cell lung cancer
(NSCLC) with conflicting results regarding overall survival (OS). In FLEX,
the larger study with 1125 patients, the HR for death was 0.871 [95%
confidence interval (CI) 0.762-0.996; p0.044], which was statistically
significant. In BMS099, with 676 patients, the HR for death was 0.89 (95%
CI 0.754-1.051, p0.169), which did not reach statistical significance.
However, the HR of 0.89 from BMS099 indicates a trend towards an OS
benefit. Neither study showed a difference in progression free survival (PFS);
FLEX HR 0.943 (CI 0.825-1.077, p0.39) and BMS 099 HR 0.902 (CI
0.761 to 1.069, p0.236). We sought to investigate whether combining the
data from these studies would support the addition of cetuximab to chemo-
therapy.
Materials/Methods: The Review Manager 5 (RevMan) software is a pro-
gram designed to yield an overall statistic and its confidence interval that
summarizes the effectiveness of an intervention across multiple studies.
BMS099 reported two HR’s for PFS, one assessed by an independent
radiologic review committee (PFS-IRRC) and one assessed by the investi-
gator. We entered the individual data from FLEX and BMS099, including the
number of subjects, HRs for OS and PFS, and CI’s. The HR for PFS from
BMS099 that was utilized in this analysis was the PFS-IRRC, as this was the
defined primary endpoint of the study.
Results: The combined HR for OS from FLEX and BMS099 is 0.87 (95%
CI 0.79-0.97). This result narrows the CI from that found in FLEX alone
supporting the significance of the finding. The combined HR for PFS is 0.92
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(95% CI 0.83-1.03). This result also narrows the CI from that found in the 2
studies alone; however it remains not statistically significant. These results
confirm an OS benefit with cetuximab plus chemotherapy as compared to
chemotherapy alone.
Conclusions: This combined analysis using RevMan 5 statistical software
supports that adding cetuximab to chemotherapy in advanced NSCLC
demonstrates a statistically significant OS advantage. The main reason for
conflicting results regarding OS between FLEX and BMS099 is likely the
difference in the number of patients in each study. The choice of chemo-
therapy doublet may also play some role. Moreover, the absolute HR’s for
OS in both studies are similar and less than 1, therefore results may not truly
conflict but instead be due to BMS099 being underpowered to detect the
apparent 11% reduction in death risk. While the lack of benefit in PFS found
in both studies is unknown, our combined analysis did show narrowing of the
CI suggesting an even larger sample size may be needed to show a PFS
benefit.
Author Disclosure Block: I.Q. Ma, None; W. Gao, None; M. Berbaum,
None; L.E. Feldman, Sanofi-Aventis, D. Speaker’s Bureau/Honoraria; Lilly
Oncology, F. Consulting/Advisory Board.
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Racial Disparities in Stage IV Non-small Cell Lung Cancer
Among the Veteran Population - A Veterans Cancer Registry
(VACCR) Database Analysis
I. A. Al-Howaidi1, L. A. Shatat2, T. Tashi1, M. Almiani1, X. Fang3, W.
Gonsalves1, P. Townley1, P. Silberstein4, A. Ganti5, S. Subbiah4, 1Creighton
University School of Medicine, omaha, NE, 2Creighton University School of
Medicine/ Department of Pathology, omaha, NE, 3Creighton University
School of Medicine/ Department of Biostatistics, omaha, NE, 4Creighton
University School of Medicine/ Department of Oncology, omaha, NE,
5University of Nebraska, omaha, NE
Purpose/Objective(s): Racial disparities in cancer outcomes have been
observed in several malignancies including lung cancer. Access to health
care has been implicated for this discrepancy. Our objective was to determine
whether racial disparities in survival exist among Afro-American (AA) and
Caucasian (CA) patients with stage IV non-small cell lung cancer (NSCLC)
in an equal access health care system.
Materials/Methods: Retrospective analysis of AA and CA patients with
stage IV NSCLC diagnosed from 1997 to 2009 in the Veterans Affairs
Central Cancer Registry was conducted. Age, race, histology, grade, therapy
received were abstracted from the database. Overall survival was estimated
by using log-rank and Kaplan-Meier analysis. Multivariate analysis was
performed using Cox proportions hazards model.
Results: A total of 21,965 patients with stage IV NSCLC were identified. Of
these 19.3% were AA and 79% were CA. Median age for AA was 66 years
(range 33-95 years) while for CA it was 67 years (range 25-96 years). In AA
patients 41% had squamous cell carcinoma (SCC), 49% had adenocarcinoma
(AdenoCA), and 7% had large cell carcinoma (LCC). In CA patients, the
corresponding incidences were 40.7%, 49.4% and 8 % respectively. Overall
survival for AA with NSCLC was 4 months compared to 3.6 mos in CA. AA
patients with AdenoCA had a better median overall survival compared to CA
(4.3 vs. 3.7 months; p0.001). There were no differences identified in
patients with SCC (4.43 vs. 4.23 months; p0.72) or LCC (3.8 vs. 3.1
months; p0.79) AA patients who received radiation (RT) alone (3.5 vs. 3
months; P0.0001) and chemotherapy alone (9.2 vs. 7.8 months; P0.02)
did better than CA. There were however no differences seen among patients
who received RT and chemotherapy (7.5mos vs. 7.5mos; P0.78) or surgery
with chemotherapy (23mos vs. 18mos; P0.46). In Multivariate analysis
age, grade, histology other than AdenoCA was not associated with survival
advantage however AdenoCA, receipt of Chemotherapy and RT alone was
associated with significant difference in survival.
Conclusions: Ethnic differences in outcomes were not identified in patients
with metastatic NSCLC in this equal to access health care system.However
AA patients with AdenoCA had improved survival compared to CA. AA
who received RT or chemotherapy alone had better outcomes compared to
CA.This observation of improved survival in AA patients with Adenoca
should be further explored in a randomized fashion.
Author Disclosure Block: I.A. Al-Howaidi: None. L.A. Shatat: None. T.
Tashi: None. M. Almiani: None. X. Fang: None. W. Gonsalves: None. P.
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Association of Clinical Activity of BMS-690514 With Veristrat®
Classification and EGFR Status in NSCLC
C. Harbison, A. Dongre, J. Chen, Q. Xiao, O. Mokliatchouk, J. Kurland, M.
Salvati, D. Berman, Bristol-Myers Squibb, Princeton, NJ
Purpose/Objective(s): BMS-690514 (514) is an oral, selective EGFR,
HER2, HER4 and VEGFR1-3 inhibitor. This is an analysis of 514 clinical
activity measured in a Ph I/II study of NSCLC patients (CA187-002), using
EGFR status and a protein-profiling-based VeriStrat® (Biodesix®) status
classification algorithm (VSC) as candidate predictive biomarkers of disease
control or PFS.
Materials/Methods: The activity of 514 (200 mg/d) was assessed in erlo-
tinib-naı¨ve and -resistant patients (pts) with advanced, metastatic NSCLC.
Disease control rate (DCR; complete response (CR), partial response (PR)
and stable disease (SD) of  4 months), safety, and candidate predictive
biomarkers (including EGFR mutations (MT), EGFR copy number, and
VSC) were assessed. The VSC algorithm was previously shown to identify
pts that benefit from treatment with anti-EGFR agents. Blinded ‘VSC-Good’
or ‘VSC-Poor’ status was determined from the integrated intensities of eight
distinct m/z features derived from matrix-assisted laser desorption ionization
time-of-flight (MALDI-TOF) mass spectrometric (MS) protein profiling of
plasma samples. Logistic and Cox proportional hazard regression as a
function of biomarker (EGFR or classifier), cohort (erlotinib-resistant or
erlotinib-naive), and biomarker-by-cohort interaction were used to assess the
association between biomarkers and efficacy (DC and PFS), and to define
hazard ratios (HR).
Results: In 61 pts, DCR was 43% (13/30) in erlotinib-naive and 23% (7/31)
in erlotinib-resistant pts. In evaluable subjects, DCR was significantly higher
in pts with MT EGFR (7/10) than with WT EGFR (6/21) (P  0.017 for the
effect in either cohort). Two erlotinib-resistant pts with MT T790M EGFR
had SD (10% and 31% change in tumor burden). PFS was also longer in
pts with MT EGFR status than with WT EGFR (P 0.059, HR 0.29 [0.08,
1.07] and 0.47 [0.15, 1.50] in the erlotinib-naive and -resistant pts, respec-
tively). DCR was higher in pts with high EGFR copy number (10/18) than in
pts with normal EGFR copy number (4/17) (P  0.089). PFS was longer in
high EGFR copy number pts only within the erlotinib-naive arm (P0.029,
HR0.24 [0.09, 0.070] and 1.48 [0.51, 4.34] in the erlotinib-naive and
-resistant groups, respectively). VSC status was available for 52 pts (36
VSC-Good and 16 VSC-Poor). All EGFR MT subjects were classified as
VSC-Good. PFS was longer in pts in the VSC-Good group (P0.011, HR 
0.23 [0.09, 0.58] and 0.64 [0.25, 1.67] in the erlotinib-naive and -resistant
groups, respectively).
Conclusions: 514 showed activity in erlotinib-naı¨ve and -resistant NSCLC
patients. EGFR mutation, high EGFR copy number, and ‘VS-Good’ status
may each identify pts expected to have enhanced benefit when treated with
BMS-690514. A randomized phase II study of 514 versus erlotinib in
NSCLC is underway.
Author Disclosure Block: C. Harbison: A. Employment; Bristol-Myers
Squibb. A. Dongre: Bristol-Myers Squibb. J. Chen: Bristol-Myers Squibb.
Q. Xiao: Bristol-Myers Squibb. O. Mokliatchouk: Bristol-Myers Squibb. J.
Kurland: Bristol-Myers Squibb. M. Salvati: Bristol-Myers Squibb. D.
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Psorinum Therapy in Treating Patients With Advanced Non-
small Cell Lung Carcinoma (NSCLC): A Phase-II Single Arm
Clinical Trial
A. Chatterjee1, J. Biswas2, A. Chatterjee1, S. Bhattacharya2, A.
Chakraborty3, R. Mukherjee1, R. Bhakta1, S. Das1, 1Critical Cancer Man-
agement Research Centre & Clinic, Calcutta, India, 2Chittaranjan National
Cancer Institute, Calcutta, India, 3R G Kar Medical College, Calcutta, India
Purpose/Objective(s): We prospectively studied the clinical efficacy of an
alternative cancer treatment “psorinum therapy” in patients with advanced
non-small cell lung carcinoma (NSCLC).
Materials/Methods: Our study was phase II, open- level, single arm, and
single stage. Participants’ eligibility criteria included (1) histopathological or
cytopathological confirmation of NSCLC; (2) inoperable; (3) no prior che-
motherapy or radiation therapy; (4) Karnofsky performance status between
40 and 70. The primary outcome measures of the study were (1) to assess the
radiological tumor response rates (using CT scan procedure and following
the RECIST criteria); (2) to assess how many participants survived at least
1 yr, 2 yrs, 3 yrs, 4 yrs, and finally, after 5 yrs of the study. The secondary
outcome measure was to assess the side effects of the investigational
anticancer drug (psorinum) if any. The drug psorinum (an alcoholic extract
of scabies,slough, and pus cells) was administered orally at 0.02ml/Kg body
weight/day as a single dose in empty stomach and ongoing for complete
course duration of 2 years to all the participants along with allopathic and
homeopathic supportive cares.
Results: 95 participants included in the final analysis at the end of the study.
According to the AJCC TNM staging system, 58 (61.05%) of them diag-
nosed at stage IV. According to the RECIST criteria, complete tumor
response occurred in 19 (20%) cases and partial tumor response occurred in
28 (29.47%) cases. 82 (86.32%) of them survived at least 1 yr, 70 (73.68%)
survived at least 2 yrs, 58 (61.05%) survived at least 3 yrs, 49 (51.58%)
survived at least 4 yrs, and 42 (44.21%) of them survived at least 5 yrs. These
participants did not receive chemotherapy, radiation therapy, or any other
investigational cancer treatments. Participants reported no side effects from
the drug psorinum.
Conclusions: The results of this study show clinical efficacy of psorinum
therapy in treating patients with advanced NSCLC. The investigational drug
psorinum does not have any adverse side effects. Randomized double-
blinded clinical trial should be conducted for further investigation of this
alternative cancer therapy in treating NSCLC.
Author Disclosure Block: A. Chatterjee: None. J. Biswas: None. A.
Chatterjee: None. S. Bhattacharya: None. A. Chakraborty: None. R.
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EML4-ALK Translocation in Lung Cancer: An Institutional
Clinical Experience
E. M. Bertino, W. Zhao, M. Villalona-Calero, G. A. Otterson, The Ohio State
Univ Medical Center, Columbus, OH
Anaplastic lymphoma kinase (ALK) gene rearrangement and oncogene
fusion is a novel carcinogenic molecular change recently described in lung
cancer. It is relatively uncommon, reported in only 1-6% of screened patients
(pts) and it has been associated with never or light smoking history, male sex,
absence of EGFR or KRAS mutation, and adenocarcinoma histology. ALK-
targeted therapy is an area of ongoing study. The experience with EML4-
ALK positive lung cancer pts at Ohio State University Medical Center is
described in this abstract. Screening for EML4-ALK translocation by FISH
has become standard for patients (pts) with non-squamous non-small cell
lung cancer (NSCLC) with negative EGFR or KRAS mutations. Of 120
screened pts over 8 months, 19 pts (16%) are positive (11 men, 8 women)
with a median age of 59 yrs. Most pts are never or light smokers (7 pts never
smokers, 5 light smokers). Seventeen pts have metastatic disease: 14 pts
lung/pleural, 5 pts brain, 2 pts bone, and 2 pts liver. Adenocarcinoma is the
most common histology (14 pts); however 3 pts have adenosquamous
histology, 1 pt has squamous cell, and 1 pt has small cell carcinoma. Average
survival is 29.4 months from diagnosis; 5 patients have survived more than
5 years (61-81 months) with metastatic disease. The ALK translocation has
been linked to therapeutic endpoints. Compared to EGFR and KRAS wild-
type, ALK positive patients in prior studies had similar response to platinum
based therapy and no difference in overall survival. ALK positive patients
are generally resistant to EGFR-directed tyrosine kinase therapy. ALK-
targeted therapies are also under development and promising data has
emerged from early phase testing. At OSU, 18 pts received platinum-based
chemotherapy, 8 pts received erlotinib, and 9 pts received pemetrexed. Three
pts had prolonged response to single agent pemetrexed (13- 36 cycles) and
1 pt had prolonged response to single agent weekly paclitaxel (37 cycles).
Two pts are enrolled on clinical trials of ALK targeted therapy. EML4-ALK
is emerging as an important therapeutic target for a subpopulation of lung
cancer pts. Our single institution experience is comparable to previously
published reports but also raises several clinical questions. Screening should
include all adenocarcinoma variants, including adenosquamous. Consider-
ation should also be given to ALK in SCLC. Moreover, the role of
pemetrexed chemotherapy deserves further investigation given our experi-
ence of benefit for ALK positive pts.
Author Disclosure Block: E.M. Bertino, None; W. Zhao, None; M.
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Treatment Patterns, Medical Resource Use and Costs Associ-
ated with Second-Line Treatment of Non-small Cell Lung Can-
cer
M. S. Walker1, G. M. Pohl2, G. Peltz2, E. J. Stepanski1, D. Faries2, M. D.
Marciniak2, L. S. Schwartzberg3, 1ACORN Research, LLC, Memphis, TN,
2Eli Lilly and Company, Indianapolis, IN, 3The West Clinic, Memphis, TN
Purpose/Objective(s): Docetaxel and pemetrexed are both approved by the
US Food and Drug Administration for second-line treatment of non-small
cell lung cancer (NSCLC). Numerous studies have reported clinical results
for pemetrexed and docetaxel treatment in the second-line NSCLC setting.
However, studies reporting the costs associated with these therapies are
limited. The objectives of this study were to compare treatment costs and
patterns, supportive medication use, and hospitalization rates for second-line
chemotherapy utilizing either pemetrexed or docetaxel monotherapy in
patients with advanced NSCLC.
Materials/Methods: Patients with Stage IIIB or IV NSCLC, treated with
either pemetrexed or docetaxel after 01 January 2004, were identified from
approximately 10 community oncology practices affiliated with ACORN
Research. Eligible patients were selected through a structured query lan-
guage analysis of demographic, diagnostic, and treatment data available
electronically from the ACORN data warehouse. Total costs were estimated
using diagnosis-related group codes plus Medicare reimbursement rates and
fees. Treatment group comparisons were calculated using a propensity score
regression model that adjusted for socio-demographic, baseline medical, and
treatment history variables.
Results: Of 1085 patients screened, 349 patients (n222, pemetrexed;
n127, docetaxel) were eligible for analysis. More pemetrexed patients had
Stage IV disease, a longer duration (180 days) between first- and second-
line therapies, and a greater use of carboplatinpaclitaxel as first-line
therapy. Propensity score analysis normalized baseline factors. Mean total
treatment costs were statistically significantly greater for pemetrexed com-
pared to docetaxel ($20,293 versus $14,121; P0.001). Component analysis
showed that both the cost of drug and the cost of hospitalization were
statistically significantly greater for pemetrexed than for docetaxel ($12,257
versus $5,862; P0.001; $3,547 versus $1,212; P0.02, respectively).
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Conclusions: The costs of chemotherapy agent and patient hospitalizations
were the major factors associated with the higher total costs for pemetrexed
therapy compared to docetaxel therapy in second-line treatment of patients
with NSCLC. The study design did not assess the impact of clinical efficacy
results in the analysis.
Author Disclosure Block: M.S. Walker: None. G.M. Pohl: A. Employ-
ment; Eli Lilly. G. Peltz: Eli Lilly. E.J. Stepanski: None. D. Faries: Eli
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EMT (Epithelial to Mesenchymal Transition) Markers and Re-
sponse to Erlotinib in Patients With Advanced Non-small Cell
Lung Cancer (NSCLC)
E. Braun1, M. J. Fidler1, N. Shah1, K. A. Kaiser1, S. Basu1, H. Harasty1, J.
Coon1, M. Pool1, T. Hensing2, P. D. Bonomi1, 1Rush University Medical
Center, Chicago, IL, 2Northshore University Health System, Evanston, IL
Purpose/Objective(s): The EMT pathway has been implicated in oncogen-
esis and resistance to EGFR tyrosine kinase inhibition in NSCLC. The
purpose of this study was to evaluate association between EMT molecular
markers and survival in patients (pts) with advanced NSCLC treated with
erlotinib.
Materials/Methods: Retrospective study utilizing Rush University Medical
Center and Northshore University Health System database. The study in-
cluded patients with diagnosis of advanced NSCLC, treated with erlotinib
and with adequate tissue specimens for performance of molecular analysis,
independently of prior chemotherapy regimens. E-cadherin (Santa Cruz
Biotechnology, G-10) and Vimentin (Dako, Clone V9) expression were
analyzed by immunohistochemistry (IHC). The IHC was performed using
the Ventana Benchmark automated staining system with the iView DAB
detection chemistry. Expression was scored semi-quantitatively for fre-
quency (0-4) and intensity (0-4). Single strand conformational polymorphism
method was used to detect EGFR mutations (exon 19 and 21) and FISH
analysis was used for EGFR amplification analysis. Outcomes measures such
as progression free survival (PFS) and overall survival (OS) were analyzed
in pts EGFR wild type and pts with EGFR mutation.
Results: 144 pts had interpretable results for E-cadherine (E-cad) and 145
patients had interpretable results for vimentin (VIM). E-cad negative patients
(E-cad frequency 1) had median PFS of 1.8 months as compared to E-cad
positive patients (E-cad frequency 1) that had PFS of 2.4 months
(p0.009) while OS was 2.9 vs. 6.6 months (p0.0009) for E-cad positive
and E-cad negative patients, respectively. When those results were stratified
according to EGFR mutation status pts E-cad negative and EGFR wild type
had median OS of 2.6 months as compared to E-cad positive patients with
wild type EGFR that had OS of 6.2 months (p0.026). VIM positive patients
(vim frequency 0) had median PFS of 1.6 months vs. 2.3 months in the
VIM negative group p0.003). There was no statistically significant differ-
ence in OS between VIM positive and VIM negative patients. We did not
obtain statistically significant difference in PFS and OS between VIM
positive and VIM negative patients once patients with mutated EGFR were
excluded from analysis.
Conclusions: Our results suggested improved survival in NSCLC patients
with increased E-cad expression by IHC treated with erlotinib. These results
suggest E-cad expression could be used as predictor of response to erlotinib
in patients with advanced NSCLC and wild type EGFR but further studies
are warranted to validate the findings.
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Bureau/Honoraria; Genentech. ; F. Consulting/Advisory Board; Genentech.
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Palliative Lung Radiotherapy: Third International Consensus
Workshop on Palliative Radiotherapy and Symptom Control
G. Rodrigues1, F. Macbeth2, B. Burmeister3, K. Kelly4, A. Bezjak5, C.
Langer6, C. Hahn7, B. Movsas8, 1London Health Sciences Centre, London,
ON, Canada, 2National Institute for Health and Clinical Excellence, Cardiff,
United Kingdom, 3Princess Alexandra Hospital, Brisbane, Australia, 4Koo-
tenai Cancer Center, Coeur d’Alene, ID, 5Princess Margaret Hospital,
Toronto, ON, Canada, 6University of Pennsylvania, Philadelphia, PA, 7Duke
University, Raleigh, NC, 8Henry Ford Hospital, Detroit, MI
Purpose/Objective(s): The purpose of this work is to disseminate a consen-
sus statement and survey results created in conjunction with the Third
International Lung Cancer (LC) Consensus Workshop which will be con-
ducted at the upcoming 2010 ASTRO meeting.
Materials/Methods: The palliative lung RT workshop committee agreed on
five questions relating to (1) patient selection, (2) thoracic external beam
(XRT) fractionation, (3) endobronchial brachytherapy (EBB), (4) concurrent
chemotherapy (CC), and (5) palliative endpoint definitions to focus on for the
2010 consensus statement. To assess criteria for palliative RT, a PubMed
search (1966 to March 2010) for primary and cross-referenced practice
guidelines, consensus statements, meta-analyses, and/or systematic reviews
was conducted. A narrative summary, consensus statements, and an interna-
tional practice survey (based on the five workshop questions) were created
after review and discussion of the available evidence.
Results: The following eight summary statements reflect the consensus of
the international working group based on current evidence in the medical
literature. 1. Key factors involved in the decision to deliver palliative RT
include performance status, tumor stage, pulmonary function, XRT volume,
symptomatology, weight loss, and patient preference. 2-4. Palliative thoracic
XRT is generally indicated for stage IV patients with current/impending
symptoms and stage III patients treated for palliative intent. Higher dose
fractionation RT schedules should be considered for good performance status
patients. When the primary treatment aim is relief of symptoms, shorter
fractionation schedules are appropriate. 5-6. There is no evidence to routinely
recommend EBB alone or in conjunction with other palliative maneuvers in
the initial palliative management of endobronchial obstruction due to LC;
however, EBB is a reasonable option in the management of a patient with
relapsed endobronchial obstruction. 7. There is currently a lack of evidence
to routinely recommend CC concomittantly with palliative-intent RT. 8.
Standard assessment of symptoms and health-related quality-of-life using
validated questionnaires should be utilized for outcome assessment in pal-
liative RT LC trials.
Conclusions: An updated consensus statement and narrative summary have
been prepared and will be presented for discussion. In addition, the interna-
tional practice survey is currently under analysis and results will be available
in the fall of 2010.
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Efficacy and Toxicity of Whole Brain Radiotherapy plus Simul-
taneous Image Guided Intensity Modulation Radiotherapy
Boost for Brain Metastases of NSCLC
L. Zhou1, J. Liu2, Y. Gong1, R. Liu1, B. Zou1, S. Bai3, J. Xiao3, T. Li3, M.
Huang1, Y. Lu1, 1Department of Thoracic Cancer, Cancer Center, West
China Hospital of Sichuan University, Cheng Du, China, 2Department of
Oncology, Cheng Du First People’s Hospital, Cheng Du, China, 3Depart-
ment of Physics, Cancer Center, West China Hospital of Sichuan University,
Cheng Du, China
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Purpose/Objective(s): To evaluate efficacy and toxicity of whole brain
radiotherapy (WBRT) plus simultaneous image guided intensity modulation
radiotherapy (IG-IMRT) boost for brain metastases of NSCLC not amenable
to surgery.
Materials/Methods: During June 2006 and April 2009, 29 non-small cell
lung cancer (NSCLC) patients with 87 brain metastases were included in this
prospective Phase II trial. All patients received WBRT at a dose of 40Gy/
20f/4weeks. 27 patients with metastases 6 received IG-IMRT boost at a
dose of 20Gy/5f concurrent with WBRT in the fourth week; 2 patients with
metastases 10 received IG-IMRT boost at a dose of 24Gy/8f, and whole
metastases were separated into two parts according to their location in right
or left half of brain, each part of metastases received IG-IMRT boost each
other day from the beginning of WBRT. All patients were immobilized in
non-invasive thermoplastic head masks (Med-Tec, U.S.A) and treated by
Synergy linear accelerator (Elekta, Sweden) with 6MV X-ray.
Results: After a median follow-up of 9 months, the objective response rate
(CR plus PR rate) was 69% (20/29), median progression-free survival was 10
months (95%CI: 5-14), median survival was 10 months (95% CI: 6-14),
six-month and one-year survival rates were 65.5% and 38.8%. Univariate
analysis revealed that adverse prognostic factors were male, uncontrolled
primary tumor, non-adenocarcinoma, intracranial lesions 3, maximum
lesion volume 3cc and total volume of lesions 10cc. 13 patients died due
to extracranial failure and 7 patients died due to intracranial failure. Patients
with intracranial lesions 3 (54.5% VS. 11.1%, p0.043), maximum lesion
volume 3cc (50% VS. 0%, p0.032) and total volume of lesions 10cc
(66.7% VS. 9.1%, p0.007) had higher rates of death due to intracranial
failure. CTC grade 1 and 2 radiation leukoencephalopathy were observed in
19 (65.5%) and 6 (20.7%) patients, grade 1 to 3 cognitive impairment were
observed in 6 (20.7%) , 3 (10.3%) and 3 (10.3%) patients. Rates of grade 2-3
cognitive impairment were higher in female (44.4% VS. 10%, p0.034), age
60 (38.5% VS. 6.3%, p0.033) patients and patients received EGFR-TKI
therapy (45.5% VS. 5.6%, p0.01). In combination with survival analysis
stated above, the higher rates of late toxicity in female patients and patients
received EGFR-TKI therapy (almost was adenocarcinoma) might be on
account of the longer survival of these patients.
Conclusions: WBRT plus simultaneous IG-IMRT boost is an effective and
safe treatment for brain metastases of NSCLC, especially for patients with
number of lesions 3, maximum lesion volume 3cc and total volume of
lesions 10cc. However, this treatment should be cautiously used to elderly
patients because of the higher rate of late toxicity.
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Predictors and Impact of Second-line Chemotherapy Administra-
tion for Advanced Non-small Cell Lung Cancer (NSCLC): Impli-
cations for the Consideration of Maintenance Chemotherapy
D. E. Gerber, D. W. Rasco, P. Le, J. Yan, Y. Xie, J. E. Dowell, University
of Texas Southwestern Medical Center, Dallas, TX
Purpose/Objective(s): Recent clinical trials incorporating maintenance che-
motherapy into the initial treatment of advanced NSCLC have highlighted
the benefits of exposing patients to second-line therapies. We therefore
determined predictors of second-line chemotherapy administration and the
effect of second-line chemotherapy on clinical outcomes in a contemporary,
diverse NSCLC population.
Materials/Methods: We performed a retrospective analysis of consecutive
patients diagnosed with stage IV NSCLC from 2000 to 2007 at clinical
facilities associated with the University of Texas Southwestern Medical
Center. Demographic, disease, treatment, and outcome data were obtained
from hospital tumor registries. The association between these variables was
assessed using univariate analysis and multivariate logistic regression.
Results: A total of 472 patients in this cohort received first-line chemother-
apy. Mean age was 60 years, 40% were women, and 49% were white.
Among these patients, 207 (44%) received second-line chemotherapy.
Among those patients who had not progressed after 4-6 cycles of first-line
chemotherapy, 67% received second-line chemotherapy. Receipt of second-
line chemotherapy was significantly associated with patient insurance type
(P0.006), type of first-line chemotherapy (single- versus multi-agent)
(P0.001), number of cycles of first-line chemotherapy (P0.001), and
presence of brain metastases (P0.02), but was not associated with patient
age, gender, race, histology, or year of diagnosis. In a multivariate model,
second-line chemotherapy administration remained associated with insur-
ance type (P0.003), type of first-line chemotherapy (single- versus multi-
agent) (P0.004), number of cycles of first-line chemotherapy (P0.001),
and presence of brain metastases (P0.003). The number of cycles of
first-line chemotherapy and administration of second-line chemotherapy
were associated with overall survival in both univariate and multivariate
analyses.
Conclusions: In this unselected cohort of patients with advanced NSCLC,
over 65% of individuals whose disease did not progress after 4-6 cycles of
first-line chemotherapy eventually received second-line chemotherapy.
Markers of socioeconomic status, disease aggressiveness, and response to
and tolerance of first-line chemotherapy were associated with receipt of
second-line chemotherapy. These factors may assist in the selection of
patients most likely to benefit from maintenance chemotherapy.
Author Disclosure Block: D.E. Gerber: None. D.W. Rasco: None. P. Le:
None. J. Yan: None. Y. Xie: None. J.E. Dowell: None.
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Translational Approach Using 2-deoxy-2-[18f]fluoro-d-glucose
Positron Emission Tomography (fdg-pet) in Xenograft Models
to Identify the Optimal Dosing Regimen in a Phase I Trial of
Intercalated BMS-690514 in Combination With Paclitaxel/Car-
boplatin (PC) in Patients With Advanced or Metastatic Solid
Tumors
L. Q. Chow1, M. Salvati2, P. Chow2, A. Gupta2, J. Kopik2, J. Kurland2, G.
Dy3, A. Adjei3, 1Ottawa Hospital Cancer Centre, Ottawa, ON, Canada,
2Bristol-Myers Squibb, Princeton, NJ, 3Roswell Park Cancer Institute, Buf-
falo, NY
Purpose/Objective(s): BMS-690514 (514) is a potent, reversible oral inhib-
itor of EGFR, HER2, HER4, and VEGFR 1-3. FDG-PET in tumor xenografts
was utilized to determine the optimal dosing regimen for the combination of
514 with chemotherapy (PC). This unique intercalated dosing schedule was
used in the clinical evaluation of patients (pts) with solid tumors.
Materials/Methods: Nude mice subcutaneously implanted with lung carci-
noma cells were treated with various doses of single agent 514, followed by
intercalated fixed-dose 514 and PC. FDG-PET was performed to assess
tumor glucose metabolism and growth inhibition to define the optimal
regimen with maximal anti-tumor and FDG-PET response. A Phase 1 study
using the preclinically-defined intercalated 514 schedule in combination with
PC was conducted in pts with advanced or metastatic solid tumors. Using a
standard 33 design, escalating doses of intercalated 514 were combined
with fixed doses of PC. Endpoints included safety, tolerability, determination
of maximal tolerated dose (MTD), pharmacokinetics and anti-tumor re-
sponse. Starting at 100 mg/d (days 4-19 of 21-day cycle), intercalated 514
was escalated 50 mg/d with fixed IV PC (PC:200 mg/m2; C:AUC 6
mg/mLmin) until the MTD was reached.
Results: In xenografts, single-agent 514 significantly reduced tumor FDG
uptake. Intercalated PC dosing followed by 514 demonstrated maximal
tumor growth inhibition (-11%) and substantial reduction in tumor glucose
metabolism (-44%) and tolerable safety. In the Phase I, 514 cohorts were
(pts):100 mg (7), 150 mg (6), and 200 mg (4). DLTs were Grade (Gr) 3 (pts):
diarrhea 100 mg (1); 150 mg (1); 200 mg (2). The MTD of 514 was
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determined to be 150 mg/d, and this cohort of PC with intercalated 514 was
expanded to 24 pts. At the MTD, Gr 3/4 treatment-related AEs (10%)
occurred in 8/24 pts and included diarrhea (21%) and leukopenia (10%).
Within 34 pts treated at MTD and 200mg, 30 were evaluable for efficacy
with 9 partial responses (PR), 6 stable disease (SD), 3 progressive disease
(PD), and 12 pts are not yet evaluable. In NSCLC pts (n8), there were 5
PR, 1 SD and 2 PD.
Conclusion: These results support preclinical use of FDG-PET to evaluate
the efficacy of TKI regimens and the exploration of unique sequential
approaches for combining targeted agents with chemotherapy. Clinically,
intercalated 514 and PC was generally well tolerated and demonstrated
promising activity in a variety of tumor types, in particular in NSCLC. Future
studies will explore this novel approach of combining 514 and PC, alongside
the potential of FDG-PET to assess alternative schedules for combination
therapy.
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A Mixed Treatment Comparison of Bevacizumab-based Thera-
pies Relative to Doublet Platinum-based and Non-platinum-
based Chemotherapy Combinations in Progression Free Sur-
vival for the Treatment of First-line Advanced or Metastatic
Non-small Cell Lung Cancer (NSCLC)
Y. Yi1, S. Cope2, C. C. Chouaid3, A. Vergnene`gre4, H. Bischoff5, G.
Bergman2, S. Walzer6, Z. Philips1, 1Mapi Values, Bollington, United King-
dom, 2Mapi Values, Houten, Netherlands, 3Hoˆpital Saint Antoine, Paris,
France, 4Hoˆpital du Cluzeau, Limoges, France, 5Thoraxklinik, Heidelberg,
Germany, 6F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland
Purpose/Objective(s): To compare the efficacy in progression-free survival
(PFS) of bevacizumab based therapies (BBT) (bevacizumab plus cisplatin
and gemcitabine (BCG) and bevacizumab plus carboplatin and paclitaxel
(BCP)), relative to doublet-chemotherapy combinations for the treatment of
first-line advanced or metastatic NSCLC.
Materials/Methods: A systematic literature review identified randomized
controlled trials (RCTs) for bevacizumab-based and doublet-chemotherapy
combinations. Studies were evaluated for comparability of design and patient
population. A Bayesian mixed treatment comparison (MTC) was performed
for reported PFS hazard ratios (HR). The base case analysis compared BBT
with grouped platinum-based doublets (PLD) and grouped non-platinum
based doublets (NPLD). Scenario analyses on PFS explored BCP and BCG
versus different combinations of doublet treatments. The impact of publica-
tion date on results was also evaluated as a proxy for potential differences in
the overall quality of care over time.
Results: 8 identified RCTs, considered comparable in design and patient
characteristics, allowed for a comparison between bevacizumab-based ther-
apies and grouped doublet-chemotherapy combinations. The expected PFS
HRs relative to PLD, for BBT and NPLD were 0.75 (95% CI: 0.68; 0.82),
and 1.05 (0.92; 1.19), respectively. When BBT was analyzed separately as
BCP and BCG expected PFS HRs relative to PLD were 0.66 (95% CI: 0.57;
0.77) and 0.80 (0.71; 0.89) respectively, indicating BCP and BCG remained
the most efficacious treatments across all included regimens.
Conclusions: Bevacizumab-based therapy appears to be the most efficacious
first-line treatment in advanced or metastatic NSCLC in terms of PFS among
the treatment regimens evaluated in this MTC. Therefore bevacizumab-based
therapy is an efficacious treatment option for non-squamous advanced or
metastatic NSCLC.
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A Quantitative Assay of ERCC1 Expression in Circulating
Tumor Cells (CTCs) in Non-small Cell Lung Cancer (NSCLC):
A Potential Predictor of Treatment Response
M. Das1, B. H. Hsieh2, R. T. Krivacic2, N. Lazarus2, R. Bennis2, J. Ly2, E.
Schwartz3, L. Zhou1, R. H. Bruce2, H. A. Wakelee1, 1Department of
Medicine, Division of Medical Oncology, Stanford University, CA, 2Palo
Alto Research Center, Palo Alto, CA, 3Department of Medicine, Division of
Pathology, Stanford University, CA
Purpose/Objective(s): The detection and characterization of circulating
tumor cells (CTCs) is a potentially useful diagnostic and prognostic tool.
Evaluation of CTCs is under active investigation in lung cancer using a
variety of platforms. We report a method with a high-speed scanning
instrument that enables accurate localization of CTCs without the need for
sample enrichment, initially presented at AACR 2009 (Bruce et al AACR
2009, abstract 2606). Samples are fixed on a large slide, stained with
immunofluorescent antibodies (anti-cytokeratin, anti-CD45, and DAPI), and
stained cells are rapidly detected with the scanning instrument which allows
for high quality light microscopy to verify the identity of detected CTCs.
Here we update data on lung cancer patient samples collected at a single
institution, including detection sensitivity and ERCC1 protein expression.
Materials/Methods: Patients with metastatic lung cancer provided a 10 cc
blood sample from which we captured CTCs and performed an immunoflu-
orescent assay for measurement of protein expression levels of ERCC1.
Results: We were able to identify 4 or more CTCs in 14 patients from a total
of 22 consecutive patient samples (3%). We had scorable ERCC1 samples in
11 patients. Preliminary analysis based upon the scorable ERRC1 samples
indicates that an ERCC1 score 5-6 predicts poorer response to therapy (7
months).
Conclusions: This was a pilot study demonstrating feasibility of this tech-
nique using peripheral blood in the detection of CTCs and biomarker analysis
in patients with lung cancer. Ongoing efforts are focusing on the capacity of
biomarker expression on CTCs to predict patient response to therapy.
Author Disclosure Block: M. Das, None; B.H. Hsieh, None; R.T. Kri-
vacic, None; N. Lazarus, None; R. Bennis, None; J. Ly, None; E.
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Improvement in Survival but not Skeletal Morbidity in Stage IV
Non-small Cell Lung Cancer Patients With Bone Metastases: Is
it Time to Consider Bone Targeted Therapy in Metastatic Lung
Cancer?
J. L. Yu, S. Verma, J. C. Victor, D. Han, S. Hogeveen, N. Leighl, C.
Simmons, University of Toronto, Toronto, ON, Canada
Purpose/Objective(s): Bone metastases are common in non-small cell lung
cancer (NSCLC) and cause significant morbidity in the form of pain,
skeletal-related events, and decreased quality of life. Because stage IV
NSCLC is associated with poor survival, therapy directed at skeletal disease
(e.g. bisphosphonates) is generally not currently the standard of care. How-
ever, with significant advances in the systemic management of metastatic
lung cancer over the last decade, we propose that patients with bone
metastases will have improved survival, and as such may now be candidates
for bone targeted therapies.
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Materials/Methods: This was a retrospective cohort study of 987 patients
diagnosed with stage IV NSCLC at 2 institutions. Demographic data, as well
as the frequency of bone metastases, specific treatments received, overall
survival, and frequency of skeletal-related events were collected from pa-
tients who presented to these centres in 1998, 2003, and 2008. Results were
then compared across the three time periods.
Results: Bone was the most common site of metastasis, occurring in
approximately half of all patients, a proportion that was stable over time
(49% in 1998, 54% in 2003, 54% in 2008). While the use of systemic therapy
increased significantly over time, very few patients received IV bisphospho-
nate therapy. Overall survival from the time of diagnosis of bone metastases
improved significantly across cohorts (P 0.001), with an actuarial proba-
bility of survival of 10.0% at 2 years among patients diagnosed in 2008,
compared with a probability of only 0.6% among those diagnosed in 1998,
and 3.6% in 2003. However, the proportion of patients experiencing skeletal-
related events did not differ significantly between time cohorts, with no
improvement over time in the frequency of radiation to bone (71% in 1998,
74% in 2003, 70% in 2008; P  0.714), surgery to bone (8% in 1998, 10%
in 2003, 10% in 2008; P  0.616), or spinal cord compression (8% in 1998,
4% in 2003, 10% in 2008; P  0.091).
Conclusions: While the overall survival of patients with bone metastases
from NSCLC has improved over the past decade, the use of bisphosphonates
is not standard practice, and the frequency of skeletal-related events remains
unchanged. These results support further investigation into the use of bone
targeted therapies in the setting of metastatic lung cancer, to reduce skeletal
morbidity and improve quality of life in these patients, who are now living
longer.
Author Disclosure Block: J.L. Yu: None. S. Verma: None. J.C. Victor:
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Brain Metastases as the Primary Site of Relapse in Two Ran-
domized Phase III Pemetrexed Trials in Advanced Non-small
Cell Lung Cancer
C. Langer1, W. Ortuzar2, N. Hanna3, G. Scagliotti4, G. Peng2, M. Monberg2,
E. Pennella2, 1University of Pennsylvania, Philadelphia, PA, 2Eli Lilly and
Company or one of its subsidiaries, Indianapolis, IN, 3Indiana University,
Indianapolis, IN, 4University of Turin, Orbassano (Torino), Italy
Purpose/Objective(s): In non-small cell lung cancer (NSCLC), symptom-
atic brain metastases (BM) frequently occur following treatment. Consider-
ing the particular activity of pemetrexed in non-squamous NSCLC, we
retrospectively analyzed two large randomized trials to determine the inves-
tigators’ reported pattern of symptomatic relapse in the brain and gauge if
pemetrexed could influence the incidence.
Materials/Methods: Two large, phase 3 studies of pemetrexed in advanced
NSCLC were included. One study compared pemetrexed to docetaxel in
previously treated patients (N  571); the other tested cisplatin plus pem-
etrexed versus cisplatin plus gemcitabine in chemotherapy-naive patients
(N  1725) with advanced NSCLC. Patients with known BM at study entry
were excluded from this analysis. Each study was analyzed separately, then
jointly to determine the rate of BM reported as the only site of progressive
disease by treatment group and histology. Logistic regression was used to
obtain an odds ratio (OR) for the treatment effect on the overall occurrence
of BM while controlling for potential confounding factors.
Results: Overall, 71.5% of patients in pemetrexed-containing arms (819 of
1145) and 68.2% of pts in non-pemetrexed-containing arms (785 of 1151)
experienced progressive disease. BM recurrence rates were 3.2% (95% CI:
2.1, 4.6) in the pemetrexed-containing arms vs 6.6% (95% CI: 5.0, 8.6) in the
non-pemetrexed-containing arms (P0.002). The OR for BM recurrence
associated with exposure to pemetrexed was 0.49 (95% CI: 0.32, 0.76,
P0.001). The effect of pemetrexed on BM rates was confined to patients
with nonsquamous NSCLC. Regardless of treatment arm, brain as the site of
disease recurrence was associated with significantly worsened survival com-
pared with other sites of disease recurrence (7.4 months vs 11.1 months;
log-rank P0.0001).
Conclusions: Patients with advanced nonsquamous NSCLC treated with
pemetrexed either in second-line or first-line may reduce the risk of devel-
oping BM as the first site of progressive disease. This retrospective analysis
is limited due to the lack of baseline and periodic brain scans; and it reflects
symptomatic BM only. Regardless, these findings suggest a potentially
beneficial effect of pemetrexed-based treatments on the control of BM. BM
recurrence as defined in this analysis was a strong prognostic factor irre-
spective of disease characteristics or assignment to treatment.
Author Disclosure Block: C. Langer: D. Speaker’s Bureau/Honoraria; Eli
Lilly & Company. F. Consulting/Advisory Board; Eli Lilly & Company. W.
Ortuzar: A. Employment; Eli Lilly & Company. N. Hanna: G. Other; Eli
Lilly & Company. G. Scagliotti: Eli Lilly & Company. G. Peng: A.
Employment; Eli Lilly & Company. M. Monberg: Eli Lilly & Company. E.
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Impact of Non-small Cell Lung Cancer (NSCLC) Histology on
Survival Predicted from the Graded Prognostic Assessment
(GPA) for Patients With Brain Metastases
S. Guo, C. A. Reddy, S. T. Chao, J. H. Suh, G. Videtic, Cleveland Clinic,
Cleveland, OH
Purpose/Objective(s): The Graded Prognostic Assessment (GPA) provides
a prognostic classification for patients with brain metastases, based on patient
and tumor data from the RTOG database of randomized trials. Recent data
suggest differential response and outcomes to selected chemotherapy for
different NSCLC histologies. Using a large single institutional database of
patients with brain metastases, we assessed the impact of histologic subtypes
on survival outcomes stratified by the GPA.
Materials/Methods: From an IRB-approved database, this retrospective
review analyzed 780 patients with NSCLC brain metastases treated from
January 1982 to September 2004. GPA classification variables included age,
KPS, number of brain metastases, and presence of extracranial disease.
Tumor histology was identified for each patient. Median survival time for
cohorts based on GPA class and histology were calculated using Kaplan-
Meier analysis, and comparisons were made to the published results using
results from the GPA. The log rank test was used to determine statistical
differences between survival curves.
Results: Median survival times (MST, in months) by histology were:
adenocarcinoma (AC) 6.2 (n464), large cell (LC) 4.1 (n98), squamous
(SQ) 4.2 (n108) (p0.0449). For GPA 3.5-4.0, MST were: AC 11.2
(n39), LC 4.1 (n2), SQ 10.6 (n12) (p0.8597). For GPA 3.0, MST
were: AC 12.1 (n54), LC 10.2 (n14), SQ 6.9 (n14) (p0.0420). For
GPA 1.5-2.5, MST were: AC 6.1 (n275), LC 4.6 (n49), SQ 3.6 (n60)
(p0.0052). For GPA 0-1.0, MST were: AC 3.2 (n83), LC 2.2 (n32), SQ
3.2 (n17) (p0.0205). For all patients with brain metastases from NSCLC,
our MST by GPA score were: GPA 3.5-4.0, 12.6; GPA 3.0, 10.2; GPA
1.5-2.5, 5.8; and GPA 0-1.0, 2.7.
Conclusions: Adenocarcinoma showed a higher median survival than other
histologies of NSCLC that was statistically significant. The use of histology
as a prognostic factor for brain metastases from NSCLC warrants further
investigation. Our cohort of patients with brain metastases from NSCLC
validates the GPA, with median survivals comparable to that of the RTOG
data.
Author Disclosure Block: S. Guo: None. C.A. Reddy: None. S.T. Chao:
None. J.H. Suh: None. G. Videtic: None.
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Radiographic Response of Brain Metastases in Patients With
Non-small Cell Lung Cancer Receiving Bevacizumab
S. B. Rhodes, M. G. Ewend, D. E. Morris, H. Chu, M. A. Socinski,
University of North Carolina School of Medicine, Chapel Hill, NC
Purpose/Objective(s): CNS metastases are a major concern in patients with
non-small cell lung cancer (NSCLC). A recent multi-center, phase II trial
(PASSPORT) demonstrated that the addition of bevacizumab to chemother-
apy regimens in patients with NSCLC and treated brain metastases has an
acceptable safety profile. However, no studies have evaluated the radio-
graphic response of brain metastases to bevacizumab in NSCLC patients.
Materials/Methods: We conducted a review of all patients enrolled in the
PASSPORT trial at the University of North Carolina site. Patients with
baseline radiologic imaging prior to bevacizumab administration, at least one
radiologic follow-up, and minimal initial tumor volume of 0.1 cm3 were
eligible to be included in the study. Tumor volumes were measured by
manual segmentation and response was categorized as either: complete
response (lesion not detectable on imaging), partial response (50% volume
decrease), progressive disease (25% volume increase), or stable disease
(neither partial response nor progressive disease criteria met).
Results: Twelve patients with 24 metastatic brain lesions met our inclusion
criteria. Nine patients received first-line chemotherapy while the remaining 3
patients received second-line regimens, as defined in the PASSPORT pro-
tocol; all regimens included bevacizumab. All patients had treatment for
brain metastases prior to chemotherapy, which included: whole brain radia-
tion therapy (WBRT, 6 patients), stereotactic radiosurgery (SRS, 3 patients),
WBRT followed by SRS (2 patients), and surgery followed by WBRT (1
patient). Median time between completion of brain metastasis treatment and
the start of bevacizumab was 37.5 days. Nine patients had radiologic
follow-up with magnetic resonance imaging; 3 patients were followed with
computed tomography. By last available radiologic follow-up, twelve lesions
(50%) achieved a complete response, while 9 (38%) lesions were partial
responders with a mean tumor volume reduction of 83%. The remaining
three lesions were classified as stable disease. No lesions progressed. Fur-
thermore, no patients experienced intracranial progression during bevaci-
zumab administration and up to 3 weeks following cessation of treatment.
Conclusion: The observed tumor volume responses suggest efficacy of
bevacizumab when combined with prior radiation therapy and subsequent
systemic therapy; it warrants further evaluation of bevacizumab as an option
for the treatment of brain metastases either during or after radiation therapy
in patients with non-small cell lung cancer.
Author Disclosure Block: S.B. Rhodes: None. M.G. Ewend: None. D.E.
Morris: None. H. Chu: None. M.A. Socinski: F. Consulting/Advisory
Board; Genentech.
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Results from a Continuation Study of Sunitinib plus Pemetrexed
in Patients With Advanced Non-small Cell Lung Cancer
(NSCLC)
N. Blais1, D. Ross Camidge2, S. A. Laurie3, C. Canil3, D. Jonker3, A. Thall4,
K. Zhang4, R. C. Chao4, L. Chow3, 1Hopital Notre-Dame du CHUM,
Montreal, QC, Canada, 2University of Colorado Cancer Center, Aurora,
CO, 3The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada, 4Pfizer
Oncology, La Jolla, CA
Purpose/Objective(s): Sunitinib (SU) is an oral inhibitor of numerous
tyrosine kinase receptors (including VEGFR, PDGFR, CSF-1R and KIT)
approved multinationally for the treatment (tx) of advanced renal cell
carcinoma and imatinib resistant/intolerant gastrointestinal stromal tumor.
Here we report long-term clinical data from a continuation study of SU in
combination with pemetrexed (PEM) in patients (pts) previously treated in a
phase I study with either SU in combination with PEM (SU/PEM) or in
combination with PEM plus cisplatin (SU/PEM/CIS) or carboplatin (SU/
PEM/CAR).
Materials/Methods: Seventeen patients (pts) with advanced/metastatic
NSCLC previously enrolled in a phase I SU study (NCT00528619; study
start date November 14th 2006) entered this open-label continuation study.
All pts received SU plus chemotherapy in the phase I study and were judged
by the investigator to have the potential to derive clinical benefit from
continuing SU tx. Enrollment occurred within 8 wks of the last SU dose. SU
(25 mg or 37.5 mg) /- PEM was administered according to the regimen
used in the previous study. SU was given in either 28-day tx cycles on a
continuous daily dosing schedule if previously administered in combination
with PEM (500 mg/m2), or in 21-day tx cycles for 2 wks on tx, 1 week off
(Schedule 2/1) if previously administered in combination with PEM (500
mg/m2) plus CIS (75 mg/m2) or CAR (AUC5 mgmin/mL). Response data
shown here are cumulative i.e. represent time enrolled in the phase I study
and the continuation study.
Results: As of June 2010, 17 pts were enrolled (n8 male; age range 34-83
years). Tumor histologies: adenocarcinoma (n13; 76%), large cell carci-
noma, bronchioloalveolar, NOS (each n1; 6%), and unknown (n1, 6%).
Of these pts, 8 had received SU/PEM in the phase I study, and 9 had received
SU/PEM/CIS or SU/PEM/CAR (total number of weeks on tx: 43.3-86.1 and
20.9-53.6, respectively).The most frequent AE associated with dosing delays
was neutropenia, including one case each of Grade 3 and 4 febrile neutro-
penia that resolved after dosing interruption and/or reduction. Best overall
responses included 5 PRs: 4 in the SU/PEM group and 1 in the SU/PEM/
CAR group (duration 35.1-63.3 and 29.9 wks, respectively). Stable disease
(SD) was achieved in 2 pts in the SU/PEM group and 6 pts in the
SU/PEM/CIS or SU/PEM/CAR groups. SD for 6 months was achieved in
2 pts in the SU/PEM group and in 4 pts in the SU/PEM/CIS or SU/PEM/
CAR groups. Median PFS in pts in the SU/PEM group was 14.6 months
[95% CI: 2.6-NA] (n4) and 9.6 months [95% CI: 9.0-9.9] (n6) in the
SU/PEM/CIS or SU/PEM/CAR groups.
Conclusions: Long-term tx with SU or SU/PEM following tx with SU/PEM,
SU/PEM/CIS or SU/PEM/CAR in these selected NSCLC pts was associated
with extended disease control and manageable tolerability.
Author Disclosure Block: N. Blais, Pfizer Oncology, B. Research Grant;
D.R. Camidge, None; S.A. Laurie, None; C. Canil, Feb 16/10 received
speaker fees from Pfizer on RCC- Kingston ON, Canada, D. Speaker’s
Bureau/Honoraria; Attended and received honoraria for advisory board
sponsored by Pfizer on RCC - Toronto, ON , Canada March 10, 2010, F.
Consulting/Advisory Board; D. Jonker, None; A. Thall, Pfizer Oncology, A.
Employment; K. Zhang, Pfizer Oncology, A. Employment; R.C. Chao,
Pfizer Oncology, A. Employment; Pfizer Oncology, E. Ownership Interest;
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Expression of Sonic Hedgehog and its Receptor Patched in
Non-small Cell Lung Cancer
O. Rouhi, K. A. Kaiser-Walters, D. Escarzaga, D. Steker, S. Basu, M. J.
Liptay, P. Gattuso, P. Bonomi, J. Coon, J. A. Borgia, Rush University
Medical Center, Chicago, IL
Purpose/Objective(s): Tumor metastasis is the primary cause of mortality in
non-small cell lung cancer (NSCLC). Many pathways and biomarkers have
been studied to clarify the mechanism of disease progression, but the exact
mechanism of metastasis remains poorly understood. Based on previous
studies, the hedgehog signaling pathway is involved in tumor growth and
differentiation. However, little is known about the associations of expression
of components of the hedgehog pathway and metastatic progression in
NSCLC. Here we examined the differential expression of sonic hedgehog
(Shh) and its receptor patched (ptc) for its involvement in metastatic
progression.
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Materials/Methods: Immunohistochemical staining for Shh, and ptc was
performed on 115 primary non-small cell lung carcinomas [adenocarcinoma (n
65) and “non-adenocarcinoma” (n50)] and 55 matching metastatic lymph
nodes. All patients were treated by complete anatomic resections and were
limited to T1-2N1-2M0. Scoring was accomplished by evaluating stain intensity
(0: no staining, 1: weak staining, 2: strong staining) and frequency of expression
by tumor cells, with 25 random fields surveyed per section. A score was then
calculated based on these parameters for statistical comparisons. Parameters that
were compared include differential primary and lymph nodes staining, tumor
histopathological subtype, and disease-free and overall survival. All statistical
comparisons were performed in SPSS v15.0 and consisted of either Mann-
Whitney rank sums test (two-sided) or Kaplan-Meier curves.
Results: There was no significant difference in the pattern of shh and ptc
staining in primary tumor versus local lymph node metastases. (p  0.2 and
0.5, respectively). Shh and ptc were expressed in adenocarcinoma at a
significantly higher level and more frequently than compared to non
adenocarcinoma samples (p  0.001 and 0.01 respectively). Disease-free
survival was higher in shh negative tumor samples compared to the
positive group (p  0.03), and shh positivity correlated with higher rate
of recurrence. (p  0.03).
Conclusions: These results are consistent with observations for the expres-
sion of hedgehog pathway proteins and patient outcome in other carcinomas
and suggest that the hedgehog pathway might play a similar role in the
development of metastases in NSCLC.
Author Disclosure Block: O. Rouhi: None. K.A. Kaiser-Walters: None.
D. Escarzaga: None. D. Steker: None. S. Basu: None. M.J. Liptay: None.
P. Gattuso: None. P. Bonomi: None. J. Coon: None. J.A. Borgia: None.
177
Expression and Functionality of Cbl in Non-small Cell Lung
Cancer
S. Nandi1, C. E. Rolle1, C. Tan1, M. Robinson2, M. Maranto3, F. Lennon1,
P. Singleton1, A. Husain1, R. Kanteti1, R. Salgia1, 1University of Chicago,
Chicago, IL, 2University of Notre Dame, South Bend, IN, 3Smith College,
Northampton, MA
Non-small cell lung cancer (NSCLC) encompasses a diverse group of
disorders characterized by genetic and proteomic alterations. The E3-ubiq-
uitin ligase and adaptor molecule c-CBL (hereafter referred to as CBL) has
been shown to play a critical role in normal homeostasis and oncogenesis.
We investigated the expression and functionality of CBL in NSCLC, as well
as its relationship to the receptor tyrosine kinases (such as EGFR and MET).
By immunohistochemical analysis, we determined that CBL was expressed
at a low level (Mean expression 3.2), while MET had a significantly higher
expression at 7.4 We also determined the IHC expression of CBL-b, for
which the mean expression was 7.4. Importantly, in the protein atlas database
(www.proteinatlas.com), CBL was weakly stained in 25% of all lung cancers
and negatively stained in the remaining 75%. CBL-B on the other hand was
strongly or moderately stained in 60% of the samples and weakly stained or
unstained in 40% of the samples. CBL-c (CBL3) was moderately stained In
40% of the samples while they are weakly stained or unstained in the
remaining 60%. Eight novel somatic CBL mutations were identified in
genomic DNA extracted from archival formalin-fixed paraffin embedded
lung tumor tissues. Interestingly, we detected somatic mutations among
different races, such that S80N/H94Y, Q249E, W802* were prevalent in
Caucasians, Taiwanese, and African Americans, respectively. The mutations
occurred independently of K-RAS or p53 mutations, but not EGFR or MET
mutations. EGFR and MET mutations occurred irrespective of CBL muta-
tions. Furthermore, significant loss of heterozygosity (LOH) was revealed by
normal/tumor tissue pairwise analysis of the c-CBL locus (22%, n8/37).
Interestingly, CBL LOH and mutations were mutually exclusive. To test the
functionality of these CBL mutations NSCLC cell lines were transiently
transfected with wild-type CBL, or S80N/H94Y, Q249E, W802* mutated
CBL. Cell viability was significantly higher in cells expressing these mu-
tants. Motility of NSCLC cells expressing these mutants were also signifi-
cantly increased in a wound healing assay.. Collectively, these data indicate
that c-CBL plays an essential role in lung tumorigenesis and potentially
metastasis by enhancing the survival and migration of tumor cells.
Author Disclosure Block: S. Nandi: None. C.E. Rolle: None. C. Tan:
None. M. Robinson: None. M. Maranto: None. F. Lennon: None. P.




Weekly Paclitaxel as Third Line Chemotherapy in Elderly Pa-
tients With Advanced Non-small Cell Lung Cancer (NSCLC)
P. Belloni, C. Cozzi, F. Zannier, G. Corradini, P. Candido, S. Della Torre, D.
Toniolo, A. Fariciotti, A. Vismara, R. Bollina, Oncology and Hematology G.
Salvini general Hospital, Rho, Italy
Purpose/Objective(s): The incidence of non-small cell lung cancer
(NSCLC) is increasing among the elderly representing about 30% of NSCLC
patients over 70 years-old. Taxanes and platinum-based chemotherapy are
considered to be a standard approach for advanced NSCLC. Weekly Pacli-
taxel has been widely used for its favorable toxicity profile especially in pts
with breast and ovarian cancer. The purpose of this study was to evaluate the
efficacy and toxicity of weekly Paclitaxel in elderly pts with advanced
NSCLC previously treated with platinum-based chemotherapy in fit pts or
single agents in frail pts.
Materials/Methods: Between November 2008 and June 2010, 21 elderly pts
with locally advanced or metastatic pre-treated NSCLC are included in this
phase II study. Paclitaxel was administered at a dose of 60 mg/m2 repeated
once a week for 3 consecutive weeks followed by a 1 week rest period (1
cycle). Pts were evaluated for tumor response every 12 weeks.Therapy was
continued for a maximum of six cycle in pts showing tumor response or
stable disease. Patient’s baseline characteristics included: median age 75
(range 70–81), 1 pts stage IIIb and 20 stage IV, 2 pts ECOG 0, 15 pts ECOG
1 and 4 ECOG 2. Histology adenocarcinoma 40%, squamous carcinoma 50%
and undifferenced 10%.
Results: 17 out of 21 pts were evaluable for response and toxicity (2 pts
underwent only 1 administration and 2 pts are still ongoing). Of the 17 pts
treated , 15% achieved partial response, 25% showed stable disease and 60%
had progressive disease. Median duration of response was 4.6 months. Grade
3-4 neutropenia in 1 pts (6%), grade 3 paresthesias in 2 pts (12%), non
serious events requiring hospitalization were reported. Other toxicities were
mild (grade 1-2): asthenia (20%), anemia (15%), constipation (30%). Non
toxic related death was reported.
Conclusions: In our trial weekly Paclitaxel in feasible and very safe in
elderly and frail NSCLC pts. The study is ongoing.
Author Disclosure Block: P. Belloni: None. C. Cozzi: None. F. Zannier:
None. G. Corradini: None. P. Candido: None. S. Della Torre: None. D.
Toniolo: None. A. Fariciotti: None. A. Vismara: None. R. Bollina: None.
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A Double-Blind, Randomized, Parallel, Two-Arm Phase II Trial
of BMS-690514 versus Erlotinib in Previous Chemotherapy-
Treated Non-small Cell Lung Cancer (NSCLC) Patients: A
Safety Review
E. Sbar1, B. Besse2, E. Felip3, A. Shaw4, M. Ahn5, M. Salvati1, P. Bhaga-
vatheeswaran1, J. Soria2, 1Bristol-Myers Squibb, Princeton, NJ, 2Institut
Gustave Roussy, Villejuif, France, 3Hospital Vall d’Hebron, Barcelona,
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Spain, 4Massachusetts General Hospital, Boston, MA, 5Samsung Medical
Center, Sungkyunkwan University, Seoul, Korea, Republic of
Purpose/Objective(s): The BR.21 study showed that erlotinib prolonged
overall survival versus placebo in patients with advanced NSCLC who had
received at least one line of chemotherapy. This agent is widely used in the
treatment of second or third line therapy in NSCLC patients. BMS-690514
(514) is an oral selective ErbB1, ErbB2, ErbB4 and VEGFR1-3 inhibitor in
development for NSCLC based on the rationale that achieving balanced
inhibition of both ErbB and VEGFR signaling pathways provides for
increased efficacy over EGFR inhibition. In the Phase I CA187002 study, the
best clinical responses noted among 61 subjects with NSCLC who received
multiple previous treatments included a disease control rate of 43% (13/30:
2-sided 90% CI: 31, 57%) in patients who were erlotinib-naive and 23%
(7/31: 2-sided 90%CI: 13, 35%) for those previously treated with erlotinib.
The objective of this study is to explore whether 514 is superior to erlotinib
as noted by improvement in PFS. Here, we present the comparative safety
analyses. The efficacy results will be presented at a later date.
Materials/Methods: This randomized study compares oral 514 at 200 mg
with erlotinib 150 mg in patients who have progressive NSCLC after one to
two previous regimens of cytotoxic chemotherapy (i.e. erlotinib-eligible per
label). The primary endpoint was PFS. Secondary endpoints were objective
response rate, overall survival, PFS rate, change in tumor size at 6 weeks,
safety, and tolerability. Safety assessments were performed as per standard
practice with additional note of those known to result from VEGFR and
EGFR inhibition.
Results: 141 subjects (41 women, 100 men) were randomized to receive
either 514 or erlotinib. Patient characteristics included: 22 current, 99
previous and 19 never smokers; histology included 79 adenocarcinoma, 35
squamous cell, 16 large cell, and 2 bronchoaveolar carcinoma. 514 adverse
events (AEs) will be compared to those known to occur at high rates with
erlotinib EGFR inhibition including but not limited to rash, diarrhea, fatigue
and hypertension.
Conclusion: The AEs related to 514 are related to the targets (EGFR, HER2,
and VEGFR) and are similar to erlotinib. The AEs are manageable and
reversible with the use of concurrent medications and dose modification.
These data indicate that the observed AEs with 514 were not “additive” or
more than that seen with VEGFR and EGFR inhibitors administered as
monotherapy.
Author Disclosure Block: E. Sbar: A. Employment; Bristol-Myers Squibb.
B. Besse: None. E. Felip: None. A. Shaw: F. Consulting/Advisory Board;
Advisor and consultant for Pfizer. M. Ahn: None. M. Salvati: A. Employ-
ment; Bristol-Myers Squibb. P. Bhagavatheeswaran: Bristol-Myers
Squibb. J. Soria: F. Consulting/Advisory Board; Consultant for Bristol-
Myers Squibb.
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Stereotactic Radiotherapy for Metastatic Non-small Cell Lung
Cancer With One or Two Contralateral Pulmonary Nodules
S. Masciullo1, L. Masi1, I. Bonucci1, C. Menichelli1, R. Doro1, F. Casa-
massima1,2, 1S. Chiara Hospital, Florence, Italy, 2University of Florence,
Florence, Italy
Purpose/Objective(s): To evaluate clinical outcomes in NSCLC patients
with lung-to-lung metastases (M1a, according to AJCC 7th ed.) treated by
stereotactic body radiation therapy (SBRT).
Materials/Methods: We retrospectively analyzed the records of 28 patients
(median age 59 years) who were treated by SBRT for pulmonary metastases
from NSCLC with curative intent (all detectable lesions concurrently
treated). The selection criteria were as follows: (1) locally controlled primary
tumor; (2) absence of metachronuos nodules in ipsilateral lung; (2) one or
two nodules in the contralateral lung ; (3) no other metastatic sites; (4) no
other local therapies for previous metastases; (5) interval between primary
tumor and nodules appearance 3 years. Seven patients (25%) received
chemotherapy within six months of SBRT, with SD or PR but without
modifications in the number of lesions. All primary tumors were controlled
by surgery (n22) or by SBRT (n6), with mediastinal lymph node
involvement in 10 cases (34%). The histologic types were epidermoid
(n13), adenocarcinoma (n10), large cells (n1), unspecified NSCLC
(n4); no bronchioalveolar carcinomas were included. Total number of
metastatic nodules was 43 (one lesion in 75% of patients, two lesions in
25%). Maximum tumor size was 40 mm. An ITV was obtained as the
envelope of 2 CTVs delineated on 2 CT data sets acquired at the end of
inspiration and expiration, plus an uniform 3-5 mm margin to create the PTV
(median PTV volume 15.7 cc, range 1.5-90 cc). Tidal volume was indicated
by a computerized spirometer (Elekta ABC). Twenty-nine lesions were
treated with single fraction SBRT (median dose at isocenter 26 Gy), others
in three fractions (median dose at isocenter 33 Gy). Image-guided technique
(IGRT) by pre-treatment Cone-Beam CT was used.
Results: With a median follow-up of 14.5 months (range 2-84), 89% of
patients are alive (40% NED, 36% without new metastatic lesions). Median
follow-up of NED patients was 30.2 months. The 2-years actuarial OS and
LC were 86% and 81%. Two patients experienced local failure and three
lesions were salvaged by a second course of SBRT. Considering the salvage
SBRT, definitive local control was achieved in 100% of cases. New pulmo-
nary and/or extrapulmonary metastases occurred in 10 patients, with pro-
gression-free rates at 2 years of 60%. No acute or late toxicity grade 2
(CTCAE v.4) was observed.
Conclusion: In the lung-to-lung metastatic NSCLC scenario SBRT can be
important in order to achieve long-term disease control. SBRT is a minimally
invasive and well tolerated option which could be offered as valid alternative
to surgery.
Author Disclosure Block: S. Masciullo: None. L. Masi: None. I. Bonucci:
None. C. Menichelli: None. R. Doro: None. F. Casamassima: None.
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Stereotactic Body Radiotherapy for Oligometastatic Non-small
Cell Lung Cancer Patients
S. Masciullo1, I. Bonucci1, C. Menichelli1, L. Masi1, R. Doro1, F. Casa-
massima1,2, 1S. Chiara Hospital, Florence, Italy, 2University of Florence,
Florence, Italy
Purpose/Objective(s): Stereotactic body radiation therapy (SBRT) could be
an alternative option to surgical resection for patients with extracranial
oligometastases. The currently available SBRT-data in oligometastatic set-
ting include patients with tumors from a wide variety of primary sites and no
studies have been focused on NSCLC patients.
Materials/Methods: We retrospectively analyzed the records of 45 NSCLC
patients who had undergone SBRT with curative intent (all detectable lesions
concurrently treated). All patients presented with oligometastatic state con-
firmed by total body CT and/or FDG-PET. Metastatic spread was limited to
a single organ (contralateral lung n35; bone n7; adrenal glands n2;
liver n1). M1a-patients (according to AJCC 7th ed.) who presented with an
interval between primary tumor and pulmonary nodules appearance3 years
were excluded. The number of lesions was one in 31 patients, two in 13,
three in 1. Primary tumor was controlled by surgery (78%) or by SBRT
(22%). Six patients (13%) were metastatic at the onset of disease, others
developed metastases after locoregional treatment of primary tumor. Thir-
teen (28%) received chemotherapy within six months of SBRT. A total of 68
lesions were irradiated with curative intent. Five patients needed further
curative SBRT for new metastases. Mostly used fractionation schemes were
10 Gy 3 and 26 Gy 1, delivered by multiple arcs. A Cone Beam CT was
acquired before each treatment for correction of setup and isocenter position.
Results:With a median follow-up of 15.3 months (2-84), 84% of patients are
alive (34% without evident disease). The actuarial 2- and 3-years OS was
83.2% and 66.8%. The 2-3 years actuarial local control (RECIST criteria)
was 90.4%. Three pulmonary local failures occurred in two patients and were
Journal of Thoracic Oncology • Volume 5, Number 12, Supplement 7, December 2010 Abstracts
Copyright © 2010 by the International Association for the Study of Lung Cancer S539
salvaged by a second course of SBRT. Considering the re-treatments of local
failure, definitive local control was achieved in 100% of cases. New lesions
after the first SBRT treatment occurred in 17 patients, with a progression free
survival of 60% and 46% at 2 and 3 years, respectively. No acute or late
toxicity grade 2 (CTCAE v.4.0) was observed.
Conclusions: Considering the high rates of LC and OS, in our experience
SBRT can be an effective and well tolerated treatment for those NSCLC
patients who present with few metastases limited to a single organ.
Author Disclosure Block: S. Masciullo: None. I. Bonucci: None. C.
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Number and Site of Metastases as the Predictor of Outcomes in
Metastatic Non-small Cell Lung Cancer: Retrospective Study
from VACCR database
R. Thota1, I. Aldoss1, T. Tashi1, W. Gonsalves1, S. Pudunagar Subbiah1, A.
Ganti2,3, 1Creighton University, Omaha, NE, 2University of Nebraska Med-
ical Center, Omaha, NE, 3VA-NWIHCS, Omaha, NE
Purpose/Objective(s): Metastatic non small cell lung cancer (NSCLC) has
poor prognosis with common sites of metastases to lung, bone and liver. It
is unclear if the number and site of metastases serve as predictors of survival.
This study was undertaken to evaluate these questions.
Materials/Methods: Data from patients with metastatic NSCLC diagnosed
from 1995 to 2009 was obtained from the Veteran’s Affairs Central Cancer
Registry. Median survivals based on number and site of metastases were
calculated by using log-rank and Kaplan-Meier analysis.
Results: Of 25,639 patients identified with metastatic NSCLC, 10,074
(39.3%) had adenocarcinoma, 7894 (30.8%) had squamous cell carcinoma
and 1540 (6 %) had large cell carcinoma. Patients older than 65 years made
up 56.4% of this cohort. The majority of patients (n  14,561, 56.8%) had
metastases to one site, while 23.5 % (n  6027) had metastases to two sites
and 13.2 % (n  3393) had metastases to three or more sites. The common
sites on involvement were, bone - 23%, lungs - 19.6%, CNS - 19%, liver -
16.7%, distant lymph nodes - 4.5%, pleura - 2.2%, peritoneum - 0.6%, skin
- 0.5% and disseminated disease - 13.2%. Median survivals based on number
of sites of metastases were as follows - one site (56.8%) was 4.2 months, two
sites (23.5%) were 2.9 months and 3 or more sites (13.2%) were 2 months.
When the sites of metastasis were evaluated in those patients who presented
with a solitary site involvement, median survival was longest in those with
lung involvement (7.6 months). Median survivals for patients with other site
involvement in months were as follows: lymph node - 5.3, peritoneum - 4.4,
skin - 4, CNS - 3.6, bone - 3.6, liver - 2.9 and pleura - 2.9.
Conclusions: The number and sites of metastases serve as prognostic factors
in patients with metastatic NSCLC. Prognosis of patients with solitary
metastasis was better compared to those with two or more sites of metastases.
Among those with solitary site of metastases, those with metastases to lung
had better survival compared to those with metastases to other sites.
Author Disclosure Block: R. Thota: None. I. Aldoss: None. T. Tashi:
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Effect of Adding More Beams on Optimizing Conformity and
Lung Dose in Lung SBRT
C. Vargas1, C. Y. Shang1, M. Kasper1, R. Benda1, A. Kyriacou2, B. J.
Greenfield3, 1Lynn Cancer Institute of Boca Raton Community Hospital,
Boca Raton, FL, 2Florida Atlantic University, Boca Raton Florida, FL,
3University of Miami, Miami, FL
Purpose/Objective(s): Lung Stereotactic Body radiotherapy (SBRT) has
employed increasing number of beam angles with 3D techniques to improve
conformity. IMRT may be employed to improve conformity while limiting
lung volume irradiated. We evaluate IMRT plans with different numbers of
beam angles to determine variations in conformity or lung dose.
Materials/Methods: A sample of 12 lung SBRT cases was randomly
selected among 86 evaluable cases from May 2009 to April 2010. The
average tumor volume is 8.4  4.0 cm3, ranging from 2.0 to 15.2 cm3, while
the ITV is 14.1  6.3 cm3. ITV is based on 8-phase 4D CT scans, while the
PTV (31.7  12.0 cm3) includes a 5 mm superior and inferior, and 3 mm
axial expansions from ITV. For each SBRT case three sets of IMRT SBRT
plans were created, with 5, 9, and 12 non-coplanar beams. V100 of PTV was
normalized to 95%, while the lung dose was optimized with V20  5% and
a mean dose  4Gy. Conformity index, lung mean doses, and Lung V5-50Gy
were analyzed every 5%. Pair-wise comparisons were done between 5, 9, and
12 beam plans.
Results: (95.3  0.3)% of the PTV is covered by prescribed 50Gy in all
cases. High and similar conformities are seen among all groups: 5-beams
1.19, 9-beams 1.16, and 12-beams 1.14 (p  0.49). Each group also
displayed comparable lung dosimetry with the mean lung doses of 5-beams
3.29  1.13, 9-beams 3.62  1.32, and 12-beams 3.45  1.27 Gy respec-
tively (p  0.51). Their corresponding lung inclusions are V10: 5-beams
9.85  3.79, 9-beams 11.36  5.76 and 12-beams 10.93  5.45 (p  0.22);
V20: 5-beams 4.16  2.08, 9-beams 4.18  1.99, and 12-beams 3.85  1.56
(p 0.33). No meaningful differences are seen at any Lung V5-50Gy between
the three plans (p  0.20).
Conclusions: No significant dosimetric differences were seen in the terms of
lung dose and or conformity among different lung IMRT SBRT plans with
5, 9, and 12 beams. It is possible that improved algorithms and optimization
for conformity while penalizing dose outside the PTV rendered similar plans
differently than that seen with conventional 3D planning techniques.
Author Disclosure Block: C. Vargas, None; C.Y. Shang, None; M.
Kasper, None; R. Benda, None; A. Kyriacou, None; B.J. Greenfield,
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Symptom-based Patient-reported Outcome Results from a
Phase II Study of Sunitinib in Patients With Non-small Cell
Lung Cancer and Brain Metastases
D. Cella1, L. Abrey2, S. Novello3, J. Wang4, T. Usari5, R. Mundayat6, A.
Thall4, R. C. Chao4, G. Scagliotti3, 1Northwestern University, Chicago, IL,
2Memorial Sloan-Kettering Cancer Center, New York, NY, 3University of
Turin, Orbassano, Italy, 4Pfizer Oncology, La Jolla, CA, 5Pfizer Oncology,
Milan, Italy, 6Pfizer Oncology, New York, NY
Purpose/Objective(s): Sunitinib is an oral, multitargeted tyrosine kinase
inhibitor of VEGFRs, PDGFRs, KIT, RET, FLT3 and CSF-1R. Brain
metastases occur in 25% of patients with non-small cell lung cancer
(NSCLC). Patient-reported outcome (PRO) data from a phase II study of
sunitinib in NSCLC patients with previously irradiated brain metastases are
reported.
Materials/Methods: Patients with NSCLC who had received whole brain
radiation therapy for brain metastases and 2 prior systemic therapies
received sunitinib at a starting dose of 37.5 mg with continuous daily dosing
in 4-week cycles. Disease- and treatment-related symptoms were assessed
using the FACT/NCCN Lung Symptom Index (FLSI) and the FACT/NCCN
Brain Symptom Index (FBrSI) questionnaires administered on Days 1 and 15
of the first two 4-week cycles, then Day 1 only in subsequent cycles, and
summarized using absolute mean scores and change from baseline (Cycle 1
Day 1 prior to first dose) at each assessment. Repeated measures mixed
models with autoregressive covariance structure tested statistically signifi-
cant changes from baseline at each nominal visit. Baseline value was
included as a continuous covariate.
Results: Sixty-four patients were enrolled; data for patients completing 1
post-baseline FLSI (n43) or FBrSI (n45) assessment are reported to
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Cycle 5 Day 1, when 10 PRO-evaluable patients remained on study.
Questionnaire completion rates ranged from 59 to 91%. Overall index scores
did not change significantly from baseline. Patients reported improvement in
FLSI item scores (P0.05) for shortness of breath, weight loss and cough,
but worsening in the fatigue score (P0.05). Improvements in FBrSI item
scores (P0.05) were recorded for headache and worry about their condition,
but worsening (P0.05) for seizure, weakness in arms/legs, trouble with
coordination, and ability to enjoy life.
Conclusions: Mean FLSI and FBrSI index scores did not differ significantly
from baseline during the treatment period. There was improvement in some
symptoms associated with lung cancer, including shortness of breath, weight
loss and cough. Fatigue, on the other hand, worsened on therapy.
Author Disclosure Block: D. Cella, Pfizer Oncology, B. Research Grant;
Novartis, B. Research Grant; Aveo, B. Research Grant; Pfizer Oncology, F.
Consulting/Advisory Board; Novartis, F. Consulting/Advisory Board; Aveo,
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Companion Diagnostic Test for Expression of -III Tubulin
(3T) in Non-small Cell Lung Cancer (NSCLC) Using an Im-
munohistochemical (IHC) Assay in Studies of Ixabepilone (ixa)
C. M. Roach1, V. Tanna1, R. Welcher1, C. Dumontet2, P. Seve3, O. Trifan4,
1Dako North America, Carpinteria, CA, 2Laboratoire D’Hematologie, Lyon,
France, 3Hotel Dieu, Lyon, France, 4Bristol-Myers Squibb Co, Wallingford, CT
Purpose/Objective(s): Preclinical and retrospective clinical data suggest
that 3T is a biomarker for poor prognosis and resistance to paclitaxel in
NSCLC. Preclinical studies have suggested that 3T expression may predict
response rates to taxanes and overall survival in NSCLC patients, with high
IHC expression of 3T being associated with low response rates and poor
prognosis [Seve et al., Clin Cancer Res 2007; 13(3) 994-999]. Dako and
BMS have developed an IHC assay for detection of 3T to explore the
potential of 3T as a biomarker to select NSCLC patients that may benefit
from Ixa. A trial of ixabepilone in NSCLC employed this assay to assess 3T
expression levels in patient tumor samples. Here we describe the application
and initial validation testing of the assay in NSCLC tumor samples.
Materials/Methods: An IHC assay employing a murine monoclonal anti-3T
antibody (TUJ1) was developed to assess 3T expression in formalin-fixed
paraffin-embedded tissue specimens. Banked specimens for initial testing in-
cluded 193 cases of NSCLC (predominately clinical stages I, II and IIIA).
Results: Patterns of 3T staining were typically homogeneous cytoplasmic
staining with normal tissue elements such as endothelial cells and nerve cells
serving as internal positive controls. Staining intensity was scored as 0, 1,
2 or 3 with 0 being no visible staining and 2 being equal to that of the
internal positive control of normal endothelial tissue. Tumors with 50%
cells staining 2 were defined as positive for 3T based on previous
published studies. Of the 193 NSCLC specimens, 83 (43%) were positive
and 110 (57%) were negative for 3T expression. Among the 193 NSCLC
specimens, 37% were adenocarcinomas (AC) and 38% squamous cell car-
cinomas (SCC), with the AC exhibiting a 3-fold greater rate of 3T positivity
than the SCC. In pathologist training exercises the inter-reader and intra-
reader agreement of 3T scoring exceeded 85%. Antigen stability has been
confirmed and other assay validation efforts are ongoing.
Conclusions: These findings are consistent with previously reported data on
3T expression in NSCLC, and support the use of this 3T IHC assay in
studies with ixabepilone.
Author Disclosure Block: C.M. Roach: A. Employment; Dako North
America, Inc. E. Ownership Interest; Dako North America, Inc. Stock. V.
Tanna: A. Employment; Dako North America, Inc. E. Ownership Interest;
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Stereotactic Body Radiotherapy for Centrally Located Lung
Tumors
D. Bryant, Via Christi Cancer Center, Wichita, KS
Purpose/Objective(s): Stereotactic radiotherapy to the lesions within 2 cm
of the major airways has been shown to carry a high risk for side effects
when treated with linac-based machines. The purpose of this retrospective
study is to investigate the safety and efficacy of stereotactic body radiother-
apy (SBRT) for patients with central tumors treated with a Cyberknife.
Materials/Methods: One hundred patients who underwent SBRT for tumors
within 2 cm of the major airways were retrospectively analyzed. Eighty-one
had NSCLC, 2 had SCLC and the rest represented metastatic disease.
Ninety-seven were treated with 48Gy in 12Gy fractions. All patients have
been followed for at least five months. Six tumors were in previously
irradiated areas.
Results: With a median follow up of the entire group of 13.7 months 59
patients remain alive at last follow up. Ten of these patients have been lost
to follow up but had progressive metastatic cancer. Five were lost to follow
up with no evidence of disease. The median follow up for living patients is
17.5 months (5-41). Forty-two of the living patients have no evidence of
disease. Two of the living patients have local failures and 9 have regional
failures (15%). Seven of the nine patients with regional failures also had
metastatic disease. Out of the patients that are living one patient developed
grade 3 esophagitis. Six patients developed consolidation of a single lobe
with mild symptoms. Out of the 42 patients that died, 14 died of metastatic
disease (33%) and 3 developed regional progression leading to death. The
cause of death in 6 patients was not documented (2 required 4L of oxygen
before treatment and 1 showed clinical pulmonary improvement before
dying). Two patients died of other medical problems including one MI and
one bowel perforation. Nine patients died with pulmonary complication,
which usually consisted of consolidation of the entire lung followed by
pneumonia. The median time between treatment and death was 4 months
(1-8). One patient with a large tracheal lesion died of hemoptysis at 7
months. One patient developed esophagitis that required a PEG tube but
ultimately died of wasting without pulmonary complaints. Eleven patients
that may have died of treatment related causes were treated in 2007.
Conclusions: Considering 42% of the patients are alive and free of disease
and 11 of the 14 patients that died of treatment related causes were treated
early in the series, SBRT may prove to be very valuable for centrally located
tumors. Considerations made later in the series to improve the therapeutic
ratio included prior doses of RT, total dose, fractional dose, irradiated
volumes, and oxygen requirement.
Author Disclosure Block: D. Bryant: None.
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Intratumoral Chemotherapy as an Adjunct to Endobronchial
Brachytherapy
D. Nader, J. Flynn, J. Stark, Cancer Treatment Centers of America at, Tulsa,
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Journal of Thoracic Oncology • Volume 5, Number 12, Supplement 7, December 2010 Abstracts
Copyright © 2010 by the International Association for the Study of Lung Cancer S541
Purpose/Objective(s): NSCLC patients (pts) with clinically significant en-
dobronchial obstruction have a poor prognosis and quality of life in both
locally advanced and metastatic stages of disease. Radiation therapy (RTx) in
conjunction with chemotherapy (CTx) improves survival compared to either
modality alone but produces great toxicity and morbidity. Significant clinical
benefit with respect to disease management and quality of life could be
realized with improved methods for controlling obstructing endobronchial
lesions. The hypothesis for this study is that optimal clinical control of
endobronchial lesions can be achieved by intratumoral injection of a drug
with both clinical activity against NSCLC and synergy with RTx. Cisplatin
(CPt), an active agent in NSCLC and a known radiosensitizer is an ideal drug
for this objective. Thus, the goal of this exploratory study was to determine
the clinical efficacy and tolerance to intratumoral CPt injection in combina-
tion with HDR brachytherapy (BTx) in NSCLC patients with obstructing
endobronchial lesions.
Materials/Methods: NSCLC pts (n23) with  75% endoluminal obstruc-
tion of a main or lobar airway were evaluated. Intratumoral CTx consisted of
CPt (1 mg/ml; 0.5-2.0 ml/session) injected into the entire visible tumor
through a flexible 21 gauge needle through the bronchoscope. BTx was given
as 500 cGy/session at one cm diameter for 4 sessions with CTx.
Results: All pts completed a maximum of 5 sessions of planned local therapy
or until complete resolution of endobronchial disease. There was complete
resolution of injected lesions in 21/23 pts confirmed bronchoscopically and,
23/23 cytologically. In the other 2 pts, necrotic tissue occupying 10 and
20% of the airway, cytologically negative for tumor was seen. There were no
adverse events or complications related to bronchoscopy or local CTx.
Conclusions: The results of this study demonstrate that intratumoral admin-
istration of CPt, as an adjunct to endobronchial BTx for the management of
endobronchial obstructing lesions in patients with NSCLC is safe and
effective. This approach offers the possibility of superior local tumor control
while reducing toxicity to normal lung and esophagus as compared to
conventional external beam radiation therapy modalities.
Author Disclosure Block: D. Nader, Cancer Treatment Centers of America
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Treatment of Metastatic Thymic Carcinomas with Sunitinib
Based on Phospho-Receptor Tyrosine Kinase Array Findings
P. Hohenberger1, A. Marx2, R. Bargou3, C. Sauer2, A. Dimitrakopoulou-
Strauss4, P. Stroebel2, 1Div. Surgical Oncology &Thoracic Surgery, Mann-
heim University Medical Center, 68167, Germany, 2Dept. of Pathology,
Mannheim University Medical Center, Mannheim, Germany, 3Div. of He-
matology and Medical Oncology, Dept. of Internal Medicine II, University of
Wu¨rzburg, 97070, Germany, 4Clinical Cooperation Unit Nuclear Medicine,
German Cancer Research Center, Heidelberg, 69120, Germany
Purpose/Objective(s): Thymic carcinoma (TC) is a rare aggressive tumor
with short median survival. Despite findings of KIT overexpression and KIT
mutations in TC, imatinib treatment has not proven useful. Sunitinib is a
multitargeted tyrosine kinase inhibitor (TKI) that has shown activity in other
metastatic cancers. In an investigator-driven approach, we explored the role
of sunitinib in selected patients based on molecular characteristics of the
tumor tissue.
Materials/Methods: To determine activation of receptor tyrosine kinases,
the Human Phospho-Receptor Tyrosine Kinase (RTK) Array Kit (R&D
systems, Wiesbaden, Germany) was used together with histology, immuno-
histochemistry and in-situ hybridisation to detect EBCV RNA in freh,
snap-frozen TC tissue. We also looked for genetic mutations in KIT, EGFR,
Kras and Braf genes. The RTK allowed for simultaneous detection of 42
different phosphorylated receptor tyrosine kinases and 6 controls.
Patients: Based on the RTK analyses, four patients with metastatic TC
refractory to conventional chemotherapy were started on a standard dose
regimen of 50mg/d of sunitinib, cycled 4 weeks on / 2 weeks off. FDG-PET
was used to monitor the functional response to application of RTK inhibition
and monitor treatment effects.
Results: Tumor tissue analysis showed activation of multiple RTK, includ-
ing PDGFR and VEGFR3. Mutations of EGFR, c-KIT, KRAS and BRAF
genes were not found. Three TC patients developed partial remissions (PR
according to RECIST) up to 21 months. Re-introduction of sunitinib after
stop for toxicity and progression of the residual tumor prompted again
immediate control of tumor spread. Overall survival under sunitinib treat-
ment ranges from 4 to 46 months. One patient with a B3 thymoma was
refractory to sunitinib but showed PR on subsequent sorafenib therapy.
Conclusions: Sunitinib may serve as a very active new treatment option for
metastatic thymic carcinoma. Proper selection of patients by sophisticated
molecular analyses of RTK activation from tumor tissue should be performed
to optimize treatment results.
Author Disclosure Block: P. Hohenberger, None; A. Marx, None; R.
Bargou, None; C. Sauer, None; A. Dimitrakopoulou-Strauss, None; P.
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CXCR4 as a Therapeutic Target in Lung Cancer
T. C. Gangadhar1, S. Nandi1, C. Rolle1, E. Ramirez1, M. Surati1, R. Kanteti1,
M. Sattler2, A. N. Husain1, R. Salgia1, 1University of Chicago, Chicago, IL,
2Dana Farber Cancer Institute, Boston, MA
Lung cancer is the leading cause of cancer death worldwide. Small cell lung
cancer (SCLC) is characterized by early, extensive metastasis, treatment
resistance and almost certain relapse. Lung cancer cells express the G-protein
coupled chemokine receptor CXCR4. CXCR4 mediated signaling is acti-
vated by its ligand, CXCL12, and is important in cell proliferation and
migration, as well as integrin up-regulation, a possible mechanism for
resistance and relapse due to tumor cell interaction with the protective
extracellular matrix. We analyzed ten tissue microarrays representing repli-
cate tumor and normal lung tissue samples from 126 patients with small cell
or non-small cell lung cancer. We found that tumor tissue expressed signif-
icantly higher levels of both CXCR4 (p0.0001) and CXCL12 (p0.0001)
levels compared to normal lung tissue from the same patient using both a
nine point pathology scoring system and also by Integrated Optical Density
calculated using an Automated Cellular Imaging System. In addition, in-
creased CXCL12 levels (p0.018) and CXCR4 levels (p0.056) were
correlated with improved survival, suggesting a prognostic role. We next
analyzed 84 tumor DNA samples for alterations in CXCR4 and CXCL12
genes. We detected one synonymous SNP in CXCR4, seen in three patients.
In addition, Two patients had a significant increase in CXCR4 gene copy
number (9) by qPCR with three additional patients having a copy number
greater than four. When analyzed as a continuous variable, CXCR4 gene
copy number correlated with decreased survival (p0.02). Finally, using an
MTT based proliferation assay, we have shown that the addition of CXCR4
inhibition with AMD3100 may have an additive effect when combined with
cytotoxic chemotherapy with etoposide, SN38 or the MET inhibitor
SU11274 in both H69 (SCLC) and A549 (NSCLC) cell lines, as well as with
erlotinib in A549 cells. This additive effect appears to be enhanced when
cells are co-cultured with HS5 human stromal cells, indicating that an
inhibitory effect on the tumor-stromal interaction may contribute to increased
cytotoxicity. We hypothesize that inhibition of CXCR4 will increase the
efficacy of cytotoxic chemotherapy when used in combination in the treat-
ment of lung cancers.
Author Disclosure Block: T.C. Gangadhar: None. S. Nandi: None. C.
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Activity of the IGF1-R/IR Inhibitor OSI-906 in Non-small Cell
Lung Cancer (NSCLC): Pre-Clinical and Early Clinical Expe-
rience
E. S. Kim1, I. Puzanov2, E. Buck3, R. Gedrich4, S. Poondru4, C. Carden5,
S. B. Kaye5, A. Davies4, P. Nava-Parada4, M. R. Miglarese4, 1M.D. Ander-
son Cancer Center, Houston, TX, 2Vanderbilt-Ingram Cancer Center., Nash-
ville, TN, 3OSIP, Melville, NY, 4OSIP, Boulder, CO, 5Royal Marsden
Hospital, London, United Kingdom
Purpose/Objective(s): OSI-906 is a selective, dual inhibitor of IGF-1R and
IR being evaluated in clinical trials. Activation of the IGF axis has been
implicated in NSCLC, and herein we present the preclinical, pharmacody-
namic, and clinical data captured for OSI-906 in this tumor type. Elevated
phospho-IGF-1R/IR, elevated IGF2 mRNA expression and epithelial phe-
notype in NSCLC cell lines were each associated with sensitivity to OSI-906
in vitro. The IC50 of OSI-906 was 0.5uM in four of eight NSCLC cells
lines tested. Each of the sensitive cell lines exhibited an epithelial phenotype
with elevated basal phospho-IGF-1R. In NCI-H322 cells, which rely on an
autocrine IGF-2 loop, both phospho-IR and phospho-IGF-1R were readily
detected. Greater inhibition of downstream signaling via IRS1 and AKT was
observed with OSI-906 compared to an anti-IGF-1R specific antibody,
supporting the importance of targeting both IGF-1R and IR in NSCLC.
Materials/Methods: Twenty-two patients (pts) with NSCLC have been
enrolled in two single agent Phase 1 trials. Four pts were treated with
continuous daily dosing and eighteen pts were treated on intermittent dosing
schedules.
Results: Data from eighteen pts (of the 22) is currently available; the pt
characteristics are as follows: median age: 61.5 yrs (41-71) and 66 yrs
(48-76); gender: 2M/12F and 7M/7F; median # of prior therapies: 7 (2-9) and
3 (1-7) and median treatment 9 weeks (3-18) and 6 (1-43) in the continuous
and intermittent dose schedules, respectively. 8 of 18 pts with available data
had stable disease (SD)12 weeks. 2 pts with 3 prior regimens and who had
rapid progression on their last treatment achieved prolonged SDs,one of them
for 43 weeks, This was a 77 y/o male smoker with adenocarcinoma, had a
12.5 % reduction overall by RECIST with a target lesion reduction of
25%.Evaluation of the diagnostic biopsy of the pt with a minor response
indicates that the tumor displayed an epithelial phenotype (E-cad /vimen-
tin-), consistent with the preclinical data.
Conclusions: At the recommended Phase 2 dose of (specify dose and
schedule), pharmacokinetic (PK) analyses of OSI-906 indicate that plasma
concentrations greater than those required for efficacy in sensitive preclinical
models, can be achieved and maintained for the entire dosing period. At these
exposures phosphorylation of IGF-1R and IR in pts’ PBMCs was substan-
tially reduced. In addition, elevated plasma concentrations of IGF-1 and
insulin were observed on both dosing schedules. OSI-906 has show an
acceptable safety profile with preliminary signs of activity in NSCLC
patients.
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HN125: A Novel High Affinity Human Immunoadhesin to
CA125/MUC16
X. Xiang, M. Feng, M. Ho, National Cancer Institute, Bethesda, MD
The mucin CA125 (also called MUC16) has been known for decades as a
well-validated pan cancer marker overexpressed on the cell surface of
mesothelioma and other solid tumors. In spite of recent efforts to make
mouse monoclonal antibodies to CA125 that are currently evaluated in
preclinical and clinical studies, a fully human monoclonal antibody against
CA125 has not been reported. Due to its slow internalization, CA125 may be
a poor target for immunoconjugates or drug conjugates that act inside cancer
cells. Recent studies show that CA125 tightly binds mesothelin. The CA125-
mesothelin interaction mediates heterotypic cancer cell adhesion, indicating
that CA125 and mesothelin may possibly play an important role in the
implantation and metastatic spread of tumors. Therefore, we postulate that a
more ideal candidate therapeutic targeting CA125 would functionally block
the interaction of CA125 and mesothelin, and would not require internaliza-
tion for its anti-tumor activity. Here, we report the first fully human
immunoadhesin (called HN125) consisting of 64 amino acids (296-359) at
the N-terminal of cell surface mesothelin, a functional binding domain for
CA125, and the Fc portion of a human antibody IgG1 (hFc). We show that
HN125 has high and specific affinity for CA125-expressing cancer cells and
the ability to completely disrupt the mesothelin-CA125 interaction on cancer
cells. It also elicits strong antibody-dependent cell mediated cytotoxicity
against cancer cells, thereby suggesting that HN125 has therapeutic potential
as a novel agent for treating mesothelioma and other CA125-expressing
tumors. This work is supported by the Intramural Research Program of the
NIH, the Mesothelioma Applied Research Foundation (MH), and the Ovar-
ian Cancer Research Fund (MH).
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Studies Of Cbl In Lung Cancer: C. Elegans As A Potential
Model System
R. P. Kanteti, E. El-Hashani, M. C. Nickels, K. Vokes, R. Salgia, University
of Chicago, Chicago, IL
Non-small cell lung cancer (NSCLC) is a heterogeneous group of disorders
with a number of alterations in the genome as well as the proteome. We have
previously shown that several of the receptor tyrosine kinases (RTK) such as
c-Met are mutated in lung cancer and that they contribute significantly to
lung tumor development and metastasis. We recently showed that c-CBL, an
E3 ubiquitin ligase and adaptor molecule that plays an indispensable role in
the regulation of the expression levels of several RTKs is frequently mutated
in NSCLC, as evidenced by the rate of somatic missense mutation and LOH
(loss of heterozygosity). It is therefore very likely that c-Cbl may play an
essential role in lung tumorigenesis and metastasis. Here, we have used the
simple soil nematode C. elegans as a model to screen c-Cbl mutants
discovered in lung cancer for their effects on survival, fecundity and
abnormal vulval development that is usually accompanied by hyperplasia;
and the later parameter correlates positively with the tumorigenic potential of
c-Met and EGFR mutants discovered in lung cancer. As a first step we
investigated the effects of three known sli-1(human c-Cbl equivalent) mu-
tants in C. elegans on survival, fecundity and vulval development. In
addition, we determined the added effect of Nicotine exposure on the above
mutants and compared the results with normal wild type worms (N2). In case
of the two sli-1 mutants, the average number of days for 50% survival was
12 whereas in N2 controls it was much higher. Upon Nicotine treatment (500
M), the 50% survival rate in sli-1 mutants dropped to 10 days whereas in
N2 it didn’t change much. Our results thus clearly demonstrate that the
survival of the worms is adversely affected in worms that have the mutant
sli-1 (c-Cbl) as compared to the control N2 worms; and this was further
worsened upon treatment with increasing concentrations of nicotine. Of the
three mutants tested, PS2728 appears to be most sensitive. Although all the
three sli-1 mutants showed relatively normal fecundity when grown under
optimal conditions, they however, suffered from significant loss in fecundity
as compared to the N2 wild type worms when treated with increasing
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concentrations of Nicotine. This clearly suggested that in addition to abnor-
mal vulval development and vulval hyperplasia, we can also use survival and
fecundity as an additional parameter to assess the combined effects of c-Cbl
mutation and exposure to nicotine for the rapid screening of mutants
discovered in NSCLC. Since c-Met related kinases are known to exist in C.
elegans and since sli-1 is known to negatively regulate the expression levels
of RTKs, we are therefore currently determining the effects of c-Met
inhibitor on the above mutants in the presence and absence of Nicotine
treatment.
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Nickels, None; K. Vokes, None; R. Salgia, None.
195
MET Mutations And Function In Lung Cancer
I. Kawada1, R. Hasina1, G. Kanade1, S. Nandi1, R. Kanteti1, E. El-Hashani1,
K. Asano2, K. Soejima2, E. E. Vokes1, R. Salgia1, 1Department of Medici-
ne,The University of Chicago, Chicago, IL, 2Department of Pulmonary
Medicine, School of Medicine, Keio University, Tokyo, Japan
MET receptor tyrosine kinase can be activated in a number of malignancies
via its ligand hepatocyte growth factor (HGF), or mutated, or amplified, or
not degraded. We have been studying the role of MET/HGF axis in lung
cancer and have identified some unique pathways through which MET gets
activated. One of the striking results has been the mutations in lung cancer,
especially in the semaphorin domain and the juxtamembrane domain, and not
in the tyrosine kinase domain. In particular, we have identified ancestral
variations of MET in comparative analysis of non-small cell lung cancer
(NSCLC) tumor tissues from Asians versus Caucasians versus African-
Americans. As an example, approximately 13% of Asian NSCLC tumor
tissues harbor the N375S MET mutation, and this is not identified in NSCLC
from African-Americans. Also, there are a number of SNPs that have been
identified for MET in NSCLC. We also identified that MET mutations are
not mutually exclusive from K-Ras or EGFR or p53 mutations. Interestingly,
there can be CBL loss of heterozygosity or mutation in the context of MET
mutations. CBL is an E3 ubiquitin ligase important in the processing of MET
and other receptor tyrosine kinases. In order to systematically study the
mutations, we have determined the HGF binding to various mutations in
semaphorin domain, and identified differential binding of E168D versus
N375S versus wild-type MET mutation. Also, there is a decreased sensitivity
to MET inhibition through SU11274 for N375S MET as compared to
wild-type MET. Interestingly, there is increased sensitivity to MET inhibi-
tion for E168D MET mutation. We are now systematically pursuing the role
of the various mutations of MET and their proliferative and migratory
capacity. It is predicted that the sensitivity to MET inhibition will be
dependent on the different MET mutations, as well their proliferative and
migratory capabilities.
Author Disclosure Block: I. Kawada: None. R. Hasina: None. G. Ka-
nade: None. S. Nandi: None. R. Kanteti: None. E. El-Hashani: None. K.
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Evaluation of Dose-Volume Metrics Associated With Local Re-
currence After Stereotactic Body Radiation Therapy for Lung
Cancer
Y. Matsuo, K. Shibuya, M. Nakamura, M. Narabayashi, K. Sakanaka, N.
Ueki, T. Mizowaki, M. Hiraoka, Kyoto University Graduate School of
Medicine, Kyoto 606-8507, Japan
Purpose/Objective(s): The purpose of this study is to evaluate dose-volume
metrics associated with local recurrence after stereotactic body radiation
therapy (SBRT) for lung cancer.
Materials/Methods: Eighty-nine patients who underwent SBRT for primary
lung cancer in our institution during September 2003 and March 2009 were
retrospectively reviewed. Sixty-six were male, and twenty-three were fe-
male. Histology was adenocarcinoma in 42 patients, squamous cell carci-
noma in 34, large cell carcinoma in 2, and non-small cell carcinoma in 11.
Prescribed dose was 48 Gy in 4 fractions at the isocenter under heterogeneity
correction of Batho power law (BPL). The planning target volume (PTV)
was defined as 5-mm margins with the internal target volume delineated on
slow-scan CT or averaged image from 4D-CT. X-ray beams from 6-MV
linear accelerators were collimated to the PTV plus 5 mm. SBRT plans
which were clinically used for the patients were recalculated with Eclipse
(Varian) under the same monitor units under the following three conditions
of heterogeneity correction: BPL, anisotropic analytical algorithm (AAA),
and no heterogeneity correction (NC). Between patients who developed local
recurrence (LR) and patients with local lesion controlled (LC), the following
dose-volumetric data under each algorithm were compared: D95, minimal
dose (Min) and mean dose (Mean) in the PTV.
Results: With a median follow-up of 30 months, local recurrence was
observed in 16 patients (18%). Under BPL, mean values in PTV D95, Min
and Mean were 45.5, 42.6 and 47.5 Gy in the LC group; and 45.2, 42.4 and
47.5 Gy in the LR group, respectively. Under AAA, those values were 42.1,
38.7 and 45.5 Gy in LC; and 42.1, 38.6 and 45.7 Gy in LR, respectively. No
significant differences were observed in any of the metrics between LC and
LR. Under NC, PTV D95, Min and Mean were 41.6, 39.0 and 44.3 Gy in LC;
and 40.9, 38.5 and 43.8 Gy in LR, respectively. Although dose-volume
metrics of PTV tended to be lower in the LR patients than those in the LC,
the differences were not significant.
Conclusions: None of the dose-volume metrics showed significant differ-
ence between the patients with local recurrence and those with local tumor
controlled. Other factors should be investigated as predictors of local recur-
rence after SBRT.
Author Disclosure Block: Y. Matsuo, None; K. Shibuya, None; M.
Nakamura, None; M. Narabayashi, None; K. Sakanaka, None; N. Ueki,
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Expression, Mutation and Functional Analysis of Paxillin
R. Hasina, I. Kawada, G. Kanade, V. Nallasura, R. Kanteti, M. Tretiakova,
A. N. Husain, W. Vigneswaran, H. Kindler, R. Salgia, The University of
Chicago, Chicago, IL
Paxillin is a 68 kDa focal adhesion protein that provides multiple docking
sites at the plasma membrane for an array of signaling molecules and helps
form a structural link between the extracellular matrix and the actin cytoskel-
eton. It is essential in actin filament assembly and focal adhesion formation.
Focal adhesion complexes are the drivers of cell spreading and migration,
adhesion to the extracellular matrix and matrix remodeling by fibrillar
adhesions in which paxillin plays a major role. It has been shown that the
modulation of tyrosine phosphorylation of paxillin regulates both the assem-
bly and turnover of adhesion sites and phosphorylated paxillin enhances
lamellipodial protrusions whereas non-phosphorylated paxillin is essential
for fibrillar adhesion formation. FAK, a focal adhesion kinase, preferentially
interacts with paxillin and its recruitment is implicated in high turnover of
focal complexes and translocation of focal adhesions. We have previously
reported that in lung cancer, paxillin was over expressed, amplified and
mutated in a significant number of patient samples and the protein upregu-
lated in higher stages of lung cancer compared with lower stages. We also
showed paxillin gene to be amplified in some pre-neoplastic lung lesions.
Among the mutations we described, A127T enhanced cell proliferation, focal
adhesion formation and colocalization with Bcl-2 in lung cancer cells. We
have now analyzed 50 epithelioid, and 16 sarcomatoid mesothelioma tumor
tissue, and compared them to 40 normal adjacent lung parenchyma. Quan-
titative staining intensity analyzed using automated cellular imaging system
(ACIS) of immunostained slides showed that whereas normal lung had IODs
of 45, 13 and 118 for FAK, pFAK and paxillin respectively, epithelioid
MPM had IODs of 273, 14 and 268 and sarcomatoid had IODs of 218, 12 and
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331. This demonstrates that paxillin and FAK are highly upregulated in both
epithelioid and sarcomatoid mesothelioma. We now report the detection of
paxillin A127T mutation in pleural mesothelioma patient samples. To study
the effects of activating mutations in lung cancer and malignant mesotheli-
oma, we have synthesized GFP tagged paxillin mutant clones including
A127T, and utilized live-cell imaging to systematically study the effects of
wild-type paxillin versus mutants. We created a mathematical model that
recapitulates the salient features of the measured dynamics, and conclude
that compared to wild-type, mutant A127T confers a) enhanced focal
adhesion formation, b) increased filopodia and lamellipodia formation c)
increased mobility and d) increased cell displacement in transiently trans-
fected HEK-293 cells. We believe that paxillin is an important molecule in
thoracic cancer including lung and malignant mesothelioma, and its thera-
peutic potential needs to be explored further.
Author Disclosure Block: R. Hasina, None; I. Kawada, None;G. Kanade,
None; V. Nallasura, None; R. Kanteti, None; M. Tretiakova, None; A.N.
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Investigation of Folate Cycle in Non-small Cell Lung Carcinoma
T. A. Boyle, R. C. Montoya, P. Lenhart, P. Chesnut, W. Franklin, University
of Colorado, Aurora, CO
Purpose/Objective(s): The folate cycle is a critical pathway for tumor
growth and proliferation. Folates are bound by folate receptors and endocy-
tosed into the cell and then folate is used as a cofactor by thymidylate
synthase to activate DNA synthesis. Our goal was to investigate the rela-
tionships between alpha-folate receptor (FR), thymidylate synthase (TS), cell
proliferation (Ki-67) and subtype diagnosis in patients with non-small cell
lung carcinoma.
Materials/Methods: Immunohistochemistry was performed on 47 non-
small cell lung tumor specimens embedded in paraffin blocks to evaluate
expression levels of FR, TS and Ki-67. The levels of these markers and
diagnosis by subtype were analyzed using Pearson’s two-tailed correlation
analysis.
Results: The expression of all combinations of FR, TS and Ki-67, were
significantly correlated (N47, p  0.001). The expression of FR was
inversely related to both the expression of TS (p0.0003) and Ki-67
(p0.0002). The expression of TS highly paralleled the expression of Ki-67
(p0.0000004). In addition, in adenocarcinomas, the expression of FR
tended to be highly expressed with low or absent expression of TS; whereas
in squamous cell carcinoma, TS was highly expressed with low or absent
expression of FR (N47, p0.01).
Conclusions: This analysis revealed a differential expression of FR and TS
in adenocarcinoma versus squamous cell carcinoma cases. In addition, TS
and Ki-67 appear to be interchangeable markers of cellular proliferation in
non-small cell lung carcinoma. The higher expression of FR and lower
expression of TS in adenocarcinoma versus squamous cell carcinomas is
consistent with studies that have found that patients with adenocarcinoma are
more likely to respond to anti-folate chemotherapeutic agents than patients
with squamous cell carcinoma.
Author Disclosure Block: T.A. Boyle, None; R.C. Montoya, None; P.
Lenhart, None; P. Chesnut, None; W. Franklin, None.
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A Phase I Study of MM-10-001 in Advanced Non-small Cell
Lung Cancer
M. Koczywas1, M. Cristea1, K. L. Reckamp1, A. Rotter1, P. Frankel1, S.
Fouladi Rad1, X. Liu1, V. Tran1, M. Kalos2, S. Lacey1, 1City Of Hope Medcl
Ctr, Duarte, CA, 2University of Pennsylvania School of Medicine, Pennsyl-
vania, PA
Purpose/Objective(s): MM-10-001 is a bioactive agent exported from
Shiitake Mycelium in aqueous medium. The MM-10-001 contains a triple
helix beta-glucan, isolated from the cell walls of the shiitake mushroom
(Lentinula edodes), with potential immunostimulating activity. The beta-
glucan in MM-10-001 binds to a lectin site within the complement receptor
3 on leukocytes, priming the receptor to trigger cytotoxic degranulation of
leukocytes when leukocyte CR3 binds to iC3b-opsonized tumor cells. This
phase I study was designed to assess the feasibility and toxicity of therapy
with beta-glucan MM-10-001. Secondary endpoints included exploratory
analysis of the effect of MM-10-001 on the innate immune compartment (in
particular NK cell activation and effector status) and the cytokine profile of
the patients as well as antitumor efficacy and patient reported functional
status.
Materials/Methods: Patients with advanced NSCLC for which standard
curative or palliative measures do not exist or are no longer effective
received orally escalating doses of MM-10-001 (5mg, 10 mg and 20 mg); a
cycle consisted of 28 days. The blood samples for correlative studies were
collected pre-study and weeks 1, 5, 9, 13. Serum cytokine levels were
measured with 30-plex cytokine/ chemokine/growth factor multiplex panels
(Invitrogen), and analyzed using a FLEXMAP-3D instrument (Luminex).
Results: To date, 20 patients (7M/13F) have been treated (MM-10-001 5 - 20
mg). The median age was 72 (range 43-88), with 9 ECOG 0, and 11 ECOG
1. All patients were evaluable for toxicity. No grade 3 treatment related
adverse events were noted. Grade 2 adverse events reported are fatigue (3
pts), anorexia (1 pt), Alk Phos (1 pt), and joint pain (1 pt), each with an
attribution of “possible”. Median time to treatment failure was 3.5 months
(range 1-13 months). Correlative studies on 19 cytokines in addition to
immunoglobulins (A, M, G), WBC, hemoglobin, PLT, ANC, C-reactive
protein, and serum complements C3 and C4 were conducted on 18/20
subjects. Significant cytokine increases were noted in three patients concur-
rent with progression, resulting in a positive trend in several cytokines over
time. Subset analysis, excluding those patients, suggested a possible decrease
in IL-12 as a function of both time and dose (p0.01, 0.02 respectively),
along with a decrease in MIP1b as a function of dose (p0.03). These results
were not significant when adjusting for multiple comparisons. However, after
accounting for multiple comparisons, low IL-2R was associated with im-
proved survival (p0.05, log-rank).
Conclusions: At the time of interim analysis, the MTD has not been reached
and study will continue with escalating doses of MM-10-001. The prelimi-
nary data indicates potential immunostimulating activity of MM-10-001.
Author Disclosure Block: M. Koczywas: None. M. Cristea: None. K.L.
Reckamp: None. A. Rotter: None. P. Frankel: None. S. Fouladi Rad:
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Early Outcomes of Thoracic Stereotactic Body Radiation Ther-
apy: Community-based Experience
A. M. Mihai1, J. G. Armstrong1, D. E. Heron2, L. Rock1, S. M. Huq2, A.
Kennedy1, C. Burke1, S. Callinan1, N. Sheehy1, P. Thirion1, 1UPMC Beacon
Hospital, Dublin, Ireland, 2University of Pittsburgh Cancer Institute, Pitts-
burgh, PA
Purpose/Objective(s): To report the outcome of patients (pts) treated by
Thoracic Stereotactic Body Radiation Therapy (T-SBRT) in a community-
based Radiation Oncology department using a trans-Atlantic hub and spoke
structure.
Materials/Methods: Since 05/2009, T-SBRT is available at UPMC Beacon
Hospital (Dublin Ireland)and was offered to pts with primary inoperable
Non-Small Cell Lung Cancer (NSCLC) and Pulmonary Oligo- Metastatic
Disease (POMD). All pts underwent retrospective 4D-planning CT scan,
allowing respiratory motion-based PTV individualization. IMRT planning
was outsourced to D3 facility (Pittsburgh, USA). Dose fractionation was
based on the tumor location and physician preference. Trilogy TX linear
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accelerator (6MV) was used to deliver T-SBRT. Respiratory monitoring
(Varian RPM system) and strict treatment verification (onboard orthogonal
KV, CBCT and fluoroscopic imaging) were strictly implemented. Toxicity
(RTOG grading system) was prospectively recorded. Tumor response was
evaluated on standard CT scan  PET-CT (RECIST modified criteria).
Results: From 05/2009 to 05/2010, 35 pts (21NSCLC and 14 POMD)
received T-SBRT. Median age was 68 y (38-88). Median tumor size was
2.5cm (0.5-8.4). PET-CT based planning was used in 32 pts. Most common
fractionations were 60Gy/3fr (16pts) and 48Gy/4fr (14pts). 18 pts had
non-gated treatment, and 17 pts required either gated (12 pts) or deep-breath
hold delivery (5 pts). Twenty nine pts with 1 month minimum follow-up
(FU) were included in the analysis. The acute radio-induced toxicity profile
was extremely favorable. Only 1 patient experienced grade3 radiation pneu-
monitis, requiring admission, oral steroids and oxygen. Other acute toxici-
ties: grade2 asthenia (6 pts) and grade2 shoulder joint discomfort (10pts),
grade2 skin erythema (1 pts). No grade3 long-term sequelae were reported.
With a median 5 months FU (1-21,10pts with FU  10 months), 26 pts were
alive, and 3 have died (2 of extra-thoracic PD, 1 exacerbation of COPD).
Amongst the 26 pts alive at the last FU, target lesion response on standard
CT was: complete in 4pts, partial in 2 pts and stable in 8 pts. In 4 pts the CT
could not differentiate between progression versus radiation changes and
PET-CT is pending. Progressive disease outside target was recorded in 6 pts:
intra-thoracic in 2pts with P-OMD and extra-thoracic in 4pts.In 5 pts (20%),
use of PET-CT changed the treatment response from SD to either CR (3pts)
or PR (2pts).
Conclusions: T-SBRT is a recognized treatment alternative in inoperable
NSCLC or P- OMD, with limited toxicity and early high response rate. Our
experience shows that it can be safely and successfully implemented in small
community centre, pending strict protocol application. Our results suggest
that PET-CT should be used in the assessment of response after T-SBRT.
Author Disclosure Block: A.M. Mihai, None; J.G. Armstrong, None;
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Urinary PGE-M as a Biomarker for COX-2 Inhibition in Ad-
vanced Non-small Cell Lung Cancer
K. L. Reckamp1, M. Koczywas1, M. Cristea1, J. E. Dowell2, B. Gardner3, G.
Milne4, S. Fouladi Rad1, R. A. Figlin5, R. Elashoff3, S. M. Dubinett3, 1City
of Hope Comprehensive Cancer Center, Duarte, CA, 2University of Texas,
Southwestern, Dallas, TX, 3David Geffen School of Medicine at UCLA, Los
Angeles, CA, 4Vanderbilt University, Nashville, TN, 5Samuel Oschin Com-
prehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA
Purpose/Objective(s): The combination of COX-2 inhibition with either
celecoxib or rofecoxib and EGFR TKI therapy with gefitinib or erlotinib has
been investigated in multiple studies. Results demonstrate that the combina-
tions are generally well tolerated, but response rates have been variable.
Selecting for tumors that overexpress COX-2 may improve the efficacy of
the combination. In addition, the magnitude of COX-2 inhibition may have
been ineffective in some studies due to an inadequate dose. Utilizing urinary
PGE-M, the predominant metabolite of PGE2, as a marker to determine the
appropriate dose for effective COX-2 inhibition may be an important strategy
for the continued use of these agents in cancer therapy. In this ongoing trial,
we measure baseline, week 4 and week 8 urinary PGE-M levels to assess
adequate COX-2 inhibition. We hypothesize that EGFR and COX-2 inhibi-
tion will augment the efficacy of EGFR TKI therapy in NSCLC by increasing
tumor E-cadherin expression and blocking PGE2 mediated resistance to
EGFR inhibition.
Materials/Methods: Randomized, placebo-controlled, phase II trial of the
combination of E (150-mg daily) and C (600-mg twice daily) vs placebo
enrolling 106 pts with advanced NSCLC. Patients who have received at least
one prior systemic therapy or refused standard chemotherapy with ECOG PS
0-1, adequate organ function, no concurrent NSAID use, and no history of
myocardial infarction, cerebrovascular accident or gastrointestinal bleed are
eligible. The study evaluates clinical efficacy by time to progression, which
will be correlated with urinary PGE-M at baseline and change in urinary
PGE-M. Urinary PGE-M was quantified by liquid chromatography/tandem
mass spectrometry as previously described (Murphey et al., 2004).
Results: 43 patients have been treated evaluated with urinary PGE-M at
baseline, week 4 and 8 (F 23, M 20; age  65 24; never smoker 11,
former/current 32). Baseline urinary PGE-M was similar in males and
females. PGE-M was significantly elevated in former/current smokers; one
patient was a current smoker. When all patients are analyzed by ITT
(celecoxib and placebo), a 40% decrease in urinary PGE-M was seen at week
4 and 48% decline at week 8. The combination has been well tolerated
without cardiovascular toxicities or gastrointestinal bleeding.
Conclusions: These preliminary data indicate that urinary PGE-M declines
with combination erlotinib and celecoxib therapy. When accrual is complete
correlation with PFS and treatment group will be assessed. Supported by
NIH 1 P50 CA90388 and K12 CA 01727 and medical research funds from
the Department of Veterans’ Affairs.
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Therapeutic Effect of Histone Deacetylase Inhibitor Panobinos-
tat on Human Esophageal Cancer Cells
Y. Chen1, C. Chi2, 1Department of Radiation Oncology, Mackay Memorial
Hospital, Taipei, Taiwan, 2Department of Medical Research, Mackay Me-
morial Hospital, Taipei, Taiwan
Purpose/Objective(s): The prognosis of unresectable esophageal cancer
remains poor without effective therapeutics. Histone deacetylase inhibitors
(HDACi) are a novel class of anticancer agents that cause increased acety-
lation of histones leading to modulation of gene expression and protein
activity involved in cancer cell growth. We examined the effect of the
HDACi panobinostat (LBH589) on human esophageal cancer cells.
Materials/Methods: MTT assay, DNA histogram, Western blotting and
immunofluorescent staining were used.
Results: LBH589 inhibited the viability of esophageal squamous cancer cell
lines, CE81T and TE2, with IC50 values in low nanomolar concentrations (10
- 100 nmol/L). At concentration of IC50, LBH589 caused hyperacetylation of
histone H3 and down-regulated the expression of heat shock protein 90.
Up-regulation of p21(cip1/waf1) along with extensive cell cycle arrest at
G2/M phase was noted. Furthermore, LBH589 increased phosphorylation of
histone H2AX, a hallmark of double strand break of DNA, which was
co-localized with acetylated H3 in the nucleus. Given that cells at G2/M
phase are sensitive to radiation and LBH589 induced double strand break of
DNA resembling radiation damage, it may sensitize esophageal cancer cells
to radiation. The cell death induced by LBH589 was not mediated by
intrinsic apoptotic pathway and was independent to caspases 3, 8 and 9.
Conclusions: LBH589 inhibited viability of esophageal cancer cells accom-
panied by modulation of cellular and molecular events related to HDAC
inhibition. These findings provide a rationale for exploring the cytotoxic and
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possible radiosensitizing activity of LBH589 in the treatment of esophageal
cancer.
Author Disclosure Block: Y. Chen, None; C. Chi, None.
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The Role of Thromboxane A2 in the Proliferation of Lung
Cancer Cells Induced by Smoking Carcinogen 4-methylnitro-
samino-1-3-pyridyl-1-butanone
G. G. Chen, R. Huang, M. Li, M. K. Y. Hsin, T. S. K. Mok, M. J.
Underwood, The Chinese University of Hong Kong, Shatin NT, Hong Kong
Despite thromboxane A2 (TxA2) has a well documented role in tumor
progression, its implication in smoking-associated lung cancer is poorly
understood, which hinders the development of new therapies based on the
regulation of thromboxane in lung cancer. This study was to observe the role
of TxA2 in smoking carcinogen NNK-induced cell proliferation in human
lung cancer cells. We found that NNK increased TxA2 synthase (TxAS)
expression and thromboxane B2 (TxB2) generation. Moreover, both TxAS
specific inhibitor furegrelate and TxA2 receptor antagonist SQ29548 totally
blocked NNK-enhanced cell proliferation, at least in part, through the
induction of apoptosis. TxA2 mimetic or TxA2 receptor agonist U46619
reconstituted a near full proliferative response to NNK during TxA2 synthe-
sis inhibition, affirming the role of TxA2 receptor in NNK-mediated cell
proliferation. The signaling pathways responsible for the involvement of
TxA2 in NNK-enhanced cell proliferation were further examined, and cAMP
response element binding protein (CREB), PI3K/Akt and ERK were identi-
fied. Suppression of CREB activity by its siRNA blocked the promoting
effect of NNK on lung cancer cell proliferation. The ERK pathway was
proved to be a key step for NNK-mediated activation of CREB in both cell
lines, whereas PI3K/Akt pathway had a partial contribution. The results
obtained by TxA2 mimetic U46619 were similar to that obtained in NNK-
treated cells. Collectively, our results have revealed that NNK stimulates
TxA2 synthesis, along with the activation of its receptor, in lung cancer cells.
The increased TxA2 then activates CREB through PI3K/Akt and ERK
pathways, thereby contributing to the NNK-induced proliferation of lung
cancer cells. Our study suggests that the pharmacological regulation of some
key steps in thromboxane-mediated pathway may stop or prevent NNK-
induced lung cancer proliferation.
Author Disclosure Block: G.G. Chen, None; R. Huang, None; M. Li,
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Mgmt Status and Role of Temozolomide In Esophageal Cancer
G. Kanade, I. Kawada, N. Mollberg, R. Kanteti, E. el-Hashani, A. N. Husain,
M. Ferguson, V. Villaflor, R. Hasina, R. Salgia, University of Chicago,
CHICAGO, IL
Esophageal cancer is the ninth most frequent cancer in the world and the
fifth most frequent cancer in developed countries. The incidence of distal
esophageal and GE junction adenocarcinoma has increased dramatically
over the past in the US. There has actually been a decrease in the rate of
SCC in the US however; Japan and other Asian countries continue to have
a large proportion of SCC. There has been a substantial increase in distal
esophageal and GE junction adenocarcinoma while the incidence of
esophageal squamous cell carcinoma has decreased. Despite advances in
treatment modalities, the prognosis for esophageal cancer patients re-
mains dismal, with  15% 5 year survival overall. MGMT is a DNA
repair protein that removes mutagenic and cytotoxic adducts from O6
position of guanine. It is expressed in all human tissues at various levels,
and is decreased in some tumors in comparison to normal tissue. It has
been shown that MGMT function is frequently diminished in association
with hypermethylation of the CpG islands within the MGMT promoter in
several human malignancies. Promoter hypermethylation of MGMT and
reduction of protein expression have also been reported to occur in
gastrointestinal malignancies (Kuester et al. 2009). Alkylating agents,
procarbazine, streptozotocin, and temozolomide are among the most
widely used chemotherapeutic drugs in human cancer. One target of
action of these compounds is the O6 position of guanine. However, the
toxicity of alkylating agents is reduced in the presence of MGMT by
rapidly reversing the formation of adducts at the O6 position of guanine,
thereby averting the formation of lethal crosslinks. Thus, a significant
relationship exists between MGMT activity and resistance to alkylating
drugs. Temozolomide, a cytotoxic prodrug has shown a broad spectrum
of antineoplastic activity and triggers the death of tumor cells by
methylating DNA at N-7 and O6 position of guanine. In an effort to
elucidate the role of MGMT methylation and treatment response to
temozolomide in esophageal cancer patients, we determined the MGMT
methylation status in 11 esophageal cancer cell lines and 32 archived
samples of esophageal cancer. We report here that 75% (12/16) of
adenocarcinoma and 19% (3/16) of squamous cell carcinoma patients
were positive for MGMT methylation. Moreover, 3/11 esophageal cancer
cell lines were also MGMT methylated. In vitro cell viability assay (MTT
Assay) on MGMT methylated cells (Kyse-140, FLO) and MGMT un-
methylated cells (Kyse-410, SKGT-4), showed that methylated cells are
sensitive to temozolomide at IC50 of 120-300 M whereas unmethylated
cells showed no sensitivity to temozolomide treatment. In the era of
targeted therapies, esophageal cancer is still under-investigated. We
believe that the MGMT methylation and targeting by temozolomide is
important in certain subsets of esophageal tumors.
Author Disclosure Block: G. Kanade, None; I. Kawada, None; N. Moll-
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Dose Distributions in SBRT of Lung Tumors Using AAA Algo-
rithms to Create a Rapidarc Plan With Eclipse Planning System
F. C. Rafie, C. Biggs, T. T. K. Lee, D. Reed, K. Rogers, Arizona Center for
Cancer Care, Peoria, AZ
Purpose/Objective(s): This study conducts a dosimetric analysis of the
Eclipse planning system as used for RapidArc in lung stereotactic body
radiotherapy (SBRT).
Materials/Methods: The Varian IX RapidArc treatment system (Varian
Medical Systems Inc., Palo Alto, CA) uses a dynamic multi-leaf collimator,
variable dose rate, and variable gantry speed to generate IMRT quality dose
distributions in a single optimized arc around the patient, with 6 megavolts
of energy used here to treat cancerous tumors. The treatment plans of more
than fifty patients who have undergone SBRT and were planned with Eclipse
planning station were examined for dose homogeneity as well as dose
conformality. The patients were administered CT scans under inhaling,
exhaling, and normal breathing conditions. These three CT’s were merged,
and the normal CT used as a base for planning. The margins of PTV were
determined utilizing the CT scans obtained during inhaling and exhaling. The
volumes of dose were examined at 5 Gy intervals to a maximum of 110% of
the prescribed dose and the percent of healthy lung tissue receiving such dose
was described.
Results: The dose to 99.5% of the PTV volume received was 91.5% /-
2.6%. The dose homogeneity index was determined to be 78%/- 7%. Dose
conformality index was determined to be 73% /- 5%. The hotspot (110%
of the prescribed dose) outside the tumor volume was minimal.
Conclusions: RapidArc demonstrated more favorable results than conven-
tional IMRT as measured by the dose conformality index, homogeneity
index, and dose distribution within healthy lung tissue.
Author Disclosure Block: F.C. Rafie, None; C. Biggs, None; T.T.K. Lee,
None; D. Reed, None; K. Rogers, None.
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The Effect of PET/CT Image Fusion on the Non-small Cell Lung
Cancer Patients’ Radiotherapy Plannings
B. Dirican1, E. Kara2, K. Oysul1, 1Gu¨lhane Military Medical Academy,
Ankara, Turkey, 2Onko Ankara Oncology Center, Ankara, Turkey
Purpose/Objective(s): The aim of this study is figured out the effects of the
CT-PET image fusion, used in radiotherapy treatment plannings, on the
GTV, CTV and the critical tissues.Computed Tomograpy (CT) imaging has
been the primary imaging modality used in conformal therapy treatment
planning.CT images are used to construct geometric and physical models of
the patient.While CT is the primary modality for most image-based treatment
planning PET can provide unique metabolic information and can quantify
partial organ function.The combination of the two offers the best of both
worlds in an integrated data set and thus improves localization of many
lesions.
Methods/Materials: In this study, immobilization and CT simulation were
performed for 15 lung cancer patient, as is routine for lung cancer patients
receiving 3DCRT in our department.The determination of the 15 lung cancer
patient’s target volume and critical tissues are firstly done by using CT
images obtained from our clinic.To overcome inter-user uncertainties all
contouring were done by the same radiation oncologist.There is two different
tumor definition in this study, one is GTV_tumoral and the other one is
GTV_nodal. To get a union GTV, GTV_tumoral and GTV_nodal volumes
are combined. After that, PET images obtained from the different clinics and
CT images are fused by using different techniques and GTV is redefined for
each fused images. In our study we have used three fusion techniques which
are Landmark Based, Manuel and Automatic Image Fusion. Patient’s critical
tissues, skin and GTV are defined and transferred to the TPS system for the
treatment planning. The isodose lines are covered the GTV between 7%
and 5% homogeneously. The plans’ dose volume histograms are obtained
for the controlling of the tumor and critical organs dose. The plan is that the
spinal cord dose not to be over the 46 Gy in any segment and the half of the
normal lung’s volume not be over the 20 Gy (V20).
Results: In our study, the volume of the GTV changed up to %63 and
GTV_nodal changed up to %88. In addition to this,V20 value of 3 of these
patients has dropped below 20 percent.
Conclusions: This study investigated the integration of PET image data
during 3DCRT planning for patients with NSCLC. Based on the PET-BT
fusion which is successfully performed, the tumor volume can be defined
more efficiently and correctly. Geographic misses can be reduced and local
control can ce improved by using image fusion in patients especially with a
risk for mediastinal disease.
Author Disclosure Block: B. Dirican: None. E. Kara: None. K. Oysul:
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An Improved Early CDT-lung Test Can Be Used to Aid the
Detection of Lung Cancer
C. J. Chapman1, A. Murray2, L. Peek3, P. Boyle4, J. Allen2, C. Parsy-
Kowalska2, P. Maddison5, G. Healey2, J. Robertson1, 1University of Notting-
ham, Nottingham, United Kingdom, 2Oncimmune Ltd, Nottingham, United
Kingdom, 3Oncimmune Ltd, Kansas, KS, 4International Prevention Research
Institute, Lyon, France, 5Nottingham NHS Trust, Nottingham, United King-
dom
Purpose/Objective(s): EarlyCDT-LungTM detects autoantibodies to a panel
of six lung cancer-associated antigens with a sensitivity of 40% and a
specificity of 90%. EarlyCDT-Lung has been shown to aid in the detection
of both early-stage and late-stage disease in high-risk individuals. The
addition of two lung cancer associated antigens to this test was investigated.
The positivity rate for each antigen by stage of disease and histological
subtype are presented.
Materials/Methods: Patients with lung cancers (N235) and age, gender
and smoking matched controls had autoantibodies to eight tumor-associated
antigens measured on serum samples taken post-diagnosis but prior to
treatment. The antigens comprised those in the EarlyCDT-Lung test (p53,
NY-ESO-1, CAGE, GBU4-5, SOX2 and Annexin I) with the addition of
MAGE-A4 and Hu-D.
Results: The addition of MAGE A4 and Hu-D to the EarlyCDT-lung panel
improved the sensitivity of the assay for the detection of lung cancer by 6%
with a loss in specificity of only 1%. The positivity rates for the panel by
stage of disease for non-small cell lung cancer (NSCLC) and for extensive vs
limited disease for small cell lung cancer (SCLC) were similar for all stages.
The positivity rate for individual autoantibody assays ranged in NSCLC from
1%-11% and in SCLC from 5%-21% with specificity for each antigen being
96%.
Conclusions: These data confirm that the addition of two new antigens to the
EarlyCDT-Lung panel increased the detection of all stages of lung cancer
giving a sensitivity of at least 45%. The presence of autoantibodies may
provide an early indication of lung cancer, even in early-stage disease and
may be useful in the management of high-risk individuals. Some antigens
were more specific for the detection of certain cancer subtypes and indeed
MAGE A4 detected NSCLC better than SCLC while the reverse was true
with HuD and SOX2. Differences in the autoantibody profiles may in the
future be useful in identifying what subtype or stage of lung cancer a patient
is most likely to have.
Author Disclosure Block: C.J. Chapman: F. Consulting/Advisory Board;
Consults for Oncimmune Ltd. A. Murray: A. Employment; Oncimmune
Ltd. L. Peek: Oncimmune Ltd. P. Boyle: F. Consulting/Advisory Board;
Oncimmune Ltd Advisory Board. J. Allen: A. Employment; Oncimmune
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The Survey on Quality Control of Lung Cancer Screening
Improves the Actual Indicators of the Screening Quality
M. Sagawa1, C. Endo2, M. Sato3, Y. Saito4, K. Usuda1, H. Aikawa1, M.
Tanaka1, Y. Machida1, M. Ueno1, T. Sakuma1, 1Department of Thoracic
Surgery, Kanazawa Medical University, Uchinada, Ishikawa, Japan, 2Insti-
tution of Development, Aging and Cancer, Tohoku University, Sendai,
Japan, 3Miyagi Prefectural Cancer Center, Natori, Japan, 4Sendai National
Hospital, Sendai, Japan
Purpose/Objective(s): In Japan, lung cancer screening has been introduced
since 1987, with chest x-ray films for all screenees and additional sputum
cytology for smokers. Although randomized controlled trials conducted in
the 1970-80s failed to prove the efficacy, the results of six case-control
studies have indicated that currently available screening in Japan might
decrease the risk of lung cancer deaths by 30-60%. Although quality control
is essential in mass screening for cancer, no standard method for quality
control has been established. In English literature, there have been very few
reports concerning the quality control of cancer screening, and we have to
establish an appropriate novel method for our own screening system.
Materials/Methods: In 2000, the Miyagi Prefectural Committee for Man-
agement of the Cancer Screening System (Miyagi PCMCSS) decided to
evaluate annually whether each local government of municipality in the
Miyagi Prefecture had appropriate informations for evaluating the quality of
lung cancer screening system, and PCMCSS announced to the local govern-
ments that the results would be informed to the residents. On the basis of the
manual developed by the Ministry of Health, Labor and Welfare, 45 items
were selected for the survey, which could be obtained easily when the
screening had been conducted according to the standard screening method.
Miyagi PCMCSS sent a questionnaire including the 45 items to the munic-
ipalities. According to the reply to the questionnaire, PCMCSS categorized
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each municipality using a 5-rank classification every year depend on the
number of insufficient items; A: 0, B: 1-4, C: 5-8, D: 9 or more, E: no reply.
The municipalities were classified into two groups according to the rank in
2002 survey; Group X (A rank) and Group Y (B to D rank). In 2005 survey,
all 58 municipalities of Group X also got A rank. On the other hand, 10 of
12 municipalities of Group Y got A rank, and the remaining two got B rank.
Then, some indicators of screening quality were compared between Group X
and Y, including 1) a detection rate of lung cancer in all screenees (DR), 2)
a ratio of (cases who actually underwent further examination / test-positive
cases) (Exam/TP).
Results: In 2002, 58, 3, 6, 3, and 0 municipalities were categorized as A, B,
C, D, and E, respectively. The distribution improved to 60, 7, 2, 1, 0 in 2003,
and 68, 2, 0, 0, 0 in 2005. Although DR and Exam/TP of Group Y in 2002
were significantly worse than those of Group X (p0.049, 0.036, respec-
tively), those differences disappeared in 2005.
Conclusions: Annual surveys to determine whether the local governments
have appropriate information for evaluating the quality of lung cancer
screening systems improve not only the governments’ ability of information
management but also the actual screening quality.
Author Disclosure Block: M. Sagawa: None. C. Endo: None. M. Sato:
None. Y. Saito: None. K. Usuda: None. H. Aikawa: None. M. Tanaka:
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A Pilot Study to Examine the Feasibility of Delivering a Tobacco
Dependence Treatment Program at the Time of Lung Cancer
Screening
A. Ferketich, G. Otterson, M. King, K. Browning, M. Wewers, The Ohio
State University, Columbus, OH
Purpose/Objective(s): Cigarette smoking is responsible for the majority of
lung cancer cases and tobacco abstinence is associated with a reduction in
lung cancer incidence. Offering a smoking cessation program at the time of
a lung cancer screening test may be an effective way to encourage high-risk
smokers to quit. The objectives of this study were to estimate the proportion
of smokers who comply with the 12-week treatment protocol and to obtain
preliminary estimates of abstinence and quit attempts at 4 and 6 months after
enrollment in a program that included both a tobacco dependence treatment
protocol and a lung cancer screening test.
Materials/Methods: Volunteers were recruited over a one-month period
using advertisements posted in various locations at our institution. Partici-
pants had to be high risk smokers defined as age 50 or older and a current
smoker with a 20 pack-year history; additionally they had to be free of a
history of cancer. Participants received a low-dose spiral CT scan and a
12-week tobacco dependence treatment program that included pharmaco-
therapy and telephone counseling; half of the subjects received tobacco
dependence treatment prior to (BCT), and the other half following (ACT),
the CT scan. The primary outcomes for this study were compliance with the
protocol and abstinence at 4 and 6 months.
Results: Of the calls received in response to the ads, 25 individuals were
eligible to participate and 18 enrolled in the study. Approximately two-thirds
of the participants were female and white. The current cigarette consumption
was 15 cigarettes per day and the average Fagerström Test of Nicotine
Dependence scores indicated moderate dependence. Seven participants had a
positive CT result defined by the presence of a nodule or the need to follow
up a suspicious finding; however, none had cancer. Only one person did not
complete all study visits (94% compliance). At 4 months post enrollment,
33% of participants in the BCT arm and 22% in the ACT arm had quit (28%
overall), and all but one had made a 24-hour attempt to quit. At 6 months
abstinence decreased to 22% in the BCT arm and 11% in the ACT arm (17%
overall), and approximately 70% of participants had made a 24-hour quit
attempt.
Conclusions: The results suggest that smokers might be interested in
participating in a program that includes lung cancer screening combined with
tobacco dependence treatment. The compliance rate for this 6-month study
was high (94%) and at 6 months close to 17% of smokers were abstinent
which on a population level would translate to a large number of high risk
smokers. While we did not have enough power to test for differences
between the two arms, the preliminary data suggest that receiving tobacco
dependence treatment prior to the CT scan could result in a higher abstinence
rate.
Author Disclosure Block: A. Ferketich, None; G. Otterson, None; M.
King, None; K. Browning, None; M. Wewers, None.
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Factors to Predict Long-term Five Years Overall Survival (OS)
Among Patients With Limited Small-cell Lung Cancer Treated
With Radiation Treatment (RT) and Chemotherapy
R. U. Komaki, X. Wei, P. K. Allen, M. S. O’Reilly, F. V. Fossella, Z. X.
Liao, J. V. Heymach, R. S. Herbst, J. Y. Change, J. D. Cox, M.D. Anderson
Cancer Center, Houston, TX
Purpose/Objective(s): To analyze the 5-year overall survival (OS) and
effect factors in patients with limited small-cell lung cancer (L-SCLC)
treated with radiation treatment (RT) and chemotherapy.
Materials/Methods: From March 1985 to August 2007, 483 patients with
newly diagnosed L-SCLC received treatment at our institution. Inclusion
criteria were: no surgery, KPS  60, radiotherapy dose  45 Gy. Patients
were treated with once-daily RT to median total dose 50 (range, 45-70 Gy)
(1.8-3.0Gy/fx, 15-37 fractions, 5 days/week) or twice-daily RT to median
total dose of 45 Gy (range, 45 60 Gy) (1.5 Gy/ fx, 30 fractions, 5
days/week, with a minimal interfraction interval of 6 hours). The most
commonly used regimens of induction chemotherapy (ICT) and concurrent
chemoradiotherapy (CCT) were cisplatin or carboplatin plus etoposide.
Median cycles of chemotherapy were 3 cycles for ICT (range, 1-12) and 2
cycles for CCT (range, 1-6). Univariate analysis and multivariate logistic
analysis were performed to evaluate the effect of following factors on
survival: gender, age, ethnic group, performance status (KPS), smoking
history, tumor location, total dose of RT, early and late BED dose of RT,
induction chemotherapy, concurrent chemoradiotherapy, prophylactic cra-
nial irradiation (PCI), treatment time periods (before 2000 and 2000 to 2007),
local-regional (LR) failure, and distant metastasis (DM). OS was defined as
the time from diagnosis to the date of death or the date of last follow-up.
Kaplan-Meier estimates were utilized to evaluate 5-year OS.
Results: The median follow-up was 20 (range, 1-205) months. The median
survival was 24.9 (range, 1.4-205) months. Univariate analyses showed
following factors were associated with 5-year OS: KPS  80 [odds ratio
(OR) 0.20, p0.03], PCI (OR0.48, p0.01), concurrent chemoradio-
therapy first (OR0.55, p0.04), patient treated from 2000-2007
(OR0.41, p0.01), local-regional failure (OR8.00, p0.01), and DM
(OR13.07, p0.01). Multivariate analysis found the same factors were
associated with 5-year OS: KPS  80 (OR0.19, p0.03), PCI
(OR0.39, p 0.01), concurrent chemoradiotherapy first (OR0.51,
p0.05), patient treated from 2000-2007 (OR0.17, p0.01), local-regional
failure (OR8.95, p0.01), and DM (OR16.37, p0.01).
Conclusions: Patient factors including good performance status, concurrent
chemoradiotherapy first, and PCI treatment contributed to the better 5-year
OS. Patients treated after 2000 also had better 5-year OS. There was no
significant difference in 5-year OS based on BED. The ongoing prospective
randomized study by the Inter group might confirm these findings.
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Revisiting the Role of Surgery in Limited-stage Small Cell Lung
Cancer - A Retrospective Analysis of VA Cancer Registry
Database
T. Tashi1, I. Aldoss1, A. Ganti2, P. Silberstein1, S. Subbiah1, 1Creighton
University Medical Center, Omaha, NE, 2University of Nebraska Medical
Center, Omaha, NE
Purpose/Objective(s): Chemo-radiation therapy has been the standard treat-
ment for limited stage small cell lung cancer for many years. However,
recent reports suggest a survival benefit for surgical resection. Our objective
is to analyze the outcome of surgical resection for patients with limited-stage
small cell lung cancer (L-SCLC).
Materials/Methods: The analysis was performed on data from 8702 patients
diagnosed with L-SCLC between 1995 and 2008, identified from the Vet-
erans Affairs Central Cancer Registry. These patients were then grouped
according to age, sex, race, T-category, nodal status and type of treatment
received. Kaplan-Meier survival analysis was used to compare the median
overall survival between surgery and non-surgical treatment modalities
among these groups.
Results: Out of 8702 patients with L-SCLC, 916 (10.5%) had undergone
surgical resection, while 5795 (66.6%) had chemotherapy, radiation therapy
or combination of both, and 1991 (22.9%) received no treatment. Median age
at diagnosis for the entire cohort was 68 years. Surgery was found to be more
commonly performed in T1/T2 and N0/N1 disease. In node-negative (N0)
group, patients who underwent surgical resection had longer median survival
in both T1 and T2 groups as compared to non-surgical treatments, 24.4 vs
15.7 months in T1 and 20.2 vs 13.2 months in T2 (p0.0001); Only few
patients with T3 and T4 had undergone surgery. Surgery was associated with
longer survival across all nodal status, 45.6 vs 14.1 months in N0; 30.1 vs
13.5 months in N1 and 22.6 vs 11.7 months in N2 (p0.0001 for all
comparisons). In the surgery subgroup of 916 patients, 562 (61.4%) had only
surgery and their median survival was 44.4 months while 354 (38.6%) had
surgery with adjuvant treatment and their median survival was 32.3 months
(p0.074). Across the entire cohort, overall median survival was 38.7
months in the surgical group and 12.4 months in the non-surgical group
(p0.0001). On multivariate analysis, age, nodal status and treatment mo-
dality were significant variables for survival.
Conclusions: Patients with L-SCLC who underwent surgical resection have
longer median survival. Survival following surgery correlates well with
tumor size and nodal status. Surgical intervention is promising and could
potentially be considered in selected patients. However, further prospective
trials are warranted to evaluate its role in multi-disciplinary treatment of
L-SCLC.
Author Disclosure Block: T. Tashi, None; I. Aldoss, None; A. Ganti,
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Outcomes of Salvage Therapy in Patients with Limited-Stage
Small Cell Lung Carcinoma With Isolated Locoregional Failure
M. E. Giuliani, P. E. Lindsay, A. M. Brade, A. Sun, A. Bezjak, L. W. Le,
J. Cho, N. Leighl, F. A. Shepherd, A. J. Hope, Princess Margaret Hospital,
Toronto, ON, Canada
Purpose/Objective(s): To determine the patterns of locoregional (LR) fail-
ure and the incidence and outcomes of salvage therapy for isolated LR failure
in patients with limited-stage small cell lung carcinoma (LS-SCLC).
Materials/Methods: A single institution, retrospective review was con-
ducted on patients who received radical intent chemo-radiation for LS-SCLC
from 1997 to 2008. Local failure was defined as within known lung
parenchymal disease. Regional failure included any nodal region (N1-3). The
cumulative LR failure rate was calculated. The distant failure-free survival
(FFS) and overall survival (OS) were calculated using Kaplan-Meier method
from diagnosis date to date of failure or death. For patients with isolated LR
failure, details and outcomes of salvage therapy were obtained. The incident
of toxicity, graded per CTCAE v3.0, from salvage treatment was determined.
Results: 252 patients with LS-SCLC were identified. Median follow-up was
18 months (2-130mo). The cumulative LR failure rate was 26% and 32% at
2 and 4 yrs respectively. The distant FFS was 33% and 21% at 2 and 4 years
respectively. OS was 43% and 27% at 2 and 4 years respectively. The site of
first failure was LR only in 33 patients, distant only in 80 patients and
simultaneous both LR and distant in 31 patients. Of the 33 patients who
experienced isolated LR failure 27 received salvage therapy; 5 curative intent
and 22 palliative intent. The median time to LR failure was 59 months in the
curative intent patients and 12 months in the palliative intent patients.
Curative intent salvage therapy consisted of chemotherapy (sequential n3;
concurrent n1) and twice daily re-irradiation in 4 patients (n3 4500cGy
in 30 fractions; n1 3900cGy in 26 fractions) and chemotherapy, lobectomy
and twice daily re-irradiation (3600cGy in 24 fractions) for a positive margin
in 1 patient. First palliative salvage therapy was chemotherapy (n12) or
palliative radiotherapy (n10). For patients who received curative and
palliative intent salvage treatment the 1yr OS were 100% and 29% respec-
tively. Of the patients who received curative intent salvage 2/5 remain free
of disease at LR and distant sites 24 months from LR failure; one patient
developed G2 pneumonitis and one patient developed G2 esophagitis.
Conclusions: LR failure remains a significant concern for patients with
LS-SCLC. Curative intent salvage therapy had minimal acute toxicity and
some patients appear to be locally controlled however long terms results are
pending.
Author Disclosure Block: M.E. Giuliani, None; P.E. Lindsay, None; A.M.
Brade, None; A. Sun, None; A. Bezjak, None; L.W. Le, None; J. Cho,
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Generation of a Comprehensive Thoracic Oncology Database:
Topoisomerase I in SCLC as an Example
M. Surati, S. Nandi, M. Robinson, C. E. Rolle, N. Campbell, E. Mendonca,
C. Kirchner, T. Karrison, E. Vokes, R. Salgia, University of Chicago,
Chicago, IL
In 2010, there will be 222,520 new cases and 157,300 deaths from lung
cancer. Though SCLC constitutes only 13% of lung cancer cases, it carries
a dismal prognosis with a median 5-year survival of 10-13% (limited stage)
and 1-2% (extensive stage). Understanding genomic and proteomic alter-
ations and correlating this with clinical parameters should aid in the identi-
fication of diagnostic, prognostic, and therapeutic markers for this aggressive
cancer. The Thoracic Oncology Research Program Access Database was
created to serve as a comprehensive repository for well-annotated cancer
specimens and clinical data to facilitate such discovery. A team of clinical
and basic science researchers, a biostatistician, and a bioinformatics expert
collaborated to develop a database to capture clinical, proteomic, and
genomic data. The Patient table houses clinical information such as tumor
characteristics, treatment, outcome, and risk factors. Proteomic data is
located in the Tissue Microarray (TMA) table where patient tissue samples
have been studied for the expression of 63 different proteins using immu-
nohistochemistry (IHC). Finally, genomic data is found in the DNA Speci-
mens table. Here mutations in up to 10 different genes in patient tissue
samples are described. As a specific example, we analyzed topoisomerase 1
expression in SCLC patients. Thus far, clinical data has been captured on
over 2600 patients with thoracic malignancies. Of these, there are 200
patients with SCLC. The expression of the protein topoisomerase 1 was
studied in 28 SCLC cases. Using IHC, protein expression was quantified on
a scale of 0 to 3, with 3 indicating high protein expression. Within the same
patient, the mean protein expression for nuclear topoisomerase 1 was 0.75,
while cytoplasmic nuclear expression for topoisomerase 1 was much higher
at 1.75 (p0.01). In addition, there was a significant difference in nuclear
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topoisomerase 1 expression between limited stage SCLC and extensive stage
SCLC (p0.01). The same relationship was not true for cytoplasmic topo-
isomerase 1. In this instance we did not find an impact on survival from
protein expression. The Thoracic Oncology Research Program Access Da-
tabase can advance cancer translational research by facilitating collaboration
among researchers. A template of this database as well as the standard
operating procedure is available via the University of Chicago iBridge
Network. Furthermore, a detailed demonstration is available in the Journal of
Visualized Experiments. In this manner other institutions can develop their
own Access databases and data may be pooled. As the database continues to
grow, so too does its ability to identify significant prognostic biomarkers to
aid in the early identification of cancers, measure response to therapy, and
development of targeted therapies.
Author Disclosure Block: M. Surati, None; S. Nandi, None;M. Robinson,
None; C.E. Rolle, None; N. Campbell, None; E. Mendonca, None; C.
Kirchner, None; T. Karrison, None; E. Vokes, None; R. Salgia, None.
215
A Phase I Study of Pomalidamide (CC-4047) in Combination
With Cisplatin and Etoposide in Patients With Extensive Stage
Small Cell Lung Cancer (ES-SCLC)
P. M. Ellis1, J. Zhang2, M. Jones2, U. Jungnelius2, F. A. Shepherd3,
1Jurvainski Cancer Centre, Hamilton, ON, Canada, 2Celgene Corporation,
Summit, NJ, 3Princess Margaret Hospital and the University of Toronto,
Toronto, ON, Canada
Purpose/Objective(s): Small Cell Lung Cancer (SCLC) comprises approx-
imately 15% of all lung cancers, with approximately two-thirds of patients
having extensive stage (ES) disease at diagnosis. Little progress has been
made in the systemic therapy of this disease in recent decades. Pomalidomide
is an IMiD® immunomodulatory compound that in solid tumor preclinical
models has demonstrated antiangiogenic, immunomodulatory effects and
enhancement of antibody dependent cell-mediated cytotoxicity (ADCC).
This phase 1 study was designed to establish the maximum tolerated dose
(MTD) of pomalidomide in combination with standard cisplatin and etopo-
side chemotherapy.
Materials/Methods: This was an open-label, multicenter phase 1 study. All
patients provided written informed consent prior to enrollment. Eligible
patients were 18 yrs with histologically or cytologically confirmed ES-
SCLC. Patients were chemotherapy-naive with an ECOG PS of 0 - 2.
Standard phase 1 methods were employed with a 33 dose escalation
design. Pomalidomide was administered orally on days 1-14 every 21 days,
in cohorts of 1 mg, 3 mg and 5 mg with a provision for 1 mg step-down doses
in the event MTD was exceeded. All patients received cisplatin 25 mg/m2 IV
and etoposide 100 mg/m2 IV on days 1-3 of a 21-day cycle. Following
completion of 4-6 cycles of chemotherapy, pomalidomide was continued as
maintenance therapy at dose of 5 mg on days 1-14 every 21 days. The
primary endpoint was the MTD of pomalidomide in combination with
cisplatin and etoposide. Secondary endpoints included safety, response rate
and overall survival.
Results: A total of 22 patients were enrolled with a median age of 64.5 yrs
(range 49 - 77), 18% female, 23% ECOG PS 2. DLTs were observed in the
1 mg cohort (1), 5 mg cohort (2) and 4 mg cohort (1). Therefore the MTD
was determined to be pomalidomide 4 mg on days 1-14 in combination with
cisplatin and etoposide on days 1-3 of a 21-day cycle. ORR (investigator-
assessed) was 36% (0 CR, 9 PR). Median OS (with 9 patients censored) was
46.1 weeks (95% CI 26.7 - 61.7). Two patients died on treatment (CVA,
sepsis). The most common grade 3/4 adverse events were neutropenia (55%),
fatigue (23%) and anemia (18%). Two patients (9%) experienced febrile
neutropenia and 2 patients (9%) experienced pulmonary embolism.
Conclusions: Pomalidomide is tolerated up to doses of 4 mg on days 1-14
of 21 day cycles when combined with cisplatin and etoposide. Neither the
observed survival nor the 36% ORR is suggestive of a significant enhance-
ment of efficacy over standard cisplatin and etoposide chemotherapy. Po-
malidamide does not warrant further study in SCLC. The combination of
IMiD® compounds with chemotherapies is being evaluated in other solid
tumors.
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Role of Adaptive Radiotherapy During Concomitant Chemora-
diotherapy for Small-Cell Lung Cancer
A. A. Yavuz, B. S. Ozdemir, E. Dundar, B. Pehlivan, I. Karakus, N. Tuncel,
M. N. Yavuz, Akdeniz University, Antalya, Turkey
Purpose/Objective(s): Tumor shrinkage is frequently observed during con-
ventionally fractionated (chemo-) radiotherapy for small-cell lung cancer
(SCLC). As the tumor reduces in size during treatment, the margin added
around the gross tumor volume (GTV) effectively becomes larger, which can
result in the excessive irradiation of normal lung tissue. The specific goals of
this study are to evaluate GTV changes during the course of radiation therapy
(RT) and examine its potential use in adaptive radiotherapy for tumor dose
escalation or normal tissue sparing in patients with SCLC.
Materials/Methods: A total of 8 SCLC patients eligible for chemoradio-
therapy underwent computed tomography at 13 and 23 fractions (at a
nominal dose of 23.4 and 41.4 Gy, respectively). The GTV was delineated on
the repeat computerized tomography scans and two treatment plans were
generated with or without adaptation to tumor shrinkage during RT for each
patient. Dosimetric and volumetric analyses were performed.
Results: Average GTV reduction observed over 13 fractions was 58%
(range, 13 to 96%; p0.001), and 23 fractions was 66% (range, 22 to 99%;
p0.001). Compared to plans without adaptation, adaptive radiotherapy
resulted in mean lung dose relative decreases of 15%, mean lung volume
receiving  20Gy (V20) relative decreases of 6%, mean lung volume
receiving  5 Gy (V5) relative decreases of 10%, mean medulla spinalis
dosenrelative decreases of 33%, mean esophagus volume receiving  50Gy
(V50) relative decreases of 17%, mean heart volume receiving  42 Gy
(V42) relative decreases of 18%. The benefits of adaptive therapy are the
greatest for tumor volumes  30 cm3 and are directly dependent on GTV
reduction during treatment.
Conclusions: Adaptation of the treatment plan twice during conventionally
fractionated (chemo-) RT of SCLC achieved a significant benefit in terms of
normal tissue sparing and significantly decreases tumor volume and dose to
normal tissues, allowing for the possibility of dose escalation.
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Meta-Analysis of Second Line Chemotherapy Efficacy in Sensi-
tive and Refractory Small Cell Lung Cancer (SCLC) Patients
T. K. Owonikoko, M. Behera, Z. Chen, C. Bhimani, W. J. Curran, F. R.
Khuri, S. S. Ramalingam, Emory University, Atlanta, GA
Purpose/Objective(s): SCLC remains a highly fatal disease with limited
treatment options. Patients unresponsive or relapsing ( 90 days) following
frontline chemotherapy are generally treated with regimens different than the
first-line regimen with the expectation of a better efficacy outcome. The
clinical benefit of this treatment paradigm has not been well-studied. We
performed a systematic analysis to compare the outcome for SCLC patients
with sensitive and refractory disease treated in the second line setting.
Materials/Methods: A detailed search of published clinical trials was
conducted using the main computerized databases of interest (MEDLINE,
EMBASE, Cochrane library) as well as manual search of the ASCO meeting
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abstracts database. Eligible studies enrolling both sensitive and refractory
SCLC patients for second-line therapy identified independently by two of the
authors were employed for data extraction. A systematic analysis was
conducted using Comprehensive Meta Analysis (Version 2.2.048) software.
Response rate (RR) data was pooled for each category and reported as Odds
ratio, using 95% confidence intervals, under a random effect model.
Weighted mean survival time for each arm was calculated and compared
using the median survival time and number of patients from each study.
Overall survival, progression free survival and treatment-related toxicities
were analyzed as secondary outcomes. Significant difference in weighted
mean survival and RR was assessed using 1-tailed t-test statistics with Excel
software.
Results: Forty nine clinical trials published between 1984 and 2010 were
identified of which 17 were eligible for this analysis. A total of 814 patients
were enrolled in the selected trials and 788 patients were evaluable for
efficacy endpoint: 407 patients with sensitive disease and 381 patients with
refractory disease. The weighted average median age for all patients was 60.7
yrs. Primary analysis showed an overall RR of 24% across the 17 studies.
Patients with sensitive disease achieved a higher mean RR of 31% (range:
0–77%) versus 16% (range: 4–70%) for refractory patients; p0.058.
Pooled overall Odds ratio of response was 2.280 (95% CI: 1.391–3.735;
p0.001) in favor of patients with sensitive disease. Weighted average
median survival time was 6.47 months and 4.56 months respectively for
sensitive and refractory patient populations (p0.031).
Conclusions: SCLC patients outcome remains very poor. Patients refractory
to initial chemotherapy regimen also fared poorly with alternative second
line regimens. More effective novel approaches are warranted for SCLC and
especially for the refractory SCLC patient population.
Author Disclosure Block: T.K. Owonikoko, None; M. Behera, None; Z.
Chen, None; C. Bhimani,, None; W.J. Curran, None; F.R. Khuri, None;
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Reduction of Standardized Uptake Value in Primary Tumor is
Associated With Locoregional Control and Disease Free Sur-
vival After Intensity Modulated Radiation Therapy for Non-
small Cell Lung Cancer
J. L. Lopez Guerra1,2, G. W. Gladish1, R. Komaki1, D. Gomez1, P. Qing-
song1,3, Y. Zhuang1, X. Wei1, M. S. O’Reilly1, J. D. Cox1, Z. Liao1, 1The
University of Texas M.D. Anderson Cancer Center, Houston, TX, 2Virgen del
Rocı´o University Hospital, Seville, Spain, 3Tianjin Medical University Can-
cer Hospital, Tianjin, China
Purpose/Objective(s): To evaluate the association between reduction of
standardized uptake value (SUV) on [18F]fluorodeoxyglucose positron emis-
sion tomography (FDG-PET) in the primary tumor (PT) and lymph nodes
(LNs) and survival outcomes for patients with non-small cell lung cancer
(NSCLC) after intensity modulated radiation therapy (IMRT).
Materials/Methods: We reviewed 60 patients with newly diagnosed
NSCLC who had FDG-PET before and after IMRT. None of them had prior
other malignancies. The stage distribution according the American Joint
Committee on Cancer 2002 staging system was as follows: 2 stage IA, 3
stage IB, 26 stage IIIA and 29 stage IIIB. Fifty-five (91.6%) of the 60
patients received concurrent chemoradiation. We studied the maximum SUV
of the PT, the sum of the maximum SUV of the LNs and the sum of the
maximum SUV of both PT and LNs. One experienced radiologist reviewed
all FDG-PET images and provided the maximal SUV on all patients. The
prognostic significance was assessed by Cox’s proportional hazards regres-
sion analysis. The log-rank test was performed to assess the best discrimi-
native value.
Results: Median follow-up was 20 (range, 4-52) months. Median radiation
dose was 66 (range, 60-73.85) Gy at 1.8-2.12 Gy per day. Median lag time
between the end of the IMRT and the time of best response by FDG-PET
evaluation was 138 days (25th-75th percentile range, 82-213 days). There
was a statistically significant association between SUV reduction in PT SUV
and the risk of locoregional recurrence (LRR) inside the radiation field (P 
0.023), and LRR both inside and outside the radiation field (P  0.015).
There was also a statistically significant association between the SUV
reduction in PT and the odds of disease-free survival (DFS) (P  0.025). We
found that SUV reduction of 68% in PT was the best discriminative value for
LRR inside the radiation field (P 0016), LRR inside and outside the
radiation field (P  0.0030) and for DFS (P  0.0012). However, the
reduction in LNs SUV and in the sum of both PT and LNs is not statistically
significant prognostic factor for any survival outcome.
Conclusion: Reduction of SUV in the PT after IMRT is a statistically
significant prognostic factor for LRR and DFS in NSCLC. This information
could help clinicians to identify patients who have a high risk of LRR and to
design treatment accordingly.
Author Disclosure Block: J.L. Lopez Guerra: None. G.W. Gladish:
None. R. Komaki: None. D. Gomez: None. P. Qingsong: None. Y.
Zhuang: None. X. Wei: None. M.S. O’Reilly: None. J.D. Cox: None. Z.
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Use of Erythropoiesis-stimulating Agents (ESAs) in Lung Can-
cer Patients: Study-level and Patient-level Meta-analyses of
Safety Outcomes
J. Crawford1, J. Glaspy2, J. Vansteenkiste3, D. H. Henry4, D. Tomita5, K.
Bridges5, H. Ludwig6, 1Duke University Health Systems, Durham, NC,
2David Geffen School of Medicine, Los Angeles, CA, 3University Hospital
Gasthuisberg, Leuven, Belgium, 4Pennsylvania Hospital, Philadelphia, PA,
5Amgen Inc., Thousand Oaks, CA, 6Wilhelminenspital, Vienna, Austria
Purpose/Objective(s): The safety of ESAs in oncology is a focus of ongoing
discussion. These meta-analyses evaluated the impact of ESA use on survival
outcomes in patients (pts) with lung cancer.
Materials/Methods: A literature search identified 8 randomized, controlled
trials that reported mortality data in lung cancer pts receiving ESAs (7 in pts
with chemotherapy-induced anemia [CIA], 1 in pts with anemia of cancer
[AoC]). These 8 studies reported long-term follow-up mortality (5 studies) or
on-study deaths (3 studies) for a total of 2247 pts (1142 ESA-treated, 1105
control). In the 7 CIA trials, study-level data were analyzed from 5 trials with
small-cell lung cancer (SCLC) pts (593 ESA-treated, 553 control) and 3 trials
with non-SCLC (NSCLC) pts (517 ESA-treated, 514 control) (1 trial had
both SCLC and NSCLC pts). Pt-level data from 4 Amgen placebo-controlled
studies of darbepoetin alfa (2 from the study-level analysis) in SCLC pts
(n  719) and NSCLC pts (n  316) were analyzed. Odds ratios (ORs) or
hazard ratios (HRs) (ESA vs control) with 95% confidence intervals (CI)
were generated to summarize outcomes in study-level and pt-level analyses,
respectively.
Results: For SCLC pts with CIA, the estimated OR (95% CI) for survival
from the study-level meta-analysis using a random effects model was 0.83
(0.54, 1.28); estimated HRs (95% CI) from the pt-level meta-analysis were
0.99 (0.69, 1.44) for overall survival (OS) on-study and 1.06 (0.87, 1.27) for
progression-free survival (PFS) on-study. For NSCLC pts with CIA, the
estimated OR (95% CI) for survival from the study-level meta-analysis using
a random effects model was 0.83 (0.53, 1.28); estimated HRs (95% CI) from
the pt-level meta-analysis were 1.12 (0.60, 2.09) for OS on-study and 0.90
(0.63, 1.30) for PFS on-study. Heterogeneity across trials was evident: the
inconsistency statistic (I2) was 34.4% for SCLC trials and 57.6% for NSCLC
trials (where 25%, 50%, and 75% represent low, moderate, and high
heterogeneity, respectively). A study-level meta-analysis of the 7 lung cancer
studies in the CIA setting had an OR of 0.85 using the random effects model
(95% CI: 0.66, 1.04) or fixed effects model (95% CI: 0.69, 1.04) with I2 
28.3%. Data from an 8th study (not included in the meta-analysis because the
Abstracts Journal of Thoracic Oncology • Volume 5, Number 12, Supplement 7, December 2010
Copyright © 2010 by the International Association for the Study of Lung CancerS552
study was performed in the AoC setting) indicated a negative effect of ESAs
on survival with an OR (95% CI) of 1.57 (0.95, 2.58).
Conclusions: Overall, when survival data from studies conducted in pts with
lung cancer and CIA receiving ESAs were pooled and meta-analyzed at
study-level, no statistically significant differences in mortality were seen
between ESA-treated and control pts. Similarly, in pt-level meta-analyses,
the risk of death or disease progression was not increased in lung cancer pts
with CIA treated with darbepoetin alfa.
Author Disclosure Block: J. Crawford, Amgen Inc., B. Research Grant;
Amgen Inc., D. Speaker’s Bureau/Honoraria; Amgen Inc., F. Consulting/
Advisory Board; Chugai, F. Consulting/Advisory Board; Roche, G. Other; J.
Glaspy, Amgen Inc., C. Other Research Support; Centocor Ortho Biotech, C.
Other Research Support; Amgen Inc., F. Consulting/Advisory Board; J.
Vansteenkiste, Amgen Inc., C. Other Research Support; D.H. Henry,
Amgen Inc., B. Research Grant; Centocor Ortho Biotech, B. Research Grant;
Watson Pharma, B. Research Grant; Amgen Inc., D. Speaker’s Bureau/
Honoraria; Centocor Ortho Biotech, D. Speaker’s Bureau/Honoraria; Watson
Pharma, D. Speaker’s Bureau/Honoraria; Amgen Inc., F. Consulting/Advi-
sory Board; Centocor Ortho Biotech, F. Consulting/Advisory Board; Watson
Pharma, F. Consulting/Advisory Board; D. Tomita, Amgen Inc., A. Em-
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harma, B. Research Grant; Celgene, B. Research Grant; Sandoz, D. Speak-
er’s Bureau/Honoraria; Ortho Biotech, D. Speaker’s Bureau/Honoraria; Cel-
gene, D. Speaker’s Bureau/Honoraria; Celgene, F. Consulting/Advisory
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Routinely Withholding Stereotactic Radiotherapy in Elderly
Patients With Stage I Non-small Cell Lung Cancer and Co-
existing COPD is Not Justified: Outcomes of a Markov Model
Analysis
A. V. Louie1,2, G. Rodrigues1,2, M. Hannouf1, F. J. Lagerwaard3, D. A.
Palma1,2, G. S. Zaric1, C. J. A. Haasbeek3, S. Senan3, 1University of Western
Ontario, London, ON, Canada, 2London Regional Cancer Program, London,
ON, Canada, 3VU University Medical Center, Amsterdam, Netherlands
Purpose/Objective(s): Up to 30% or more of patients aged 75 years with
a stage I NSCLC presently receive no curative therapy [Holmberg, Chest
2010]. High cure rates with low toxicity have been reported after SBRT in
elderly patients [Haasbeek, Cancer 2010]. As severe chronic obstructive lung
disease (COPD) is often cited as a reason for not using SBRT, we con-
structed a Markov model to simulate the clinical history of elderly patients
with COPD that undergo either SBRT or best supportive care.
Materials/Methods: A Markov model was constructed to simulate the
quality-adjusted life expectancy (QALE) and overall survival in patients75
years undergoing either SBRT or best supportive care for a 5-year timeframe.
For SBRT, the rates of local, regional, and distant recurrences were obtained
from 247 elderly patients entered into a prospective cohort at the VUMC,
Amsterdam. Recurrences were converted into monthly transition probabili-
ties and stratified into 4 classes according to T stage (1 vs. 2) and COPD
GOLD score (I-II vs. III-IV). The 4 patient classes were: I (T1, GOLD I-II),
II (T2, GOLD I-II), III (T1, GOLD III-IV), and IV (T2, GOLD III-IV). For
untreated patients, overall survival data by T stage was similarly modeled
according to population based data from the California Cancer Registry [Raz,
Chest 2010]. Markov state utilities, consistent with the four stages of the
AJCC staging system and COPD status based on GOLD score, were
extracted and adapted from the literature [Szende, Qual Life Res 2009].
Results: The constructed Markov model showed a close correlation with
overall survival data for all 4 classes treated with SBRT, with differences at
3 years ranging from 0.8% to 3.1%. Similar findings were seen for untreated
patients, where the differences were 0.1% for T1 patients and 2.2% for T2
patients at 5 years. After SBRT, our model predicted for 5-year overall
survival of 47.2%, 33.3%, 24.7%, 6.8% and QALE of 27.4, 25.6, 21.2, and
14.9 quality adjusted life months (QALMs) for classes I to IV, respectively.
The model further predicted for a 5-year overall survival of 9.0% and 2.8%,
and QALMs of 10.1 and 6.1, for untreated T1 and T2 patients, respectively.
Outcomes were not sensitive to the published quality of life post-SBRT or
the disutility of disease progression in untreated patients. The benefit of
SBRT appears to be least for class IV patients.
Conclusions: In elderly patients with COPD, our validated Markov model
predicts superior overall and quality-adjusted survival at 5 years after SBRT
across all 4 classes when compared to no treatment. Advanced age, COPD,
and tumor size should not preclude such patients from curative SBRT.
Author Disclosure Block: A.V. Louie, None; G. Rodrigues, None; M.
Hannouf, None; F.J. Lagerwaard, None; D.A. Palma, None; G.S. Zaric,
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Is Diabetes an Independent Risk Factor for Local Recurrence
After Surgery for Non-small Cell Lung Cancer?
I. R. Washington1, J. Pepek1, J. Chino1, L. B. Marks2, C. R. Kelsey1, 1Duke
University Medical Center, Durham, NC, 2University of North Carolina,
Chapel Hill, NC
Purpose/Objective(s): Investigators from two institutions have recently
reported an association between local/regional recurrence (LRR) after sur-
gery for non-small cell lung cancer (NSCLC) and diabetes1-2. We evaluated
this further in a much larger cohort of patients.
Materials/Methods: The medical records and pertinent radiographs of all
patients who underwent surgery for pathological I-IIIA NSCLC at Duke
University from 1995-2005 were reviewed. Patients receiving any preoper-
ative therapy or postoperative RT, or with positive surgical margins, were
excluded. Disease recurrence at the surgical margin, ipsilateral hilum, and/or
mediastinum was considered a LRR. Nodal failures were defined as a new or
enlarging LN  1 cm on short axis on CT or hypermetabolic on PET, which
in the patient’s subsequent history, was consistent with a local recurrence.
Failure in the contralateral hilum, supraclavicular fossae, or ipsilateral lung
parenchyma was scored as a distant failure. The actuarial rate of LRR was
estimated using the Kaplan-Meier method. Univariate and multivariate
regression analysis assessed the association between candidate factors and
LRR and distant recurrence. Factors with a p-value  0.10 on univariate
analysis, and diabetes, were included in the multivariate model.
Results: Of 962 patients, 46% were stage IA, 26% IB, 18% IIA, 5% IIB, and
5% IIIA (AJCC 7). 80% underwent  lobectomy; 86% had sampling/
dissection of mediastinal LNs; 6% received adjuvant chemotherapy. Diabe-
tes was present in 122 (13%). The 5-year actuarial rate of LRR was 23%
(95% CI 19-26%). On multivariate analysis, sublobar resection (HR 1.81,
p0.01), squamous or large cell histology (HR 1.74, p0.01), increasing
stage (p0.01), lymphovascular space invasion (HR 1.48, p0.04), and
visceral pleural invasion (HR 1.56, p0.05) were independently associated
with a higher risk of LRR. Though there was a trend, diabetes was not
statistically significant on univariate (p0.17) or multivariate (p0.13)
analysis. Similarly, diabetes was not associated with the development of
distant metastases (p0.61) on multivariate analysis.
Conclusions: The risk of LRR after surgery for stage I-IIIA NSCLC is

23%. Independent risk factors for LRR in our cohort included sublobar
resection, increasing pathologic stage, squamous or large cell histology,
lymphovascular space invasion, and visceral pleural invasion. Diabetes was
not independently associated with LRR (or distant recurrence) in our series.
1Varlotto et al., Cancer 2009;115:1059
2Recht et al., Proceedings of ASCO 2010;28:531s
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A Quantitative Methodology for Categorizing Contouring Abil-
ity in Lung Cancer With Potential Clinical Trial Credentialing
and Autocontouring Assessment Applications
G. Rodrigues1, A. Louie1, G. Videtic2, L. Best1, N. Patil1, S. Gaede1, J.
Kempe1, G. Bauman1, J. Battista1, 1London Health Sciences Centre, London,
ON, Canada, 2Cleveland Clinic, Cleveland, OH, Canada
Purpose/Objective(s): Technological advances have improved the precision
of radiation treatment delivery for malignancies such as lung cancer (LC).
However, obtaining high levels of intra-/inter-physician consistency in target
contouring continues to be a major limiting step in optimizing the therapeutic
ratio. We describe a novel quantitative methodology for the assessment of
consistency of physician-generated contours versus an a-priori defined “ex-
pert” community standard. We also propose broader implications of such a
quality assurance/improvement methodology for minimizing the variability
of target contouring for multi-centre clinical trials and for autocontouring
algorithm assessment.
Materials/Methods: Gross tumor volume and nodal contours were gener-
ated on a series of 10 stage I-III LC CT simulation cases (total of 10 primary
and 8 nodes) by a panel of 6 expert (E) radiation oncologists. For each group
of E contours, a consensus contour was created using the STAPLE algorithm.
To define the observed differences between each E contour and the corre-
sponding consensus contour, we developed contouring penalty metrics (PM,
StructSure, Standard Imaging, Inc. Middleton, WI) To assess the contouring
ability of three new observers, they each contoured the same 10 cases in
order to calculate the PM for each observer-STAPLE paired comparison.
Subsequent comparison of these PM parameters versus the inter-physician
variability was performed by means of a normally distributed z-score based
high/moderate/low/outlier categorical scale.
Results: The average StructSure PM for the physician E set of contours
when compared to the STAPLE standard were 60.0 (SD 47.5) for the primary
contours and 44.8 (SD 30.7) for the nodal contours (maximum possible score
100). In this assessment, the concordance frequencies (reported as high/
moderate/low/outlier categories with a total 18 cases) for the three new
observers when compared to the respective STAPLE contouring dataset were
9/3/4/2, 8/2/3/5, and 9/4/1/4. This demonstrated that the majority of cases
were contoured with high to moderate concordance; however, significant
numbers of low/outlier contours were still identified. These outlier contours
were associated with significant levels of overcontouring, undercontouring,
and in one case a missed lymph node contour.
Conclusions: A practical quantitative quality assurance methodology for the
assessment of contouring variability has been demonstrated. Future investi-
gation will assess the utility of this methodology to provide information to
both investigators and clinicians with regards to the suitability of contours
generated during clinical trial credentialing procedures or by autocontouring
algorithms.
Author Disclosure Block: G. Rodrigues: None. A. Louie: None. G.
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Non-small Cell Lung Cancer (NSCLC) Patients Presenting With
Obstruction: Factors Prognostic for Response to External Beam
Radiation Therapy (EBRT)
I. M. Kang, S. Wang, T. M. Jahan, P. R. Theodore, J. Kukreja, D. M. Jablons,
S. S. Yom, University of California, San Francisco, San Francisco, CA
Purpose/Objective(s): To evaluate symptom relief and survival achieved by
EBRT in NSCLC patients who present with bronchial obstruction.
Materials/Methods: Retrospective review of patients treated from 2003-
2010 who presented with bronchial obstruction and had EBRT. Demographic
data, presenting symptoms, EBRT plan, clinical/radiographic response, and
survival were recorded.
Results: Twenty-nine patients (21 men, 8 women) had a median age of 65
years (range, 43-79). Stages were IIIA (45%), IIIB (21%) and IV (34%).
Histologies were NOS (24%), adenocarcinoma (28%) and squamous cell
carcinoma (48%). Presenting symptoms included dyspnea (45%), hemopty-
sis (17%), pneumonia (17%) and oxygen dependence (13%). Eight patients
(28%) had complete lung collapse, 17 (59%) had complete obstruction/
collapse of one or more lobes; and 4 14% had incomplete obstruction.
Median obstructing tumor size was 5.8 cm (range, 2.9-11.5). Pre-EBRT
stenting or laser was used in 4 patients. Over half of the patients (55%) had
chemotherapy: 6 after RT, 7 before RT, and 3 concurrently. Four (14%)
patients had EBRT alone. After EBRT, 2 patients were able to have surgery.
Median EBRT dose was 30 Gy, with 6 patients (21%) receiving 20 Gy, 11
(38%) receiving 21-50 Gy, and 12 (41%) receiving 51-63 Gy. Median
fraction size was 300 cGy (range, 150-400). The ratio of positive to negative
clinical responses was 6.0 in patients receiving 57-63 Gy, versus 2.0 for20
Gy (p0.43). Symptom resolution was good in 68%, moderate in 4%, and
none-poor in 28%. Lung reexpansion was radiographically confirmed in 10
(34%) patients, including 1 (3%) with disease resolution. Decreased tumor
burden was seen in 8 (28%) cases, while 5 (17%) had obstruction relief but
other disease progression, for a total of 23/29 (79%) positive radiographic
responses. Six (21%) showed no improvement or worsening. Median sur-
vival after EBRT was 0.77 years (range, 0.03-5.7) and 6 patients were alive
at last follow-up (range, 0.2-5.7 years). In patients with complete lung
collapse, median survival was 2 months versus 13 months for lobar collapse
or partial obstruction (p0.04). Patients with moderate-good radiographic
response had a median survival of 1.01 years versus 0.33 years for no-poor
radiographic response (p0.11). For stage III, the median time to metastasis
was 4 months (range, 0-34), most commonly to brain (4/11, 36%). Survival
by stage was 0.83 years (range, 0.14-4.64) for IIIA, 1.03 years (range,
0.11-3.99) for IIIB, and 0.46 years (range, 0.03-5.7) for IV.
Conclusion: For NSCLC patients with obstruction, bridging to definitive
treatment should be attempted, as extended survival can occasionally be
achieved if obstruction is limited and distant disease is not present. Higher
EBRT dose is associated with clinical response.
Author Disclosure Block: I.M. Kang: None. S. Wang: None. T.M. Jahan:
None. P.R. Theodore: None. J. Kukreja: None. D.M. Jablons: None. S.S.
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Assessment of the Usefulness of Fentanyl Patches in Outpatient
Opioid Rotation
Y. Tsunezuka, T. Yachi, T. Furusawa, Ishikawa Prefectural Central Hospi-
tal, Kanazawa, Japan
Purpose/Objective(s): We prospectively investigated the efficacy of opioid
rotation from oral oxycodone to transdermal fentanyl (TDF) in lung cancer
outpatients.
Materials/Methods: The subjects were 16 patients (10 males, 6 females) on
oral opioid therapy among the lung cancer patients being treated in an
outpatient clinic. Basically, we selected patients taking orally a daily dose of
oxycodone that was equivalent to no more than 60 mg of morphine a day,
and after obtaining their consent, we changed their treatment to TDF. Every
week for 4 weeks after the opioid switch a questionnaire was administered in
regard to pain (VAS scale), appetite, drowsiness, sleep quality, and nausea,
and 4 weeks after the switch an opinion survey was conducted in regard to
the preferred dosage form (oral, patch, injection, suppository) and in regard
to selection of the type of drug by patients themselves. The t-test was used
to perform the statistical analysis, and 2-tailed probability values were
calculated.
Results:
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1. TDF continuation rate: After the change, TDF consisted of a 2.5 mg (25
g/hr) Durotep® Patch in every patient, and it was possible to continue
treatment for 4 weeks in 13 patients (81.2%).
2. Changes in pain:The mean VAS score when taking oxycodone (before
opioid rotation) was 7.5  0.8 (6-9). The mean score after the change to
TDF was 3.6  1.1 (2-6) at 2 weeks, and 2.8  0.7 (2-4) at 4 weeks.
3. Adverse effects : Appetite:Appetite improved over time. Drowsiness:At 1
week 6.3% (1 patient) of the patients complained of slight drowsiness
during the daytime. Although 37.5% (6 patients) replied that drowsiness
“was the same as before”, after 4 weeks the percentage had decreased by
half to 18.8% (3 patients). Sleep:At 1 week, the quality of sleep of half of
the patients each was “satisfactory” and “the same”, but their quality of
sleep gradually improved, and by 2 weeks 68.8% (11 patients) had “very
satisfactory” or “satisfactory” sleep, and by 3 and 4 weeks they accounted
for 75% (12 patients) Nausea:At 1 week, there was 1 patient (6.3%) who
had severer nausea than before the switch, but at 2 weeks none had severer
nausea than before the switch.
4. Dosage form:After 4 weeks of wearing TDF patches the 75% (12 patients)
who replied that the preferred patches exceeded the 25% (4 patients) who
replied that they preferred oral medication. 5. Drug selection In reply to
the question about choosing the drug themselves, the opinion of 31% (5
patients) was “very satisfied”, and the opinion of 53% (8 patients) was
“satisfied”.
Conclusions: For most outpatients who had continued oral oxycodone
treatment, early opioid rotation to TDF may be an effective approach to
alleviate intolerable side effects along with pain.
Author Disclosure Block: Y. Tsunezuka: None. T. Yachi: None. T.
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Is Non-small Cell Lung Cancer (NSCLC) More Aggressive in
Younger Patients? A Case Report and Review of the Literature
A. Nallari1, W. Gao2, N. Snow2, L. Feldman2, 1Delnor Community Hospital,
Geneva, IL, 2University of Illinois at Chicago, Chicago, IL
Purpose/Objective(s): Younger adults with NSCLC are often thought to have
a more aggressive form of the disease than their younger counterparts. In order
to test this notion we conducted this study review of published literature to
evaluate the veracity of this common conception and/or that the disease may be
poorly responsive to standard therapy as compared to the general population.
The primary endpoint of this study was overall survival by comparing our patient
and published case reports to the general NSCLC population.
Materials/Methods: We found 30 patient reports in the literature of adult
patients 40 yrs old with NSCLC that met our predefined criteria . The
PubMed search words used were “non-small cell lung cancer” and “adeno-
carcinoma of the lung” and the limits used in the search included: adults, age
40yrs or younger, case reports and English language journals. The date limit
for the search was the past 15 yrs. Overall survival (OS) of this study
population was estimated using the Kaplan-Meier method. Our patient was a
27 yr-old woman with a 15 pack-yr smoking history diagnosed with adeno-
carcinoma of the right lung stage T4N0M0 (Stage III). She underwent a right
lower lobectomy after neoadjuvant chemoradiotherapy. Pathological stage
was pT2N0M0 (Stage Ib). Molecular diagnostic testing showed that her
tumor was positive for the K-ras mutation. She is currently receiving
postoperative chemotherapy.
Results: A total of 30 published case reports in the peer-reviewed literature
published from 1997 to 2009 were analyzed for this review. Twenty-one pts
were female and 9 were male. Sixteen of these 30 pts had adenocarcinoma
of the lung, of which 13 were female and 3 were male. Fourteen of the 30 pts
had other histologies, including 6 with large- cell, 5 with squamous cell, and
2 were reported as poorly differentiated. Of the 16 pts with adenocarcinoma,
6 were smokers and 9 were non-smokers and 1 unknown. Among the 30 pts,
2 were Stage II, 7 were Stage III, 15 were Stage IV and 6 were unknown
stage. There were 6 reported positive EGFR cases using IHC, of which 3
reported the presence of the EGFR mutation by DNA analysis. Two other pts
had positive EGFR mutations and no IHC testing reported. Median overall
survival (MOS) time was 48 months (range 5 days to 240 months) for all
stages combined. For Stage III the MOS was 116 months (range 3.5 to 116
months) and for Stage IV it was 9 months (range 0.16 to 240 months).
Conclusions: Young pts with NSCLC may have a similar prognosis in terms
of MOS to that of older pts. Therefore, it is important to recognize this point
and to approach younger pts without therapeutic nihilism.
Author Disclosure Block: A. Nallari: None. W. Gao: None. N. Snow:
None. L. Feldman: D. Speaker’s Bureau/Honoraria; Sanofi-Aventis. ; F.
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Purpose/Objective(s): This National Cancer Institute funded Program Project
(P01) supports a program of interdisciplinary research with central themes
related to palliative care, quality of life (QOL), and symptom management
across the trajectory of lung cancer affecting 213,000 Americans. Consistent
with the recommendations of the Institute of Medicine Report on palliative care,
symptom management and attention to QOL concerns of patients and families
will be addressed throughout the trajectory of lung cancer. The purpose of this
project is to test usual care versus a palliative care intervention encompassing a
four component patient and family caregiver education intervention and is
guided by the City of Hope QOL model.
Materials/Methods: The P01 intervention was established through two pilot
projects demonstrating the unmet needs in lung cancer across QOL domains
and the limited use of supportive care services by those with lung cancer.
From these 2 pilot studies, the most common symptoms were pain, cough,
dyspnea and fatigue with only 64 referrals in 57 of the 100 patients. The
patient and family interventions are delivered by an Advanced Practice Nurse
based on input from an interdisciplinary team. The project includes distinct
education interventions for early and late stage lung cancer and for family
caregivers. Project 1, Early Stage Lung Cancer (N207), provides a model
of integrating palliative care throughout the trajectory of disease. Project 2
focuses on Late Stage Lung Cancer (326), a population who has decreased
survival and high QOL and symptom concerns. Project 3 focuses on Family
Caregivers (N533) of patients with lung cancer.
Results: Outcomes evaluation of the project include assessment of the
impact of the education on patient symptoms, QOL, and supportive resource
use as well as family caregiver QOL, self care and skills preparedness for
care giving.
Conclusions: This project will provide important comprehensive educa-
tion interventions and resources for lung cancer patients and their family
caregiver.
Author Disclosure Block: M. Koczywas: None. T. Borneman: None. M.
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The oncology department at Tygerberg Hospital/University of Stellenbosch
treats about 160 unoperated lung cancer patients annually (1). These have
generally had limited educational and vocational opportunities. Their back-
ground to radiation and chemo- therapy is limited, something that may be
further exacerbated by cultural, educational and socio-economic factors yet
they receive relatively advanced investigational and therapeutic procedures
and their consent and counseling procedures are likely influenced by scien-
tific and legal considerations. The aim of this study is through qualitative
research to gain a better understanding of their perceptions of their disease
and the expectations of their treatment. The study consists of interviews with
forty newly-diagnosed lung cancer patients all histology and stages who have
been through all the normal staging and consent procedures but have neither
started their radiation planning or treatment nor received any chemotherapy.
None will be earmarked for any other trial at that stage. Most will be on
course for a palliative procedure. The researchers will have noted fundamen-
tal demographic, social, educational and disease characteristics and have a
set of questions as a guideline but the interview is open-ended. They
present each case individually but seek common themes and concepts
especially exploring the patients’ expectations of the disease and treat-
ment, their sources of information and how this may have been modified
by the hospital environment and procedures. The study aims to suggest
guidelines towards making future counseling and consent procedures
more patient orientated, especially in less developed environments, and
creating possibilities for future quantitative studies that may explore
certain subsections more decisively; it also presents a limited literature
review of previous similar investigations for comparative purposes and an
assessment of the value of qualitative research in the acquisition of
knowledge in this arena.
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